10-Q 1 d714950d10q.htm FORM 10-Q Form 10-Q
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 10-Q

 

 

(Mark One)

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

For The Quarterly Period Ended March 31, 2014

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

Commission File Number: 814-00702

 

 

HERCULES TECHNOLOGY GROWTH

CAPITAL, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Maryland   743113410

(State or Jurisdiction of

Incorporation or Organization)

 

(IRS Employer

Identification No.)

 

400 Hamilton Ave., Suite 310  
Palo Alto, California   94301
(Address of Principal Executive Offices)   (Zip Code)

(650) 289-3060

(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this Chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ¨    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer   x       Accelerated Filer   ¨
Non-Accelerated Filer   ¨       Smaller Reporting Company   ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

On April 28, 2014, there were 62,610,806 shares outstanding of the Registrant’s common stock, $0.001 par value.

 

 

 


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

FORM 10-Q TABLE OF CONTENTS

 

PART I. FINANCIAL INFORMATION

     3   

Item 1.

  

Consolidated Financial Statements

     3   
  

Consolidated Statement of Assets and Liabilities as of March 31, 2014 (unaudited) and December 31, 2013

     3   
  

Consolidated Statement of Operations for the three month periods ended March 31, 2014 and 2013 (unaudited)

     5   
  

Consolidated Statement of Changes in Net Assets for the three month periods ended March 31, 2014 and 2013 (unaudited)

     6   
  

Consolidated Statement of Cash Flows for the three month periods ended March 31, 2014 and 2013 (unaudited)

     7   
  

Consolidated Schedule of Investments as of March 31, 2014 (unaudited)

     8   
  

Consolidated Schedule of Investments as of December 31, 2013

     22   
  

Notes to Consolidated Financial Statements (unaudited)

     37   

Item 2.

  

Management’s Discussion and Analysis of Financial Condition and Results of Operations

     63   

Item 3.

  

Quantitative and Qualitative Disclosures About Market Risk

     94   

Item 4.

  

Controls and Procedures

     95   

PART II. OTHER INFORMATION

     96   

Item 1.

  

Legal Proceedings

     96   

Item 1A.

  

Risk Factors

     96   

Item 2.

  

Unregistered Sales of Equity Securities and Use of Proceeds

     97   

Item 3.

  

Defaults Upon Senior Securities

     97   

Item 4.

  

Mine Safety Disclosures

     97   

Item 5.

  

Other Information

     97   

Item 6.

  

Exhibits

     97   

SIGNATURES

     98   

 

2


Table of Contents

PART I: FINANCIAL INFORMATION

In this Quarterly Report, the “Company,” “Hercules,” “we,” “us” and “our” refer to Hercules Technology Growth Capital, Inc. and its wholly owned subsidiaries and its affiliated securitization trusts unless the context otherwise requires.

 

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

(unaudited)

(dollars in thousands, except per share data)

 

     March 31,
2014
    December 31,
2013
 

Assets

    

Investments:

    

Non-control/Non-affiliate investments (cost of $872,226 and $891,059, respectively)

   $ 879,469      $ 899,314   

Affiliate investments (cost of $15,402 and $15,238, respectively)

     11,193        10,981   
  

 

 

   

 

 

 

Total investments, at value (cost of $887,628 and $906,297, respectively)

     890,662        910,295   

Cash and cash equivalents

     224,538        268,368   

Restricted cash

     4,784        6,271   

Interest receivable

     8,176        8,962   

Other assets

     31,239        27,819   
  

 

 

   

 

 

 

Total assets

   $ 1,159,399      $ 1,221,715   
  

 

 

   

 

 

 

Liabilities

    

Accounts payable and accrued liabilities

   $ 8,962      $ 14,268   

Long-term Liabilities (Convertible Senior Notes)

     72,789        72,519   

Asset-Backed Notes

     63,782        89,557   

2019 Notes

     170,364        170,364   

Long-term SBA Debentures

     190,200        225,000   
  

 

 

   

 

 

 

Total liabilities

   $ 506,097      $ 571,708   

Commitments and Contingencies (Note 10)

    

Net assets consist of:

    

Common stock, par value

     62        62   

Capital in excess of par value

     656,869        656,594   

Unrealized appreciation on investments

     2,607        3,598   

Accumulated realized losses on investments

     (10,368     (15,240

Undistributed net investment income

     4,132        4,993   
  

 

 

   

 

 

 

Total net assets

   $ 653,302      $ 650,007   
  

 

 

   

 

 

 

Total liabilities and net assets

   $ 1,159,399      $ 1,221,715   
  

 

 

   

 

 

 

Shares of common stock outstanding ($0.001 par value, 100,000,000 authorized)

     61,760        61,837   

Net asset value per share

   $ 10.58      $ 10.51   

See notes to consolidated financial statements.

 

3


Table of Contents

The following table presents the assets and liabilities of our consolidated securitization trust for asset-backed notes (see Note 4), which is a variable interest entity (“VIE”). The assets of our securitization VIE can only be used to settle obligations of our consolidated securitization VIE, these liabilities are only the obligations of our consolidated securitization VIE, and the creditors (or beneficial interest holders) do not have recourse to our general credit. These assets and liabilities are included in the Consolidated Statements of Assets and Liabilities above.

 

(Dollars in thousands)

   March 31,
2014
     December 31,
2013
 

ASSETS

     

Restricted Cash

   $ 4,784       $ 6,271   

Total investments, at value (cost of $137,301 and $166,513, respectively)

     135,138         165,445   
  

 

 

    

 

 

 

Total assets

   $ 139,922       $ 171,716   
  

 

 

    

 

 

 

LIABILITIES

     

Asset-Backed Notes

   $ 63,782       $ 89,557   
  

 

 

    

 

 

 

Total liabilities

   $ 63,782       $ 89,557   
  

 

 

    

 

 

 

See notes to consolidated financial statements.

 

4


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(in thousands, except per share data)

 

     Three Months Ended March 31,  
         2014              2013      

Investment income:

    

Interest Income

    

Non-Control/Non-Affiliate investments

   $ 29,382      $ 28,319   

Affiliate investments

     1,464        610   
  

 

 

   

 

 

 

Total interest income

     30,846        28,929   
  

 

 

   

 

 

 

Fees

    

Non-Control/Non-Affiliate investments

     4,913        2,028   

Affiliate investments

     11        —     
  

 

 

   

 

 

 

Total fees

     4,924        2,028   
  

 

 

   

 

 

 

Total investment income

     35,770        30,957   

Operating expenses:

    

Interest

     7,148        7,631   

Loan fees

     2,076        1,079   

General and administrative

     2,461        2,252   

Employee Compensation:

    

Compensation and benefits

     4,221        3,798   

Stock-based compensation

     1,560        1,165   
  

 

 

   

 

 

 

Total employee compensation

     5,781        4,963   
  

 

 

   

 

 

 

Total operating expenses

     17,466        15,925   
  

 

 

   

 

 

 

Net investment income

     18,304        15,032   

Net realized gain on investments

    

Non-Control/Non-Affiliate investments

     4,872        1,991   
  

 

 

   

 

 

 

Total net realized gain on investments

     4,872        1,991   
  

 

 

   

 

 

 

Net change in unrealized appreciation (depreciation) on investments

    

Non-Control/Non-Affiliate investments

     (1,038     (768

Affiliate investments

     47        434   
  

 

 

   

 

 

 

Total net change in unrealized appreciation (depreciation) on investments

     (991     (334
  

 

 

   

 

 

 

Total net realized and unrealized gain

     3,881        1,657   
  

 

 

   

 

 

 

Net increase in net assets resulting from operations

   $ 22,185      $ 16,689   
  

 

 

   

 

 

 

Net investment income before investment gains and losses per common share:

    

Basic

   $ 0.30      $ 0.27   
  

 

 

   

 

 

 

Change in net assets per common share:

    

Basic

   $ 0.36      $ 0.30   
  

 

 

   

 

 

 

Diluted

   $ 0.35      $ 0.30   
  

 

 

   

 

 

 

Weighted average shares outstanding

    

Basic

     60,870        53,682   
  

 

 

   

 

 

 

Diluted

     62,695        53,823   
  

 

 

   

 

 

 

Dividends declared per common share:

    

Basic

   $ 0.31      $ 0.27   

See notes to consolidated financial statements.

 

5


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED STATEMENT OF CHANGES IN NET ASSETS

(unaudited)

(dollars and shares in thousands)

 

    Common Stock     Capital  in
excess
of par value
    Unrealized
Appreciation
(Depreciation)

on Investments
    Accumulated
Realized

Gains(Losses)
on Investments
    Undistributed
Net
Investment
Income/
(Distributions
in Excess of
Investment

Income)
    Provision for
Income Taxes

on Investment
Gains
    Net
Assets
 
    Shares     Par Value              

Balance at December 31, 2012

    52,925      $ 53      $ 564,508      $ (7,947   $ (36,916   $ (3,388   $ (342   $ 515,968   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net increase in net assets resulting from operations

    —          —          —          (334     1,991        15,032        —          16,689   

Issuance of common stock

    80        —          910        —          —          —          —          910   

Issuance of common stock under restricted stock plan

    531        1        (1     —          —          —          —          —     

Issuance of common stock as stock dividend

    40        —          488        —          —          —          —          488   

Retired shares from net issuance

    (72     —          (1,808     —          —          —          —          (1,808

Public Offering

    8,050        8        95,550        —          —          —          —          95,558   

Dividends declared

    —          —          —          —          —          (13,382     —          (13,382

Stock-based compensation

    —          —          1,185        —          —          —          —          1,185   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance at March 31, 2013

    61,554      $ 62      $ 660,833      $ (8,281   $ (34,925   $ (1,739   $ (342   $ 615,608   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance at December 31, 2013

    61,837      $ 62      $ 656,594      $ 3,598      $ (15,240   $ 5,335      $ (342   $ 650,007   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net increase in net assets resulting from operations

    —          —          —          (991     4,872        18,304        —          22,185   

Issuance of common stock

    62        —          727        —          —          —          —          727   

Retired shares from restricted stock vesting

    (120     —          —          —          —          —          —          —     

Issuance of common stock as stock dividend

    29        —          440        —          —          —          —          440   

Retired shares from net issuance

    (48     —          (2,472     —          —          —          —          (2,472

Dividends declared

    —          —          —          —          —          (19,165     —          (19,165

Stock-based compensation

    —          —          1,580        —          —          —          —          1,580   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance at March 31, 2014

    61,760      $ 62      $ 656,869      $ 2,607      $ (10,368   $ 4,474      $ (342   $ 653,302   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

See notes to consolidated financial statements.

 

6


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(dollars in thousands)

 

     For the Three Months Ended
March 31,
 
     2014     2013  

Cash flows from operating activities:

    

Net increase in net assets resulting from operations

   $ 22,185      $ 16,689   

Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities:

    

Purchase of investments

     (113,887     (139,095

Principal payments received on investments

     132,646        75,987   

Proceeds from sale of investments

     7,598        5,212   

Net unrealized depreciation on investments

     991        334   

Net realized gain on investments

     (4,872     (1,991

Accretion of paid-in-kind principal

     (659     (555

Accretion of loan discounts

     (3,378     (1,455

Accretion of loan discount on Convertible Senior Notes

     271        271   

Accretion of loan exit fees

     1,705        (1,819

Change in deferred loan origination revenue

     (457     313   

Unearned fees related to unfunded commitments

     (2,723     (856

Amortization of debt fees and issuance costs

     1,913        938   

Depreciation

     54        68   

Stock-based compensation and amortization of restricted stock grants

     1,579        1,185   

Change in operating assets and liabilities:

    

Interest and fees receivable (payable)

     786        (41

Prepaid expenses and other assets

     (2,557     33   

Accounts payable

     (41     (250

Accrued liabilities

     (5,307     (2,682
  

 

 

   

 

 

 

Net cash provided by (used in) operating activities

     35,847        (47,714

Cash flows from investing activities:

    

Purchases of capital equipment

     (4     (24

Reduction of (investment in) restricted cash

     1,487        (810

Other long-term assets

     —          (30
  

 

 

   

 

 

 

Net cash provided by (used in) investing activities

     1,483        (864

Cash flows from financing activities:

    

Proceeds from issuance (repurchase of employee shares due to restricted stock vesting) of common stock, net

     (1,873     94,660   

Dividends paid

     (18,725     (12,894

Repayments of Asset-Backed Notes

     (25,775     —     

Repayments of credit facilities

     (34,800     (9,254

Fees paid for credit facilities and debentures

     13        —     
  

 

 

   

 

 

 

Net cash provided by (used in) financing activities

     (81,160     72,512   
  

 

 

   

 

 

 

Net increase (decrease) in cash and cash equivalents

     (43,830     23,934   

Cash and cash equivalents at beginning of period

     268,368        182,994   
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 224,538      $ 206,928   
  

 

 

   

 

 

 

Supplemental non-cash investing and financing activities:

    

Dividends Reinvested

   $ 440      $ 488   

Paid-in-Kind Principal

   $ 659      $ 555   

See notes to consolidated financial statements.

 

7


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2014

(unaudited)

(dollars in thousands)

 

Portfolio Company

    

Sub-Industry

    

Type of
Investment(1)

    

      Maturity      
Date

    

    Interest Rate and Floor    

     Principal
Amount
     Cost(2)      Value(3)  

Debt

                              

Biotechnology Tools

                              

1-5 Years Maturity

                              

Labcyte, Inc.(11)(14)(15)

     Biotechnology Tools      Senior Secured      June 2016      Interest rate PRIME + 6.70% or Floor rate of 9.95%      $ 3,890       $ 3,976       $ 3,936   
                           

 

 

    

 

 

 

Subtotal: 1-5 Years Maturity

                              3,976         3,936   
                           

 

 

    

 

 

 

Subtotal: Biotechnology Tools (0.60%)*

                              3,976         3,936   
                           

 

 

    

 

 

 

Energy Technology

                              

Under 1 Year Maturity

                              

American Superconductor Corporation(3)(11)(14)

     Energy Technology      Senior Secured      December 2014      Interest rate PRIME + 7.25% or Floor rate of 11.00%      $ 3,462         3,892         3,892   

Enphase Energy, Inc.(11)(14)

     Energy Technology      Senior Secured      June 2014      Interest rate PRIME + 5.75% or Floor rate of 9.00%      $ 669         717         717   

Scifiniti (pka Integrated Photovoltaics, Inc.)(15)

     Energy Technology      Senior Secured      February 2015      Interest rate PRIME + 7.38% or Floor rate of 10.63%      $ 1,166         1,154         1,154   

Stion Corporation(4)(6)(14)

     Energy Technology      Senior Secured      February 2015      Interest rate PRIME + 8.75% or Floor rate of 12.00%      $ 4,182         4,169         4,169   

TAS Energy, Inc.(14)

     Energy Technology      Senior Secured      February 2015      Interest rate PRIME + 7.75% or Floor rate of 11.00%      $ 12,803         12,811         12,811   
     Energy Technology      Senior Secured      February 2015      Interest rate PRIME + 6.25% or Floor rate of 9.50%      $ 3,000         2,900         2,900   
                        

 

 

    

 

 

    

 

 

 

Total TAS Energy, Inc.

                         $ 15,803         15,711         15,711   
                           

 

 

    

 

 

 

Subtotal: Under 1 Year Maturity

                              25,644         25,644   
                           

 

 

    

 

 

 

1-5 Years Maturity

                              

Agrivida, Inc.(15)

     Energy Technology      Senior Secured      December 2016      Interest rate PRIME + 6.75% or Floor rate of 10.00%      $ 6,000         5,940         5,902   

American Superconductor(3)(11)(14)

     Energy Technology      Senior Secured      November 2016      Interest rate PRIME + 7.25% or Floor rate of 11.00%      $ 10,000         9,894         9,894   

Amyris, Inc.(10)(14)

     Energy Technology      Senior Secured      February 2017      Interest rate PRIME + 6.25% or Floor rate of 9.50%      $ 25,000         24,703         24,703   

BioAmber, Inc.(5)(10)(14)

     Energy Technology      Senior Secured      June 2016      Interest rate PRIME + 6.75% or Floor rate of 10.00%      $ 25,000         25,704         26,201   

Enphase Energy, Inc.(11)

     Energy Technology      Senior Secured      August 2016      Interest rate PRIME + 8.25% or Floor rate of 11.50%      $ 7,181         7,229         7,373   

Fluidic, Inc.(14)

     Energy Technology      Senior Secured      March 2016      Interest rate PRIME + 8.00% or Floor rate of 11.25%      $ 5,000         4,961         5,009   

Fulcrum Bioenergy, Inc.(11)

     Energy Technology      Senior Secured      November 2016      Interest rate PRIME + 7.75% or Floor rate of 11.00%      $ 9,733         9,713         9,545   

Glori Energy, Inc.(11)(14)

     Energy Technology      Senior Secured      June 2015      Interest rate PRIME + 6.75% or Floor rate of 10.00%      $ 4,444         4,616         4,601   

 

See notes to consolidated financial statements.

 

8


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2014

(unaudited)

(dollars in thousands)

 

Portfolio Company

    

Sub-Industry

    

Type of
Investment(1)

    

      Maturity      

Date

    

    Interest Rate and Floor    

     Principal
Amount
     Cost(2)      Value(3)  

Polyera Corporation(14)(15)

     Energy Technology      Senior Secured      June 2016      Interest rate PRIME + 6.75% or Floor rate of 10.00%      $ 5,289       $ 5,346       $ 5,273   

TPI Composites, Inc.(14)

     Energy Technology      Senior Secured      June 2016      Interest rate PRIME + 8.00% or Floor rate of 11.25%      $ 5,000         4,905         4,905   
     Energy Technology      Senior Secured      June 2016      Interest rate PRIME + 8.00% or Floor rate of 11.25%      $ 15,000         15,008         15,149   
                        

 

 

    

 

 

    

 

 

 

Total TPI Composites, Inc.

                         $ 20,000         19,913         20,054   

ULTURA Inc.(13)(14)

     Energy Technology      Senior Secured      April 2017      Interest rate PRIME + 6.75% or Floor rate of 10.00%      $ 18,210         18,032         17,556   
                           

 

 

    

 

 

 

Subtotal: 1-5 Years Maturity

                              136,051         136,111   
                           

 

 

    

 

 

 

Subtotal: Energy Technology (24.76%)*

                              161,695         161,755   
                           

 

 

    

 

 

 

Communications & Networking

                              

1-5 Years Maturity

                              

OpenPeak, Inc.(11)(14)

     Communications & Networking      Senior Secured      April 2017      Interest rate PRIME + 8.75% or Floor rate of 12.00%      $ 10,500         10,367         10,367   

Spring Mobile Solutions, Inc.(14)

     Communications & Networking      Senior Secured      November 2016      Interest rate PRIME + 8.00% or Floor rate of 11.25%      $ 20,000         19,837         20,237   
                           

 

 

    

 

 

 

Subtotal: 1-5 Years Maturity

                              30,204         30,604   
                           

 

 

    

 

 

 

Subtotal: Communications & Networking (4.68%)*

                         30,204         30,604   
                           

 

 

    

 

 

 

Consumer & Business Products

                              

1-5 Years Maturity

                              

Fluc, Inc.(9)

     Consumer & Business Products      Convertible Senior Debt      March 2017      Interest rate FIXED 4.00%      $ 100         100         100   
                           

 

 

    

 

 

 

Subtotal: 1-5 Years Maturity

                              100         100   
                           

 

 

    

 

 

 

Subtotal: Consumer & Business Products (0.02%)*

                              100         100   
                           

 

 

    

 

 

 

Drug Delivery

                              

Under 1 Year Maturity

                              

Revance Therapeutics, Inc.(3)(14)

     Drug Delivery      Senior Secured      March 2015      Interest rate PRIME + 6.60% or Floor rate of 9.85%      $ 794         827         827   
     Drug Delivery      Senior Secured      March 2015      Interest rate PRIME + 6.60% or Floor rate of 9.85%      $ 7,942         8,222         8,222   
                        

 

 

    

 

 

    

 

 

 

Total Revance Therapeutics, Inc.

                         $ 8,736         9,049         9,049   
                           

 

 

    

 

 

 

Subtotal: Under 1 Year Maturity

                              9,049         9,049   
                           

 

 

    

 

 

 

1-5 Years Maturity

                              

AcelRx Pharmaceuticals, Inc.(3)(10)(14)(15)

     Drug Delivery      Senior Secured      October 2017      Interest rate PRIME + 3.85% or Floor rate of 9.10%      $ 15,000         14,613         14,613   

BIND Therapeutics, Inc.(3)(14)(15)

     Drug Delivery      Senior Secured      September 2016      Interest rate PRIME + 7.00% or Floor rate of 10.25%      $ 4,500         4,425         4,560   

Celsion Corporation(3)(14)

     Drug Delivery      Senior Secured      June 2017      Interest rate PRIME + 8.00% or Floor rate of 11.25%      $ 5,000         4,923         4,923   

Dance Biopharm, Inc.(14)(15)

     Drug Delivery      Senior Secured      August 2017      Interest rate PRIME + 7.40% or Floor rate of 10.65%      $ 1,000         981         981   

kaleo, Inc.(11)(14)

     Drug Delivery      Senior Secured      June 2016      Interest rate PRIME + 5.75% or Floor rate of 11.00%      $ 13,678         13,958         13,958   

Neos Therapeutics, Inc.(14)(15)

     Drug Delivery      Senior Secured      October 2017      Interest rate FIXED + 9.00%      $ 10,000         9,828         9,828   
                           

 

 

    

 

 

 

Subtotal: 1-5 Years Maturity

                              48,728         48,863   
                           

 

 

    

 

 

 

Subtotal: Drug Delivery (8.86%)*

                              57,777         57,912   
                           

 

 

    

 

 

 

 

See notes to consolidated financial statements.

 

9


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2014

(unaudited)

(dollars in thousands)

 

Portfolio Company

    

Sub-Industry

    

Type of
Investment(1)

    

      Maturity      

Date

    

    Interest Rate and Floor    

     Principal
Amount
     Cost(2)      Value(3)  

Drug Discovery & Development

                              

Under 1 Year Maturity

                              

Dicerna Pharmaceuticals, Inc.(3)(15)

     Drug Discovery & Development      Senior Secured      January 2015      Interest rate PRIME + 4.40% or Floor rate of 10.15%      $ 3,922       $ 3,901       $ 3,901   
                           

 

 

    

 

 

 

Subtotal: Under 1 Year Maturity

                              3,901         3,901   
                           

 

 

    

 

 

 

1-5 Years Maturity

                              

ADMA Biologics, Inc.(3)(13)(14)

     Drug Discovery & Development      Senior Secured      June 2017      Interest rate PRIME + 3.00% or Floor rate of 8.75%, PIK Interest 1.95%      $ 10,003         9,824         9,824   

Anacor Pharmaceuticals, Inc.(15)

     Drug Discovery & Development      Senior Secured      July 2017      Interst rate PRIME + 6.40% or Floor rate of 11.65%      $ 30,000         29,171         30,071   

Aveo Pharmaceuticals, Inc.(3)(10)(11)(14)(15)

     Drug Discovery & Development      Senior Secured      September 2015      Interest rate PRIME + 7.15% or Floor rate of 11.90%      $ 16,872         16,872         17,040   

Cell Therapeutics, Inc.(11)(14)

     Drug Discovery & Development      Senior Secured      October 2016      Interest rate PRIME + 9.00% or Floor rate 12.25%      $ 15,000         14,946         14,946   

Cempra, Inc.(3)(11)(14)

     Drug Discovery & Development      Senior Secured      June 2017      Interest rate PRIME + 6.30% or Floor rate of 9.55%      $ 15,000         14,975         14,975   

Cleveland BioLabs, Inc.(3)(14)(15)

     Drug Discovery & Development      Senior Secured      January 2017      Interest rate PRIME + 6.20% or Floor rate of 10.45%      $ 6,000         5,954         6,055   

Concert Pharmaceuticals, Inc.(3)(4)

     Drug Discovery & Development      Senior Secured      October 2015      Interest rate PRIME + 3.25% or Floor rate of 8.50%      $ 13,172         13,052         12,933   

Insmed, Incorporated(11)(14)

     Drug Discovery & Development      Senior Secured      January 2016      Interest rate PRIME + 4.75% or Floor rate of 9.25%      $ 20,000         19,815         19,904   

Merrimack Pharmaceuticals, Inc.(3)(14)

     Drug Discovery & Development      Senior Secured      November 2016      Interest rate PRIME + 5.30% or Floor rate of 10.55%      $ 40,000         40,446         40,204   

Neuralstem, Inc.(14)(15)

     Drug Discovery & Development      Senior Secured      June 2016      Interest rate PRIME + 7.75% or Floor rate of 11.00%      $ 7,295         7,239         7,385   

uniQure B.V.(3)(5)(10)(11)(14)

     Drug Discovery & Development      Senior Secured      October 2016      Interest rate PRIME + 8.60% or Floor rate of 11.85%      $ 10,000         9,731         9,806   
                           

 

 

    

 

 

 

Subtotal: 1-5 Years Maturity

                              182,025         183,143   
                           

 

 

    

 

 

 

Subtotal: Drug Discovery & Development (28.63%)*

                         185,926         187,044   
                           

 

 

    

 

 

 

Electronics & Computer Hardware

                              

1-5 Years Maturity

                              

Plures Technologies, Inc.(8)(13)

     Electronics & Computer Hardware      Senior Secured      October 2016      Interest rate PRIME + 8.75% or Floor rate of 12.00%, PIK Interest 4.00%      $ 571         483         307   
                           

 

 

    

 

 

 

Subtotal: 1-5 Years Maturity

                              483         307   
                           

 

 

    

 

 

 

Subtotal: Electronics & Computer Hardware (0.05%)

                         483         307   
                           

 

 

    

 

 

 

Healthcare Services, Other

                              

1-5 Years Maturity

                              

InstaMed Communications, LLC(14)(15)

    

Healthcare

Services, Other

     Senior Secured      December 2016      Interest rate PRIME + 7.25% or Floor rate of 10.50%      $ 3,000         3,008         3,068   

 

See notes to consolidated financial statements.

 

10


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2014

(unaudited)

(dollars in thousands)

 

Portfolio Company

    

Sub-Industry

    

Type of
Investment(1)

    

      Maturity      
Date

    

    Interest Rate and Floor    

     Principal
Amount
     Cost(2)      Value(3)  

MDEverywhere, Inc.

    

Healthcare

Services, Other

     Senior Secured      June 2016      Interest rate LIBOR + 9.50% or Floor rate of 10.75%      $ 1,875       $ 1,754       $ 1,792   

Orion Healthcorp, Inc.(13)

    

Healthcare

Services, Other

     Senior Secured      June 2016      Interest rate LIBOR + 8.25% or Floor rate of 9.50%      $ 500         469         469   
    

Healthcare

Services, Other

     Senior Secured      June 2017      Interest rate LIBOR + 9.50% or Floor rate of 11.00%      $ 8,775         8,627         8,684   
    

Healthcare

Services, Other

     Senior Secured      June 2017      Interest rate LIBOR + 10.50% or Floor rate of 12.00%, PIK Interest 3.00%      $ 6,641         6,524         6,580   
                        

 

 

    

 

 

    

 

 

 

Total Orion Healthcorp, Inc.

                         $ 15,916         15,620         15,733   
                           

 

 

    

 

 

 

Subtotal: 1-5 Years Maturity

                              20,382         20,593   
                           

 

 

    

 

 

 

Subtotal: Healthcare Services, Other (3.15%)*

                         20,382         20,593   
                           

 

 

    

 

 

 

Information Services

                              

1-5 Years Maturity

                              

Eccentex Corporation(11)(14)

     Information Services      Senior Secured      May 2015      Interest rate PRIME + 7.00% or Floor rate of 10.25%      $ 548         553         244   

InXpo, Inc.(14)(15)

     Information Services      Senior Secured      April 2016      Interest rate PRIME + 7.50% or Floor rate of 10.75%      $ 2,307         2,264         2,207   

Womensforum.com(11)(13)

     Information Services      Senior Secured      October 2016      Interest rate LIBOR + 7.50% or Floor rate of 10.25%, PIK Interest 2.00%      $ 4,630         4,565         4,565   
     Information Services      Senior Secured      April 2015      Interest rate LIBOR + 6.50% or Floor rate of 9.00%      $ 1,250         1,231         1,231   
     Information Services      Senior Secured      October 2016      Interest rate LIBOR + 6.50% or Floor rate of 9.25%      $ 6,600         6,506         6,506   
                        

 

 

    

 

 

    

 

 

 

Total Womensforum.com

                         $ 12,480         12,302         12,302   
                           

 

 

    

 

 

 

Subtotal: 1-5 Years Maturity

                              15,119         14,753   
                           

 

 

    

 

 

 

Subtotal: Information Services (2.26%)*

                         15,119         14,753   
                           

 

 

    

 

 

 

 

See notes to consolidated financial statements.

 

11


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2014

(unaudited)

(dollars in thousands)

 

Portfolio Company

    

Sub-Industry

    

Type of
Investment(1)

    

      Maturity      
Date

    

    Interest Rate and Floor    

     Principal
Amount
     Cost(2)      Value(3)  

Internet Consumer & Business Services

                              

Under 1 Year Maturity

                              

Gazelle, Inc.(13)

     Internet Consumer & Business Services      Senior Secured      October 2014      Interest rate PRIME + 6.50% or Floor rate of 9.75%      $ 1,021       $ 1,006       $ 1,006   

Tectura Corporation(8)(13)

     Internet Consumer & Business Services      Senior Secured      May 2014      Interest rate LIBOR + 10.00% or Floor rate of 13.00%      $ 563         563         180   
     Internet Consumer & Business Services      Senior Secured      May 2014      Interest rate LIBOR + 10.00% or Floor rate of 13.00%      $ 277         277         89   
     Internet Consumer & Business Services      Senior Secured      May 2014      Interest rate LIBOR + 10.00% or Floor rate of 13.00%      $ 6,468         6,467         2,067   
     Internet Consumer & Business Services      Senior Secured      May 2014      Interest rate LIBOR + 8.00% or Floor rate of 11.00%, PIK Interest 1.00%      $ 10,777         10,777         3,445   
     Internet Consumer & Business Services      Senior Secured      May 2014      Interest rate LIBOR + 10.00% or Floor rate of 13.00%      $ 5,000         5,000         1,599   
                        

 

 

    

 

 

    

 

 

 

Total Tectura Corporation

                         $ 23,085         23,084         7,380   
                           

 

 

    

 

 

 

Subtotal: Under 1 Year Maturity

                              24,090         8,386   
                           

 

 

    

 

 

 

1-5 Years Maturity

                              

Blurb, Inc.(15)

     Internet Consumer & Business Services      Senior Secured      December 2015      Interest rate PRIME + 5.25% or Floor rate of 8.50%      $ 5,616         5,511         5,456   

CashStar, Inc.(13)(15)

     Internet Consumer & Business Services      Senior Secured      June 2016      Interest rate PRIME + 6.25% or Floor rate 10.50%, PIK Interest 1.00%      $ 8,028         7,846         7,993   

Education Dynamics(13)(15)

     Internet Consumer & Business Services      Senior Secured      March 2016     

Interest rate LIBOR + 12.5% or Floor rate 12.50%, PIK Interest 1.50%

     $ 23,779         23,386         23,909   

Gazelle, Inc.(13)(15)

     Internet Consumer & Business Services      Senior Secured      April 2016      Interest rate PRIME + 7.00% or Floor rate of 10.25%, PIK Interest 2.50%      $ 12,443         12,375         12,375   

Just Fabulous, Inc.(14)

     Internet Consumer & Business Services      Senior Secured      February 2017      Interest rate PRIME + 8.25% or Floor rate of 11.50%      $ 5,000         4,879         5,029   

NetPlenish(8)(9)(15)

     Internet Consumer & Business Services      Senior Secured      April 2015      Interest rate FIXED 10.00%      $ 96         96         —     
     Internet Consumer & Business Services      Senior Secured      September 2015      Interest rate FIXED 10.00%      $ 382         374         —     
                        

 

 

    

 

 

    

 

 

 

Total NetPlenish

                         $ 478         470         —     

Reply! Inc.(11)(13)(14)

     Internet Consumer & Business Services      Senior Secured      September 2015      Interest rate PRIME + 7.25% or Floor rate of 11.00%, PIK Interest 2.00%      $ 1,944         1,987         1,989   
     Internet Consumer & Business Services      Senior Secured      September 2015      Interest rate PRIME + 6.88% or Floor rate of 10.13%, PIK Interest 2.00%      $ 8,821         8,840         8,884   

 

See notes to consolidated financial statements.

 

12


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2014

(unaudited)

(dollars in thousands)

 

Portfolio Company

    

Sub-Industry

    

Type of
Investment(1)

    

      Maturity      
Date

    

    Interest Rate and Floor    

     Principal
Amount
     Cost(2)      Value(3)  
     Internet Consumer & Business Services      Senior Secured      February 2016      Interest rate PRIME + 7.25% or Floor rate of 10.50%, PIK Interest 2.00%      $ 3,046       $ 2,828       $ 2,887   
                        

 

 

    

 

 

    

 

 

 

Total Reply! Inc.

                         $ 13,811         13,655         13,760   

Vaultlogix(13)(14)(15)

     Internet Consumer & Business Services      Senior Secured      September 2016      Interest rate LIBOR + 8.50% or Floor rate of 10.00%, PIK Interest 2.50%      $ 7,999         7,961         7,961   
     Internet Consumer & Business Services      Senior Secured      September 2015      Interest rate LIBOR + 7.00% or Floor rate of 8.50%      $ 7,318         7,386         7,386   
                        

 

 

    

 

 

    

 

 

 

Total Vaultlogix

                         $ 15,317         15,347         15,347   

WaveMarket, Inc.(11)(14)

     Internet Consumer & Business Services      Senior Secured      March 2017      Interest rate PRIME + 6.50% or Floor rate of 9.75%      $ 402         402         402   
     Internet Consumer & Business Services      Senior Secured      September 2016      Interest rate PRIME + 5.75% or Floor rate of 9.50%      $ 10,000         9,961         9,747   
                        

 

 

    

 

 

    

 

 

 

Total WaveMarket, Inc.

                         $ 10,402         10,363         10,149   
                           

 

 

    

 

 

 

Subtotal: 1-5 Years Maturity

                              93,832         94,018   
                           

 

 

    

 

 

 

Subtotal: Internet Consumer & Business Services (15.67%)*

                         117,922         102,404   
                           

 

 

    

 

 

 

Media/Content/Info

                              

Under 1 Year Maturity

                              

Zoom Media and Marketing(13)

     Media/Content/Info      Senior Secured      December 2014      Interest rate PRIME + 5.25% or Floor rate of 8.50%      $ 4,000         3,896         3,807   
                           

 

 

    

 

 

 

Subtotal: Under 1 Year Maturity

                              3,896         3,807   
                           

 

 

    

 

 

 

1-5 Years Maturity

                              

Rhapsody International Inc.(15)

     Media/Content/Info      Senior Secured      April 2018     

Interest rate PRIME + 5.25% or Floor rate of 9.00%, PIK Interest 1.50%

     $ 20,000         19,383         19,383   

Zoom Media and Marketing(13)

     Media/Content/Info      Senior Secured      December 2015      Interest rate PRIME + 7.25% or Floor rate of 10.50%, PIK Interest 3.75%      $ 3,866         3,736         3,729   
                           

 

 

    

 

 

 

Subtotal: 1-5 Years Maturity

                              23,119         23,112   
                           

 

 

    

 

 

 

Subtotal: Media/Content/Info (4.12%)*

                              27,015         26,919   
                           

 

 

    

 

 

 

Medical Devices & Equipment

                              

Under 1 Year Maturity

                              

Oraya Therapeutics, Inc.(9)(11)(14)

     Medical Devices & Equipment      Senior Secured      December 2014      Interest rate FIXED 7.00%      $ 500         500         164   
                           

 

 

    

 

 

 

Subtotal: Under 1 Year Maturity

                              500         164   
                           

 

 

    

 

 

 

1-5 Years Maturity

                              

Baxano Surgical, Inc.(3)(14)

     Medical Devices & Equipment      Senior Secured      March 2017      Interest rate PRIME + 7.75% or Floor rate of 12.5%      $ 7,500         7,284         7,225   

Home Dialysis Plus(14)

     Medical Devices & Equipment      Senior Secured      April 2017      Interest rate PRIME + 6.35% or Floor rate of 9.60%      $ 10,000         9,804         9,640   

InspireMD, Inc.(3)(5)(10)(14)

     Medical Devices & Equipment      Senior Secured      February 2017      Interest rate PRIME + 5.00% or Floor rate of 10.50%      $ 10,000         9,791         9,791   

 

See notes to consolidated financial statements.

 

13


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2014

(unaudited)

(dollars in thousands)

 

Portfolio Company

    

Sub-Industry

    

Type of
Investment(1)

    

      Maturity      
Date

    

    Interest Rate and Floor    

     Principal
Amount
     Cost(2)      Value(3)  

Medrobotics Corporation(14)(15)

    

Medical Devices &

Equipment

     Senior Secured      March 2016      Interest rate PRIME + 7.85% or Floor rate of 11.10%      $ 4,109       $ 4,082       $ 4,049   

NetBio, Inc.

     Medical Devices & Equipment      Senior Secured      August 2017      Interest rate PRIME + 5.00% or Floor rate of 11.00%      $ 5,000         4,790         4,743   

NinePoint Medical, Inc.(14)(15)

     Medical Devices & Equipment      Senior Secured      January 2016      Interest rate PRIME + 5.85% or Floor rate of 9.10%      $ 5,291         5,301         5,236   

Oraya Therapeutics, Inc.(9)(11)(14)

     Medical Devices & Equipment      Senior Secured      September 2015     

Interest rate PRIME + 5.50% or Floor rate of 10.25%, PIK Interest 1.00%

     $ 6,132         6,069         4,380   

SonaCare Medical, LLC
(pka US HIFUM LLC)(11)(14)

     Medical Devices & Equipment      Senior Secured      April 2016      Interest rate PRIME + 7.75% or Floor rate of 11.00%      $ 5,167         5,307         5,390   

United Orthopedic Group, Inc.(14)

     Medical Devices & Equipment      Senior Secured      July 2016      Interest rate PRIME + 8.60% or Floor rate of 11.85%      $ 25,000         24,898         24,898   

ViewRay, Inc.(13)(15)

     Medical Devices & Equipment      Senior Secured      June 2017      Interest rate PRIME + 7.00% or Floor rate of 10.25%, PIK Interest 1.50%      $ 15,047         14,585         14,585   
                           

 

 

    

 

 

 

Subtotal: 1-5 Years Maturity

                              91,911         89,937   
                           

 

 

    

 

 

 

Subtotal: Medical Devices & Equipment (13.79%)*

                         92,411         90,101   
                           

 

 

    

 

 

 

Semiconductors

                              

Under 1 Year Maturity

                              

Achronix Semiconductor

     Semiconductors      Senior Secured      January 2015      Interest rate PRIME + 10.60% or Floor rate of 13.85%      $ 809       $ 804       $ 804   
                           

 

 

    

 

 

 

Subtotal: Under 1 Year Maturity

                              804         804   
                           

 

 

    

 

 

 

1-5 Years Maturity

                              

Avnera Corporation(14)

     Semiconductors      Senior Secured      April 2017      Interest rate PRIME + 5.75% or Floor rate of 9.00%      $ 5,000         4,924         4,924   

SiTime Corporation(14)(15)

     Semiconductors      Senior Secured      September 2016      Interest rate PRIME + 6.50% or Floor rate of 9.75%      $ 3,500         3,504         3,526   
                           

 

 

    

 

 

 

Subtotal: 1-5 Years Maturity

                              8,428         8,450   
                           

 

 

    

 

 

 

Subtotal: Semiconductors (1.42%)

                              9,232         9,254   
                           

 

 

    

 

 

 

Software

                              

Under 1 Year Maturity

                              

Clickfox, Inc.(15)

     Software      Senior Secured      September 2014      Interest rate PRIME + 6.75% or Floor rate of 10.00%      $ 2,000         1,987         1,973   

StartApp, Inc.(14)

     Software      Senior Secured      December 2014      Interest rate PRIME + 2.75% or Floor rate of 6.00%      $ 200         193         193   

Touchcommerce, Inc.(15)

     Software      Senior Secured      December 2014      Interest rate PRIME + 2.25% or Floor rate of 6.50%      $ 3,511         3,481         3,356   
                           

 

 

    

 

 

 

Subtotal: Under 1 Year Maturity

                              5,661         5,522   
                           

 

 

    

 

 

 

 

See notes to consolidated financial statements.

 

14


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2014

(unaudited)

(dollars in thousands)

 

Portfolio Company

    

Sub-Industry

    

Type of
Investment(1)

    

      Maturity      

Date

    

    Interest Rate and Floor    

     Principal
Amount
     Cost(2)      Value(3)  

1-5 Years Maturity

                              

Clickfox, Inc.(15)

     Software      Senior Secured      November 2015      Interest rate PRIME + 8.25% or Floor rate of 11.50%      $ 5,152       $ 4,911       $ 4,911   

Hillcrest Laboratories, Inc.(15)

     Software      Senior Secured      July 2015      Interest rate PRIME + 7.50% or Floor rate of 10.75%      $ 2,270         2,249         2,252   

Knowledge Adventure, Inc.(14)(15)

     Software      Senior Secured      March 2018      Interest rate PRIME + 8.25% or Floor rate of 11.50%      $ 11,750         11,598         11,598   

Mobile Posse, Inc.(14)(15)

     Software      Senior Secured      December 2016      Interest rate PRIME + 7.50% or Floor rate of 10.75%      $ 3,896         3,804         3,883   

Neos Geosolutions, Inc.(14)(15)

     Software      Senior Secured      May 2016      Interest rate PRIME + 5.75% or Floor rate of 10.50%      $ 3,427         3,488         3,427   

Sonian, Inc.(14)(15)

     Software      Senior Secured      July 2017      Interest rate PRIME + 7.00% or Floor rate of 10.25%      $ 5,500         5,362         5,362   

StartApp, Inc.

     Software      Senior Secured      March 2017      Interest rate PRIME + 7.75% or Floor rate of 11.00%      $ 3,500         3,521         3,554   

Touchcommerce, Inc.(15)

     Software      Senior Secured      June 2017      Interest rate PRIME + 6.00% or Floor rate of 10.25%      $ 5,000         4,690         4,840   
                           

 

 

    

 

 

 

Subtotal: 1-5 Years Maturity

                              39,623         39,827   
                           

 

 

    

 

 

 

Subtotal: Software (6.94%)*

                              45,284         45,349   
                           

 

 

    

 

 

 

Specialty Pharmaceuticals

                              

1-5 Years Maturity

                              

Cranford Pharmaceuticals, LLC(13)(14)(15)

     Specialty Pharmaceuticals      Senior Secured      February 2017      Interest rate LIBOR + 9.55% or Floor rate of 10.80%, PIK Interest 1.35%      $ 18,017         17,711         17,711   
     Specialty Pharmaceuticals      Senior Secured      August 2015      Interest rate LIBOR + 8.25% or Floor rate of 9.50%      $ 2,500         2,446         2,446   
                        

 

 

    

 

 

    

 

 

 

Total Cranford Pharmaceuticals, LLC

                         $ 20,517         20,157         20,157   

Rockwell Medical, Inc.(14)(15)

     Specialty Pharmaceuticals      Senior Secured      March 2017      Interest rate PRIME + 9.25% or Floor rate of 12.50%      $ 20,000         20,183         20,060   
                           

 

 

    

 

 

 

Subtotal: 1-5 Years Maturity

                              40,340         40,217   
                           

 

 

    

 

 

 

Subtotal: Specialty Pharmaceuticals (6.16%)*

                         40,340         40,217   
                           

 

 

    

 

 

 

Surgical Devices

                              

1-5 Years Maturity

                              

Transmedics, Inc.(11)(14)

     Surgical Devices      Senior Secured      November 2015      Interest rate FIXED 12.95%      $ 7,250         7,111         7,111   
                           

 

 

    

 

 

 

Subtotal: 1-5 Years Maturity

                              7,111         7,111   
                           

 

 

    

 

 

 

Subtotal: Surgical Devices (1.09%)*

                              7,111         7,111   
                           

 

 

    

 

 

 

Total Debt (122.20%)*

                              814,977         798,359   
                           

 

 

    

 

 

 

 

See notes to consolidated financial statements.

 

15


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2014

(unaudited)

(dollars in thousands)

 

Portfolio Company

 

Sub-Industry

 

Type of Investment(1)

 

Series

   Shares      Cost(2)      Value(3)  

Equity

              

Biotechnology Tools

              

NuGEN Technologies, Inc.(15)

  Biotechnology Tools   Equity   Preferred Series C      189,394       $ 500       $ 476   
           

 

 

    

 

 

 

Subtotal: Biotechnology Tools (0.07%)*

          500         476   
           

 

 

    

 

 

 

Energy Technology

              

SCIEnergy, Inc.

  Energy Technology   Equity   Preferred Series 1      385,000         761         29   
           

 

 

    

 

 

 

Subtotal: Energy Technology (0.00%)*

            761         29   
           

 

 

    

 

 

 

Communications & Networking

              

GlowPoint, Inc.(3)

  Communications & Networking   Equity   Common Stock      114,192         102         192   

Peerless Network, Inc.

  Communications & Networking   Equity   Preferred Series A      1,000,000         1,000         3,201   

Stoke, Inc.(15)

  Communications & Networking   Equity   Preferred Series E      152,905         500         215   
           

 

 

    

 

 

 

Subtotal: Communications & Networking (0.55%)*

          1,602         3,608   
           

 

 

    

 

 

 

Consumer & Business Products

              

Caivis Acquisition Corporation(15)

  Consumer & Business Products   Equity   Common Stock      295,861         819         597   

IPA Holdings, LLC

  Consumer & Business Products   Equity   LLC Interest      500,000         500         830   

Market Force Information, Inc.

  Consumer & Business Products   Equity   Preferred Series B      187,970         500         500   
           

 

 

    

 

 

 

Subtotal: Consumer & Business Products (0.30%)*

          1,819         1,927   
           

 

 

    

 

 

 

Diagnostic

              

Singulex, Inc.

  Diagnostic   Equity   Common Stock      937,998         750         750   
           

 

 

    

 

 

 

Subtotal: Diagnostic (0.11%)*

          750         750   
           

 

 

    

 

 

 

Drug Delivery

              

AcelRx Pharmaceuticals, Inc.(3)(10)(15)

  Drug Delivery   Equity   Common Stock      54,240         108         642   

Merrion Pharmceuticals, Plc(3)(5)(10)

  Drug Delivery   Equity   Common Stock      20,000         9         —     

Neos Therapeutics, Inc.(15)

  Drug Delivery   Equity   Preferred Series C      300,000         1,500         1,505   

Transcept Pharmaceuticals, Inc.(3)

  Drug Delivery   Equity   Common Stock      41,570         500         129   
           

 

 

    

 

 

 

Subtotal: Drug Delivery (0.35%)*

          2,117         2,276   
           

 

 

    

 

 

 

Drug Discovery & Development

              

Acceleron Pharma, Inc.(3)(15)

  Drug Discovery & Development   Equity   Common Stock      262,786         1,505         9,030   

Aveo Pharmaceuticals, Inc.(3)(10)(15)

  Drug Discovery & Development   Equity   Common Stock      167,864         841         251   

Dicerna Pharmaceuticals, Inc.(3)(15)

  Drug Discovery & Development   Equity   Common Stock      142,858         1,000         4,036   

Inotek Pharmaceuticals Corporation

  Drug Discovery & Development   Equity   Common Stock      15,334         1,500         —     

Merrimack Pharmaceuticals, Inc.(3)

  Drug Discovery & Development   Equity   Common Stock      848,591         3,213         4,122   

Paratek Pharmaceuticals, Inc.

  Drug Discovery & Development   Equity   Common Stock      2,882         5         —     
  Drug Discovery & Development   Equity   Preferred Series A      167,468         1,126         —     
        

 

 

    

 

 

    

 

 

 

Total Paratek Pharmaceuticals, Inc.

           170,350         1,131         —     
           

 

 

    

 

 

 

Subtotal: Drug Discovery & Development (2.67%)*

          9,190         17,439   
           

 

 

    

 

 

 

Information Services

              

Good Technologies, Inc. (pka Visto Corporation)(15)

  Information Services   Equity   Common Stock      500,000         604         —     
           

 

 

    

 

 

 

Subtotal: Information Services (0.00%)*

          604         —     
           

 

 

    

 

 

 

Internet Consumer & Business Services

              

Blurb, Inc.(15)

  Internet Consumer & Business Services   Equity   Preferred Series B      220,653         174         365   

Philotic, Inc.

  Internet Consumer & Business Services   Equity   Common Stock      8,121         93         —     

Progress Financial

  Internet Consumer & Business Services   Equity   Preferred Series G      218,351         250         267   

Trulia, Inc.(3)

  Internet Consumer & Business Services   Equity   Common Stock      29,340         141         951   
           

 

 

    

 

 

 

Subtotal: Internet Consumer & Business Services (0.25%)*

          658         1,583   
           

 

 

    

 

 

 

Media/Content/Info

              

Everyday Health, Inc. (pka Waterfront Media, Inc.)(3)

  Media/Content/Info   Equity   Common Stock      97,060         1,000         1,358   
           

 

 

    

 

 

 

Subtotal: Media/Content/Info (0.21%)*

          1,000         1,358   
           

 

 

    

 

 

 

Medical Devices & Equipment

              

Gelesis, Inc.(6)(15)

  Medical Devices & Equipment   Equity   LLC Interest      2,024,092         925         492   

Medrobotics Corporation(15)

  Medical Devices & Equipment   Equity   Preferred Series E      136,798         250         288   

Novasys Medical, Inc.

  Medical Devices & Equipment   Equity   Preferred Series D-1      4,118,444         1,000         —     

Optiscan Biomedical, Corp.(6)(15)

  Medical Devices & Equipment   Equity   Preferred Series B      6,185,567         3,000         440   
  Medical Devices & Equipment   Equity   Preferred Series C      1,927,309         655         145   
  Medical Devices & Equipment   Equity   Preferred Series D      41,352,489         3,945         4,211   
        

 

 

    

 

 

    

 

 

 

Total Optiscan Biomedical, Corp.

         49,465,365         7,600         4,796   
           

 

 

    

 

 

 

Subtotal: Medical Devices & Equipment (0.85%)*

            9,775         5,576   
           

 

 

    

 

 

 

 

See notes to consolidated financial statements.

 

16


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2014

(unaudited)

(dollars in thousands)

 

Portfolio Company

 

Sub-Industry

 

Type of Investment(1)

 

Series

   Shares      Cost(2)      Value(3)  

Software

              

Atrenta, Inc.

  Software   Equity   Preferred Series C      1,196,845       $ 986       $ 1,953   
  Software   Equity   Preferred Series D      635,513         508         1,151   
        

 

 

    

 

 

    

 

 

 

Total Atrenta, Inc.

           1,832,358         1,494         3,104   

Box, Inc.(15)

  Software   Equity   Preferred Series B      271,070         251         4,955   
  Software   Equity   Preferred Series C      589,844         872         10,782   
  Software   Equity   Preferred Series D      158,133         500         2,891   
  Software   Equity   Preferred Series D-1      186,766         1,694         3,414   
  Software   Equity   Preferred Series D-2      220,751         2,001         4,035   
  Software   Equity   Preferred Series E      38,183         500         698   
        

 

 

    

 

 

    

 

 

 

Total Box, Inc.

           1,464,747         5,818         26,775   

CapLinked, Inc.

  Software   Equity   Preferred Series A-3      53,614         51         88   

ForeScout Technologies, Inc.

  Software   Equity   Preferred Series D      319,099         398         940   

HighRoads, Inc.

  Software   Equity   Preferred Series B      190,170         307         300   
           

 

 

    

 

 

 

Subtotal: Software (4.78%)*

              8,068         31,207   
           

 

 

    

 

 

 

Specialty Pharmaceuticals

              

QuatRx Pharmaceuticals Company

  Specialty Pharmaceuticals   Equity   Preferred Series E      241,829         750         —     
  Specialty Pharmaceuticals   Equity   Preferred Series E-1      26,955         —           —     
  Specialty Pharmaceuticals   Equity   Preferred Series G      4,667,636         —           —     
        

 

 

    

 

 

    

 

 

 

Total QuatRx Pharmaceuticals Company

           4,936,420         750         —     
           

 

 

    

 

 

 

Subtotal: Specialty Pharmaceuticals (0.00%)*

            750         —     
           

 

 

    

 

 

 

Surgical Devices

              

Gynesonics, Inc.(15)

  Surgical Devices   Equity   Preferred Series B      219,298         250         78   
  Surgical Devices   Equity   Preferred Series C      656,538         282         129   
  Surgical Devices   Equity   Preferred Series D      1,621,553         580         804   
        

 

 

    

 

 

    

 

 

 

Total Gynesonics, Inc.

           2,497,389         1,112         1,011   

Transmedics, Inc.

  Surgical Devices   Equity   Preferred Series B      88,961         1,100         315   
  Surgical Devices   Equity   Preferred Series C      119,999         300         211   
  Surgical Devices   Equity   Preferred Series D      260,000         650         923   
        

 

 

    

 

 

    

 

 

 

Total Transmedics, Inc

           468,960         2,050         1,449   
           

 

 

    

 

 

 

Subtotal: Surgical Devices (0.38%)*

              3,162         2,460   
           

 

 

    

 

 

 

Total Equity (10.52%)*

              40,756         68,689   
           

 

 

    

 

 

 

Warrant

              

Biotechnology Tools

              

Labcyte, Inc.(15)

  Biotechnology Tools   Warrant   Preferred Series C      1,127,624         323         129   
           

 

 

    

 

 

 

Subtotal: Biotechnology Tools (0.02%)*

              323         129   
           

 

 

    

 

 

 

 

See notes to consolidated financial statements.

 

17


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2014

(unaudited)

(dollars in thousands)

 

Portfolio Company

 

Sub-Industry

 

Type of Investment(1)

 

Series

   Shares      Cost(2)      Value(3)  

Energy Technology

              

Agrivida, Inc.(15)

  Energy Technology   Warrant   Preferred Series C      77,447       $ 120       $ 285   

Alphabet Energy, Inc.(15)

  Energy Technology   Warrant   Preferred Series A      86,329         82         139   

American Superconductor Corporation(3)

  Energy Technology   Warrant   Common Stock      512,820         391         152   

Brightsource Energy, Inc.(15)

  Energy Technology   Warrant   Preferred Series 1      175,000         779         135   

Calera, Inc.(15)

  Energy Technology   Warrant   Preferred Series C      44,529         513         —     

EcoMotors, Inc.(15)

  Energy Technology   Warrant   Preferred Series B      437,500         308         498   

Fluidic, Inc.

  Energy Technology   Warrant   Preferred Series C      59,665         102         79   

Fulcrum Bioenergy, Inc.

  Energy Technology   Warrant   Preferred Series C-1      280,897         274         185   

Glori Energy, Inc.(12)

  Energy Technology   Warrant   Preferred Series C      145,932         165         54   

GreatPoint Energy, Inc.(15)

  Energy Technology   Warrant   Preferred Series D-1      393,212         548         —     

Polyera Corporation(15)

  Energy Technology   Warrant   Preferred Series C      161,575         69         48   

Propel Fuels(15)

  Energy Technology   Warrant   Preferred Series C      3,200,000         211         141   

SCIEnergy, Inc.

  Energy Technology   Warrant   Common Stock      530,811         181         —     
  Energy Technology   Warrant   Preferred Series 1      145,811         50         —     
        

 

 

    

 

 

    

 

 

 

Total SCI Energy, Inc.

           676,622         231         —     

Scifiniti (pka Integrated Photovoltaics, Inc.)(15)

  Energy Technology   Warrant   Preferred Series B      390,000         82         83   

Solexel, Inc.(15)

  Energy Technology   Warrant   Preferred Series C      1,171,625         1,162         553   

Stion Corporation(6)

  Energy Technology   Warrant   Preferred Series Seed      2,154         1,378         1,495   

TAS Energy, Inc.

  Energy Technology   Warrant   Preferred Series F      428,571         299         419   

TPI Composites, Inc.

  Energy Technology   Warrant   Preferred Series B      160         273         425   

Trilliant, Inc.(15)

  Energy Technology   Warrant   Preferred Series A      320,000         162         7   
           

 

 

    

 

 

 

Subtotal: Energy Technology (0.71%)*

              7,149         4,698   
           

 

 

    

 

 

 

Communications & Networking

              

Intelepeer, Inc.(15)

  Communications & Networking   Warrant   Preferred Series C      117,958         101         94   

OpenPeak, Inc.

  Communications & Networking   Warrant   Common Stock      108,982         149         174   

PeerApp, Inc.

  Communications & Networking   Warrant   Preferred Series B      298,779         61         46   

Peerless Network, Inc.

  Communications & Networking   Warrant   Preferred Series A      135,000         95         330   

Ping Identity Corporation

  Communications & Networking   Warrant   Preferred Series B      1,136,277         52         109   

Spring Mobile Solutions, Inc.

  Communications & Networking   Warrant   Preferred Series D      2,834,375         418         559   

Stoke, Inc.(15)

  Communications & Networking   Warrant   Preferred Series C      158,536         53         1   
  Communications & Networking   Warrant   Preferred Series D      118,181         65         1   
        

 

 

    

 

 

    

 

 

 

Total Stoke, Inc.

           276,717         118         2   
           

 

 

    

 

 

 

Subtotal: Communications & Networking (0.20%)*

            994         1,314   
           

 

 

    

 

 

 

Consumer & Business Products

              

Intelligent Beauty, Inc.(15)

  Consumer & Business Products   Warrant   Preferred Series B      190,234         230         708   

IPA Holdings, LLC

  Consumer & Business Products   Warrant   Common Stock      650,000         275         517   

Market Force Information, Inc.

  Consumer & Business Products   Warrant   Preferred Series A      99,286         24         30   
           

 

 

    

 

 

 

Subtotal: Consumer & Business Products (0.08%)*

            529         1,255   
           

 

 

    

 

 

 

Diagnostic

              

Navidea Biopharmaceuticals, Inc. (pka Neoprobe)(3)(15)

  Diagnostic   Warrant   Common Stock      333,333         244         108   
           

 

 

    

 

 

 

Subtotal: Diagnostic (0.02%)*

              244         108   
           

 

 

    

 

 

 

Drug Delivery

              

AcelRx Pharmaceuticals, Inc.(3)(10)(15)

  Drug Delivery   Warrant   Common Stock      176,730         786         983   

Alexza Pharmaceuticals, Inc.(3)

  Drug Delivery   Warrant   Common Stock      37,639         645         —     

BIND Therapeutics, Inc.(3)(15)

  Drug Delivery   Warrant   Common Stock      71,359         366         141   

Celsion Corporation(3)

  Drug Delivery   Warrant   Common Stock      97,493         227         210   

Dance Biopharm, Inc.(15)

  Drug Delivery   Warrant   Preferred Series A      97,701         74         159   

kaleo, Inc.

  Drug Delivery   Warrant   Preferred Series B      82,500         594         1,062   

Neos Therapeutics, Inc.(15)

  Drug Delivery   Warrant   Preferred Series C      60,000         113         113   

Revance Therapeutics, Inc.(3)

  Drug Delivery   Warrant   Common Stock      53,511         557         477   

Transcept Pharmaceuticals, Inc.(3)

  Drug Delivery   Warrant   Common Stock      61,452         87         2   
           

 

 

    

 

 

 

Subtotal: Drug Delivery (0.48%)*

              3,449         3,147   
           

 

 

    

 

 

 

 

See notes to consolidated financial statements.

 

18


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2014

(unaudited)

(dollars in thousands)

 

Portfolio Company

 

Sub-Industry

 

Type of Investment(1)

 

Series

   Shares      Cost(2)      Value(3)  

Drug Discovery & Development

              

Acceleron Pharma, Inc.(3)(15)

  Drug Discovery & Development   Warrant   Common Stock      11,611       $ 39       $ 249   

ADMA Biologics, Inc.(3)

  Drug Discovery & Development   Warrant   Common Stock      66,550         218         170   

Anthera Pharmaceuticals, Inc.(3)(15)

  Drug Discovery & Development   Warrant   Common Stock      40,178         984         4   

Cempra, Inc.(3)

  Drug Discovery & Development   Warrant   Common Stock      138,797         458         604   

Chroma Therapeutics, Ltd.(5)(10)

  Drug Discovery & Development   Warrant   Preferred Series D      325,261         490         500   

Cleveland BioLabs, Inc.(3)(15)

  Drug Discovery & Development   Warrant   Common Stock      156,250         105         31   

Concert Pharmaceuticals, Inc.(3)

  Drug Discovery & Development   Warrant   Common Stock      70,796         367         202   

Coronado Biosciences, Inc.(3)

  Drug Discovery & Development   Warrant   Common Stock      73,009         142         44   

Dicerna Pharmaceuticals, Inc.(3)(15)

  Drug Discovery & Development   Warrant   Common Stock      200         28         —     

Horizon Pharma, Inc.(3)

  Drug Discovery & Development   Warrant   Common Stock      22,408         231         46   

uniQure B.V.(3)(5)(10)

  Drug Discovery & Development   Warrant   Common Stock      37,174         218         202   
           

 

 

    

 

 

 

Subtotal: Drug Discovery & Development (0.31%)*

            3,280         2,052   
           

 

 

    

 

 

 

Electronics & Computer Hardware

              

Clustrix, Inc.

  Electronics & Computer Hardware   Warrant   Common Stock      50,000         12         18   

Identive Group, Inc.(3)

  Electronics & Computer Hardware   Warrant   Common Stock      992,084         247         467   
           

 

 

    

 

 

 

Subtotal: Electronics & Computer Hardware (0.07%)*

            259         485   
           

 

 

    

 

 

 

Healthcare Services, Other

              

MDEverywhere, Inc.

  Healthcare Services, Other   Warrant   Common Stock      129         94         33   
           

 

 

    

 

 

 

Subtotal: Healthcare Services, Other (0.01%)*

            94         33   
           

 

 

    

 

 

 

Information Services

              

Cha Cha Search, Inc.(15)

  Information Services   Warrant   Preferred Series G      48,232         59         10   

InXpo, Inc.(15)

  Information Services   Warrant   Preferred Series C      648,400         98         30   
  Information Services   Warrant   Preferred Series C-1      582,015         49         27   
        

 

 

    

 

 

    

 

 

 

Total InXpo, Inc.

           1,230,415         147         57   

Jab Wireless, Inc.(15)

  Information Services   Warrant   Preferred Series A      266,567         265         282   

RichRelevance, Inc.(15)

  Information Services   Warrant   Preferred Series E      112,612         98         —     
           

 

 

    

 

 

 

Subtotal: Information Services (0.16%)*

              569         349   
           

 

 

    

 

 

 

Internet Consumer & Business Services

              

Blurb, Inc.(15)

  Internet Consumer & Business Services   Warrant   Preferred Series B      218,684         299         108   
  Internet Consumer & Business Services   Warrant   Preferred Series C      234,280         636         183   
        

 

 

    

 

 

    

 

 

 

Total Blurb, Inc.

           452,964         935         291   

CashStar, Inc.(15)

  Internet Consumer & Business Services   Warrant   Preferred Series C-2      727,272         130         70   

Gazelle, Inc.(15)

  Internet Consumer & Business Services   Warrant   Preferred Series D      151,827         165         —     

Just Fabulous, Inc.

  Internet Consumer & Business Services   Warrant   Preferred Series B      137,456         589         1,095   

Prism Education Group, Inc.(15)

  Internet Consumer & Business Services   Warrant   Preferred Series B      200,000         43         —     

Progress Financial

  Internet Consumer & Business Services   Warrant   Preferred Series G      174,562         77         53   

Reply! Inc.

  Internet Consumer & Business Services   Warrant   Preferred Series B      137,225         320         144   

ShareThis, Inc.(15)

  Internet Consumer & Business Services   Warrant   Preferred Series C      493,502         547         250   

Tectura Corporation

  Internet Consumer & Business Services   Warrant   Preferred Series B-1      253,378         51         —     

WaveMarket, Inc.

  Internet Consumer & Business Services   Warrant   Preferred Series B-1      1,083,779         106         74   
           

 

 

    

 

 

 

Subtotal: Internet Consumer & Business Services (0.30%)

            2,963         1,977   
           

 

 

    

 

 

 

Media/Content/Info

              

Everyday Health, Inc. (pka Waterfront Media, Inc.)(3)

  Media/Content/Info   Warrant   Common Stock      73,345         60         500   

Glam Media, Inc.(15)

  Media/Content/Info   Warrant   Preferred Series D      407,457         482         —     

Rhapsody International Inc.(15)

  Media/Content/Info   Warrant   Common Stock      715,755         384         385   

Zoom Media and Marketing

  Media/Content/Info   Warrant   Preferred Series A      1,204         348         285   
           

 

 

    

 

 

 

Subtotal: Media/Content/Info (0.18%)*

              1,274         1,170   
           

 

 

    

 

 

 

 

See notes to consolidated financial statements.

 

19


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2014

(unaudited)

(dollars in thousands)

 

Portfolio Company

 

Sub-Industry

 

Type of Investment(1)

 

Series

   Shares      Cost(2)      Value(3)  

Medical Devices & Equipment

              

Baxano Surgical, Inc.(3)

  Medical Devices & Equipment   Warrant   Common Stock      882,353       $ 440       $ 319   

Gelesis, Inc.(6)(15)

  Medical Devices & Equipment   Warrant   LLC Interest      263,688         78         5   

Home Dialysis Plus

  Medical Devices & Equipment   Warrant   Preferred Series A      300,000         245         313   

InspireMD, Inc.(3)(5)(10)

  Medical Devices & Equipment   Warrant   Common Stock      168,351         242         221   

Medrobotics Corporation(15)

  Medical Devices & Equipment   Warrant   Preferred Series E      455,539         370         339   

MELA Sciences, Inc.(3)

  Medical Devices & Equipment   Warrant   Common Stock      693,202         401         82   

NetBio, Inc.

  Medical Devices & Equipment   Warrant   Common Stock      2,568         408         243   

NinePoint Medical, Inc.(15)

  Medical Devices & Equipment   Warrant   Preferred Series A-1      587,840         170         253   

Novasys Medical, Inc.

  Medical Devices & Equipment   Warrant   Common Stock      109,449         2         —     
  Medical Devices & Equipment   Warrant   Preferred Series D      526,840         125         —     
  Medical Devices & Equipment   Warrant   Preferred Series D-1      53,607         6         —     
        

 

 

    

 

 

    

 

 

 

Total Novasys Medical, Inc.

           689,896         133         —     

Optiscan Biomedical, Corp.(6)(15)

  Medical Devices & Equipment   Warrant   Preferred Series D      10,535,275         1,252         235   

Oraya Therapeutics, Inc.

  Medical Devices & Equipment   Warrant   Common Stock      95,498         66         —     
  Medical Devices & Equipment   Warrant   Preferred Series C-1      716,948         676         —     
        

 

 

    

 

 

    

 

 

 

Total Oraya Therapeutics, Inc.

           812,446         742         —     

SonaCare Medical, LLC (pka US HIFUM LLC)

  Medical Devices & Equipment   Warrant   Preferred Series A      409,704         188         214   

United Orthopedic Group, Inc.

  Medical Devices & Equipment   Warrant   Preferred Series A      423,076         608         820   

ViewRay, Inc.(15)

  Medical Devices & Equipment   Warrant   Preferred Series C      312,500         333         340   
           

 

 

    

 

 

 

Subtotal: Medical Devices & Equipment (0.52%)*

            5,610         3,384   
           

 

 

    

 

 

 

Semiconductors

              

Achronix Semiconductor Corporation

  Semiconductors   Warrant   Preferred Series C      360,000         160         189   

Avnera Corporation

  Semiconductors   Warrant   Preferred Series E      102,958         14         14   

SiTime Corporation(15)

  Semiconductors   Warrant   Preferred Series G      195,683         23         7   
           

 

 

    

 

 

 

Subtotal: Semiconductors (0.03%)*

              197         210   
           

 

 

    

 

 

 

Software

              

Atrenta, Inc.

  Software   Warrant   Preferred Series D      392,670         121         361   

Braxton Technologies, LLC

  Software   Warrant   Preferred Series A      168,750         188         —     

Central Desktop, Inc.(15)

  Software   Warrant   Preferred Series B      522,769         108         289   

Clickfox, Inc.(15)

  Software   Warrant   Preferred Series B      1,038,563         329         523   
  Software   Warrant   Preferred Series C      592,019         730         380   
        

 

 

    

 

 

    

 

 

 

Total Clickfox, Inc.

           1,630,582         1,059         903   

Daegis Inc. (pka Unify Corporation)(3)(15)

  Software   Warrant   Common Stock      718,860         1,434         99   

ForeScout Technologies, Inc.

  Software   Warrant   Preferred Series E      80,587         41         116   

Hillcrest Laboratories, Inc.(15)

  Software   Warrant   Preferred Series E      1,865,650         55         153   

Knowledge Adventure, Inc.(15)

  Software   Warrant   Preferred Series E      550,781         15         15   

Mobile Posse, Inc.(15)

  Software   Warrant   Preferred Series C      396,430         129         118   

Neos Geosolutions, Inc.(15)

  Software   Warrant   Preferred Series 3      221,150         22         —     

Sonian, Inc.(15)

  Software   Warrant   Preferred Series C      185,949         106         83   

SugarSync, Inc.(15)

  Software   Warrant   Preferred Series CC      332,726         78         101   
  Software   Warrant   Preferred Series DD      107,526         34         34   
        

 

 

    

 

 

    

 

 

 

Total SugarSync, Inc.

           440,252         112         135   

Touchcommerce, Inc.(15)

  Software   Warrant   Preferred Series E      992,595         252         187   

White Sky, Inc.(15)

  Software   Warrant   Preferred Series B-2      124,295         54         1   

WildTangent, Inc.(15)

  Software   Warrant   Preferred Series 3      100,000         238         61   
           

 

 

    

 

 

 

Subtotal: Software (0.39%)*

              3,934         2,521   
           

 

 

    

 

 

 

 

See notes to consolidated financial statements.

 

20


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

March 31, 2014

(unaudited)

(dollars in thousands)

 

Portfolio Company

 

Sub-Industry

 

Type of Investment(1)

 

Series

   Shares      Cost(2)      Value(3)  

Specialty Pharmaceuticals

              

QuatRx Pharmaceuticals Company

  Specialty Pharmaceuticals   Warrant   Preferred Series      155,324       $ 307       $ —     
           

 

 

    

 

 

 

Subtotal: Specialty Pharmaceuticals (0.00%)*

            307         —     
           

 

 

    

 

 

 

Surgical Devices

              

Gynesonics, Inc.(15)

  Surgical Devices   Warrant   Preferred Series C      180,480         75         29   
  Surgical Devices   Warrant   Preferred Series D      1,575,965         320         406   
        

 

 

    

 

 

    

 

 

 

Total Gynesonics, Inc.

           1,756,445         395         435   

Transmedics, Inc.

  Surgical Devices   Warrant   Preferred Series B      40,436         225         7   
  Surgical Devices   Warrant   Preferred Series D      175,000         100         340   
        

 

 

    

 

 

    

 

 

 

Total Transmedics, Inc.

           215,436         325         347   
           

 

 

    

 

 

 

Subtotal: Surgical Devices (0.12%)*

              720         782   
           

 

 

    

 

 

 

Total Warrant (3.60%)*

              31,895         23,614   
           

 

 

    

 

 

 

Total Investments (136.32%)*

            $ 887,628       $ 890,662   
           

 

 

    

 

 

 

 

* Value as a percent of net assets
(1) Preferred and common stock, warrants, and equity interests are generally non-income producing.
(2) Gross unrealized appreciation, gross unrealized depreciation, and net depreciation for federal income tax purposes totaled $47.2 million, $45.8 million and $1.4 million respectively. The tax cost of investments is $885.7 million.
(3) Except for warrants in twenty-four publicly traded companies and common stock in ten publicly traded companies, all investments are restricted at March 31, 2014 and were valued at fair value as determined in good faith by the Valuation Committee of the Board of Directors. No unrestricted securities of the same issuer are outstanding. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies.
(4) Debt investments of this portfolio company have been pledged as collateral under the Wells Facility.
(5) Non-U.S. company or the company’s principal place of business is outside the United States.
(6) Affiliate investment that is defined under the Investment Company Act of 1940 as companies in which HTGC owns at least 5% but not more than 25% of the voting securities of the company.
(7) Control investment that is defined under the Investment Company Act of 1940 as companies in which HTGC owns at least 25% of the voting securities of the company or has greater than 50% representation on its board.
(8) Debt is on non-accrual status at March 31, 2014, and is therefore considered non-income producing.
(9) Denotes that all or a portion of the debt investment is convertible senior debt.
(10) Indicates assets that the Company deems not “qualifying assets” under section 55(a) of the Investment Company Act of 1940, as amended. Qualifying assets must represent at least 70% of the Company’s total assets at the time of acquisition of any additional non-qualifying assets.
(11) Denotes that all or a portion of the debt investment secures the notes offered in the Debt Securitization (as defined in Note 4).
(12) Subsequent to March 31, 2014, this company completed a reverse merger. Note that the March 31, 2014 fair value does not reflect any potential impact of the conversion of our preferred shares to the new entity.
(13) Denotes that all or a portion of the debt investment principal includes accumulated PIK, or paid-in-kind, interest and is net of repayments.
(14) Denotes that all or a portion of the debt investment includes an exit fee receivable.
(15) Denotes that all or a portion of the investment in this portfolio company is held by HT II or HT III, the Company’s wholly-owned SBIC subsidiaries.

 

See notes to consolidated financial statements.

 

21


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

(dollars in thousands)

 

Portfolio Company

 

Sub-Industry

  Type of
Investment(1)
   

Maturity
Date

 

Interest Rate and Floor

  Principal
Amount
    Cost(2)     Value(3)  

Debt

  

 

Biotechnology Tools

  

 

1-5 Years Maturity

  

 

Labcyte, Inc.(11)

  Biotechnology Tools     Senior Secured      June 2016   Interest rate PRIME + 6.70% or Floor rate of 9.95%   $ 4,270      $     4,323      $     4,289   
           

 

 

   

 

 

 

Subtotal: 1-5 Years Maturity

  

    4,323        4,289   
           

 

 

   

 

 

 

Subtotal: Biotechnology Tools (0.66%)*

  

    4,323        4,289   
           

 

 

   

 

 

 

Energy Technology

  

 

Under 1 Year Maturity

  

 

American Superconductor Corporation(3)(11)

 

Energy Technology

    Senior Secured      December 2014   Interest rate PRIME + 7.25% or Floor rate of 11.00%   $ 4,615        4,991        4,991   

Brightsource Energy, Inc.

 

Energy Technology

    Senior Secured      January 2014   Interest rate Prime + 8.25% or Floor rate of 11.50%   $ 15,000        15,886        15,886   

Enphase Energy, Inc.(11)

 

Energy Technology

    Senior Secured      June 2014   Interest rate PRIME + 5.75% or Floor rate of 9.00%   $ 1,315        1,358        1,358   
           

 

 

   

 

 

 

Subtotal: Under 1 Year Maturity

  

    22,236        22,236   
           

 

 

   

 

 

 

1-5 Years Maturity

  

 

Agrivida, Inc.

 

Energy Technology

    Senior Secured      December 2016   Interest rate PRIME + 6.75% or Floor rate of 10.00%   $ 6,000        5,887        5,770   

American Superconductor Corporation(3)(11)

 

Energy Technology

    Senior Secured      November 2016   Interest rate PRIME + 7.25% or Floor rate of 11.00%   $ 10,000        9,801        9,801   

APTwater, Inc

 

Energy Technology

    Senior Secured      April 2017   Interest rate PRIME + 6.75% or Floor rate of 10.00%, PIK Interest 2.75%   $ 18,085        17,874        17,874   

BioAmber, Inc.(5)(10)

 

Energy Technology

    Senior Secured      June 2016   Interest rate PRIME + 6.75% or Floor rate of 10.00%   $ 25,000        25,298        25,798   

Enphase Energy, Inc.(11)

 

Energy Technology

    Senior Secured      August 2016   Interest rate PRIME + 8.25% or Floor rate of 11.50%   $ 7,400        7,422        7,314   

Fluidic, Inc.

 

Energy Technology

    Senior Secured      March 2016   Interest rate PRIME + 8.00% or Floor rate of 11.25%   $ 5,000        4,922        4,922   

Fulcrum Bioenergy, Inc.(11)

 

Energy Technology

    Senior Secured      November 2016   Interest rate PRIME + 7.75% or Floor rate of 11.00%   $ 10,000        9,944        9,694   

Glori Energy, Inc.(11)

 

Energy Technology

    Senior Secured      June 2015   Interest rate PRIME + 6.75% or Floor rate of 10.00%   $ 5,333        5,457        5,414   

Polyera Corporation

 

Energy Technology

    Senior Secured      June 2016   Interest rate PRIME + 6.75% or Floor rate of 10.00%   $ 5,809        5,797        5,686   

SCIEnergy, Inc.(4)

 

Energy Technology

    Senior Secured      September 2015   Interest rate PRIME + 8.75% or Floor rate of 12.00%   $ 4,448        4,596        4,685   

Scifiniti (pka Integrated Photovoltaics, Inc.)

 

Energy Technology

    Senior Secured      February 2015   Interest rate PRIME + 7.38% or Floor rate of 10.63%   $ 1,463        1,443        1,429   

Stion Corporation.(4)(6)

 

Energy Technology

    Senior Secured      February 2015   Interest rate PRIME + 6.75% or Floor rate of 10.00%   $ 4,571        4,005        4,096   

TAS Energy, Inc.

 

Energy Technology

    Senior Secured      February 2015   Interest rate PRIME + 7.75% or Floor rate of 11.00%   $ 15,000        15,277        15,421   
 

Energy Technology

    Senior Secured      February 2015   Interest rate PRIME + 6.25% or Floor rate of 9.50%   $ 4,503        4,374        4,338   
           

 

 

   

 

 

 

Total TAS Energy, Inc.

  

    19,651        19,760   

TPI Composites, Inc.

 

Energy Technology

    Senior Secured      June 2016   Interest rate PRIME + 8.00% or Floor rate of 11.25%   $ 15,000        14,888        14,889   
           

 

 

   

 

 

 

Subtotal: 1-5 Years Maturity

  

    136,985        137,131   
           

 

 

   

 

 

 

Subtotal: Energy Technology (24.52%)*(13)

  

    159,221        159,367   
           

 

 

   

 

 

 

 

See notes to consolidated financial statements.

 

22


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

(dollars in thousands)

 

Portfolio Company

 

Sub-Industry

  Type of
Investment(1)
 

Maturity
Date

 

Interest Rate and Floor

  Principal
Amount
    Cost(2)     Value(3)  

Communications & Networking

  

 

1-5 Years Maturity

             

OpenPeak, Inc.(11)

  Communications & Networking   Senior Secured   July 2015   Interest rate PRIME + 8.75% or Floor rate of 12.00%   $ 10,029      $ 10,714      $ 10,814   

Spring Mobile Solutions, Inc.

  Communications & Networking   Senior Secured   November 2016   Interest rate PRIME + 8.00% or Floor rate of 11.25%   $ 20,000        19,682        19,875   
           

 

 

   

 

 

 

Subtotal: 1-5 Years Maturity

  

    30,396        30,690   
           

 

 

   

 

 

 

Subtotal: Communications & Networking (4.72%)*

  

    30,396        30,690   
           

 

 

   

 

 

 

Drug Delivery

  

 

1-5 Years Maturity

  

 

AcelRx Pharmaceuticals, Inc.(3)(10)

  Drug Delivery   Senior Secured   October 2017   Interest rate PRIME + 3.85% or Floor rate of 9.10%   $ 15,000        14,556        15,006   

BIND Therapeutics, Inc.(3)

  Drug Delivery   Senior Secured   September 2016   Interest rate Prime + 7.00% or Floor rate of 10.25%   $ 4,500        4,407        4,458   

Celsion Corporation(3)

  Drug Delivery   Senior Secured   June 2017   Interest rate Prime + 8.00% or Floor rate of 11.25%   $ 5,000        4,897        4,897   

Dance Biopharm, Inc.

  Drug Delivery   Senior Secured   August 2017   Interest rate PRIME + 7.4% or Floor rate of 10.65%   $ 1,000        974        974   

Intelliject, Inc.(11)

  Drug Delivery   Senior Secured   June 2016   Interest rate PRIME + 5.75% or Floor rate of 11.00%   $ 15,000        15,150        15,450   

NuPathe, Inc.(3)

  Drug Delivery   Senior Secured   May 2016   Interest rate Prime - 3.25% or Floor rate of 9.85%   $ 5,749        5,629        5,744   

Revance Therapeutics, Inc.

  Drug Delivery   Senior Secured   March 2015   Interest rate PRIME + 6.60% or Floor rate of 9.85%   $ 9,798        10,032        9,943   
  Drug Delivery   Senior Secured   March 2015   Interest rate PRIME + 6.60% or Floor rate of 9.85%   $ 980        1,011        994   

Total Revance Therapeutics, Inc.

  

    11,043        10,937   
           

 

 

   

 

 

 

Subtotal: 1-5 Years Maturity

  

    56,655        57,466   
           

 

 

   

 

 

 

Subtotal: Drug Delivery (8.84%)*

  

    56,655        57,466   
           

 

 

   

 

 

 

Drug Discovery & Development

  

 

1-5 Years Maturity

  

 

ADMA Biologics, Inc.(3)

  Drug Discovery & Development   Senior Secured   April 2016   Interest rate Prime + 2.75% or Floor rate of 8.50%   $ 5,000        4,956        4,892   

Anacor Pharmaceuticals, Inc.

  Drug Discovery & Development   Senior Secured   July 2017   Interst rate PRIME + 6.40% or Floor rate of 11.65%   $ 30,000        29,083        29,810   

Aveo Pharmaceuticals, Inc.(3)(10)(11)

  Drug Discovery & Development   Senior Secured   September 2015   Interest rate PRIME + 7.15% or Floor rate of 11.90%   $ 19,396        19,396        19,590   

Cell Therapeutics, Inc.(3)(11)

  Drug Discovery & Development   Senior Secured   October 2016   Interest rate Prime + 9.00% or Floor rate of 12.25%   $ 15,000        14,750        15,200   

Cempra, Inc.(3)(11)

  Drug Discovery & Development   Senior Secured   June 2017   Interest rate PRIME + 6.30% or Floor rate of 9.55%   $ 15,000        14,795        14,550   

Cleveland BioLabs, Inc.(3)

  Drug Discovery & Development   Senior Secured   January 2017   Interest rate PRIME + 6.20% or Floor rate of 10.45%   $ 6,000        5,909        5,909   

Concert Pharmaceuticals, Inc.(4)

  Drug Discovery & Development   Senior Secured   October 2015   Interest rate PRIME + 3.25% or Floor rate of 8.50%   $ 15,091        14,933        14,649   

Coronado Biosciences, Inc.(3)(11)

  Drug Discovery & Development   Senior Secured   March 2016   Interest rate PRIME + 6.00% or Floor rate of 9.25%   $ 13,654        13,720        13,449   

Dicerna Pharmaceuticals, Inc.

  Drug Discovery & Development   Senior Secured   January 2015   Interest rate PRIME + 4.40% or Floor rate of 10.15%   $ 5,026        4,991        4,981   

Insmed, Incorporated(11)

  Drug Discovery & Development   Senior Secured   January 2016   Interest rate PRIME + 4.75% or Floor rate of 9.25%   $ 20,000        19,708        19,535   

Merrimack Pharmaceuticals, Inc.(3)

  Drug Discovery & Development   Senior Secured   November 2016   Interest rate PRIME + 5.30% or Floor rate of 10.55%   $ 40,000        40,314        39,455   

Neuralstem, Inc.(3)

  Drug Discovery & Development   Senior Secured   June 2016   Interest rate PRIME + 7.75% or Floor rate of 11.00%   $ 8,000        7,874        8,035   

 

See notes to consolidated financial statements.

 

23


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

(dollars in thousands)

 

Portfolio Company

 

Sub-Industry

  Type of
Investment(1)
 

Maturity
Date

 

Interest Rate and Floor

  Principal
Amount
    Cost(2)     Value(3)  

Paratek Pharmaceuticals, Inc.

  Drug Discovery & Development   Senior Secured   N/A   Interest rate Fixed 10.00%   $ 36      $ 36      $   
  Drug Discovery & Development   Senior Secured   N/A   Interest rate Fixed 10.00%   $ 45        45          
  Drug Discovery & Development   Senior Secured   N/A   N/A   $ 28        28          
         

 

 

   

 

 

   

 

 

 

Total Paratek Pharmaceuticals, Inc.

  $ 109        109          

uniQure B.V.(5)(10)(11)

  Drug Discovery & Development   Senior Secured   October 2016   Interest rate PRIME + 8.60% or Floor rate of 11.85%   $ 10,000        9,695        9,818   
         

 

 

   

 

 

   

 

 

 

Subtotal: 1-5 Years Maturity

  

    200,232        199,872   
           

 

 

   

 

 

 

Subtotal: Drug Discovery & Development (30.75%)*

  

    200,232        199,872   
           

 

 

   

 

 

 

Electronics & Computer Hardware

  

 

1-5 Years Maturity

  

 

Clustrix, Inc.

  Electronics & Computer Hardware   Senior Secured   December 2015   Interest rate PRIME + 6.50% or Floor rate of 9.75%   $ 524        526        526   

Identive Group, Inc.(3)(11)

  Electronics & Computer Hardware   Senior Secured   November 2015   Interest rate PRIME + 7.75% or Floor rate of 11.00%   $ 5,938        5,696        5,755   

OCZ Technology Group, Inc.

  Electronics & Computer Hardware   Senior Secured   April 2016   Interest rate Prime + 8.75% or Floor rate of 12.50%, PIK Interest 3.00%   $ 1,221        1,221        1,221   

Plures Technologies, Inc.(3)

  Electronics & Computer Hardware   Senior Secured   October 2016   Interest rate Prime + 12.75% or Floor rate of 16.00%, PIK Interest 4.00%   $ 2,046        1,958        1,458   
           

 

 

   

 

 

 

Subtotal: 1-5 Years Maturity

  

    9,400        8,959   
           

 

 

   

 

 

 

Subtotal: Electronics & Computer Hardware (1.38%)*

  

    9,400        8,959   
           

 

 

   

 

 

 

Healthcare Services, Other

  

 

1-5 Years Maturity

  

 

InstaMed Communications, LLC

  Healthcare Services, Other   Senior Secured   December 2016   Interest rate PRIME + 7.25% or Floor rate of 10.50%   $ 3,000        2,979        2,979   

MDEverywhere, Inc.

  Healthcare Services, Other   Senior Secured   June 2016   Interest rate LIBOR + 9.50% or Floor rate of 10.75%   $ 2,000        1,875        1,907   

Orion Healthcorp, Inc.

  Healthcare Services, Other   Senior Secured   June 2017   Interest rate LIBOR + 10.50% or Floor rate of 12.00%, PIK Interest 3.00%   $ 6,591        6,467        6,413   
  Healthcare Services, Other   Senior Secured   June 2017   Interest rate LIBOR + 9.50% or Floor rate of 11.00%   $ 9,000        8,838        8,445   
  Healthcare Services, Other   Senior Secured   June 2016   Interest rate LIBOR + 8.25% or Floor rate of 9.50%   $ 500        465        461   
         

 

 

   

 

 

   

 

 

 

Total Orion Healthcorp, Inc.

  $ 16,091        15,769        15,318   

Pacific Child & Family Associates, LLC

  Healthcare Services, Other   Senior Secured   January 2015   Interest rate LIBOR + 9.00% or Floor rate of 11.50%   $ 1,946        2,017        1,988   
  Healthcare Services, Other   Senior Secured   January 2015   Interest rate LIBOR + 11.00% or Floor rate of 14.00%, PIK interest 3.75%   $ 6,836        6,867        6,833   
         

 

 

   

 

 

   

 

 

 

Total Pacific Child & Family Associates, LLC

  $ 8,782        8,884        8,822   
           

 

 

   

 

 

 

Subtotal: 1-5 Years Maturity

  

    29,508        29,025   
           

 

 

   

 

 

 

Subtotal: Healthcare Services, Other (4.47%)*

  

    29,508        29,025   
           

 

 

   

 

 

 

 

See notes to consolidated financial statements.

 

24


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

(dollars in thousands)

 

Portfolio Company

 

Sub-Industry

  Type of
Investment(1)
 

Maturity
Date

 

Interest Rate and Floor

  Principal
Amount
    Cost(2)     Value(3)  

Information Services

  

   

1-5 Years Maturity

  

   

Eccentex Corporation(11)

  Information Services   Senior Secured   May 2015   Interest rate PRIME + 7.00% or Floor rate of 10.25%   $ 657      $ 658      $ 185   

InXpo, Inc.

  Information Services   Senior Secured   April 2016   Interest rate PRIME + 7.50% or Floor rate of 10.75%   $ 2,550        2,489        2,384   

Jab Wireless, Inc.

  Information Services   Senior Secured   November 2017   Interest rate Libor + 6.75% or Floor rate of 8.00%   $ 30,000        29,822        29,822   
  Information Services   Senior Secured   November 2017   Interest rate Prime + 6.75% or Floor rate of 8.00%   $ 2,000        1,996        1,996   
         

 

 

   

 

 

   

 

 

 

Total Jab Wireless, Inc.

  $ 32,000        31,818        31,818   

Womensforum.com(11)

  Information Services   Senior Secured   October 2016   Interest rate LIBOR + 7.50% or Floor rate of 10.25%, PIK Interest 2.00%   $ 4,607        4,536        4,127   
  Information Services   Senior Secured   October 2016   Interest rate LIBOR + 6.50% or Floor rate of 9.25%   $ 6,900        6,793        6,470   
  Information Services   Senior Secured   April 2015   Interest rate LIBOR + 6.50% or Floor rate of 9.00%   $ 1,250        1,227        1,156   
         

 

 

   

 

 

   

 

 

 

Total Womensforum.com

  $ 12,757        12,556        11,754   
           

 

 

   

 

 

 

Subtotal: 1-5 Years Maturity

  

    47,521        46,140   
           

 

 

   

 

 

 

Subtotal: Information Services (7.10%)*

  

    47,521        46,140   
           

 

 

   

 

 

 

Internet Consumer & Business Services

  

   

Under 1 Year Maturity

  

   

Gazelle, Inc.

  Internet Consumer & Business Services   Senior Secured   October 2014   Interest rate PRIME + 6.50% or Floor rate of 9.75%   $ 2,137        2,115        2,115   

Tectura Corporation(8)

  Internet Consumer & Business Services   Senior Secured  

May 2014

  Interest rate LIBOR + 10.00% or Floor rate of 13.00%   $ 6,468        6,467        3,566   
  Internet Consumer & Business Services   Senior Secured  

May 2014

  Interest rate LIBOR + 8.00% or Floor rate of 11.00%, PIK Interest 1.00%   $ 10,777        10,777        5,943   
  Internet Consumer & Business Services   Senior Secured  

May 2014

  Interest rate LIBOR + 10.00% or Floor rate of 13.00%   $ 563        563        310   
  Internet Consumer & Business Services   Senior Secured  

May 2014

  Interest rate LIBOR + 10.00% or Floor rate of 13.00%   $ 5,000        5,000        2,757   
         

 

 

   

 

 

   

 

 

 

Total Tectura Corporation

  $ 22,807        22,806        12,576   
           

 

 

   

 

 

 

Subtotal: Under 1 Year Maturity

  

    24,921        14,691   
           

 

 

   

 

 

 

1-5 Years Maturity

  

   

Blurb, Inc.

  Internet Consumer & Business Services   Senior Secured   December 2015   Interest rate PRIME + 5.25% or Floor rate of 8.50%   $ 6,351        6,216        6,054   

CashStar, Inc.

  Internet Consumer & Business Services   Senior Secured   June 2016   Interest rate Prime + 6.25% or Floor rate 10.50%, PIK Interest 1.00%   $ 4,018        3,944        3,916   

Education Dynamics, LLC

  Internet Consumer & Business Services   Senior Secured   March 2016   Interest rate Libor + 12.5% or Floor rate 12.50%, PIK Interest 1.5%   $ 24,685        24,284        23,582   

Gazelle, Inc.

  Internet Consumer & Business Services   Senior Secured   April 2016   Interest rate Prime + 7.00% or Floor rate of 10.25%, PIK Interest 2.50%   $ 12,365        12,283        12,128   

Just Fabulous, Inc.

  Internet Consumer & Business Services   Senior Secured   February 2017   Interest rate PRIME + 8.25% or Floor rate of 11.50%   $ 5,000        4,842        4,842   

 

See notes to consolidated financial statements.

 

25


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

(dollars in thousands)

 

Portfolio Company

 

Sub-Industry

  Type of
Investment(1)
 

Maturity
Date

 

Interest Rate and Floor

  Principal
Amount
    Cost(2)     Value(3)  

NetPlenish(8)

  Internet Consumer & Business Services   Senior Secured   September 2015   Interest rate FIXED 10.00%   $ 383      $ 375      $   
  Internet Consumer & Business Services   Senior Secured   April 2015   Interest rate FIXED 10.00%   $ 97        97          
         

 

 

   

 

 

   

 

 

 

Total NetPlenish

  $ 480        472          

Reply! Inc.(11)

  Internet Consumer & Business Services   Senior Secured   February 2016   Interest rate PRIME + 7.25% or Floor rate of 10.50%, PIK Interest 2.00%   $ 3,031        3,051        3,034   
  Internet Consumer & Business Services   Senior Secured   September 2015   Interest rate Prime + 6.88% or Floor rate of 10.13%, PIK Interest 2.00%   $ 9,169        9,086        9,169   
  Internet Consumer & Business Services   Senior Secured   September 2015   Interest rate Prime + 7.25% or Floor rate of 11.00%, PIK Interest 2.00%   $ 2,020        2,044        2,070   
         

 

 

   

 

 

   

 

 

 

Total Reply! Inc.

  $ 14,220        14,181        14,273   

ShareThis, Inc.

  Internet Consumer & Business Services   Senior Secured   June 2016   Interest rate PRIME + 7.50% or Floor rate of 10.75%   $

 

14,578

 

  

 

   

 

14,160

 

  

 

   

 

14,160

 

  

 

VaultLogix, LLC

  Internet Consumer & Business Services   Senior Secured   September 2015   Interest rate LIBOR + 7.00% or Floor rate of 8.50%   $

 

7,897

 

  

 

   

 

7,927

 

  

 

   

 

7,525

 

  

 

  Internet Consumer & Business Services   Senior Secured   September 2016   Interest rate LIBOR + 8.50% or Floor rate of 10.00%, PIK interest 2.50%   $ 7,949        7,898        7,397   
         

 

 

   

 

 

   

 

 

 

Total VaultLogix, LLC

  $ 15,847        15,826        14,923   

WaveMarket, Inc.(11)

  Internet Consumer & Business Services   Senior Secured   September 2015   Interest rate Prime + 5.75% or Floor rate of 9.50%   $ 10,000        9,940        9,665   
           

 

 

   

 

 

 

Subtotal: 1-5 Years Maturity

  

    106,148        103,545   
           

 

 

   

 

 

 

Subtotal: Internet Consumer & Business Services (18.19%)*

  

    131,069        118,236   
           

 

 

   

 

 

 

Media/Content/Info

  

   

Under 1 Year Maturity

  

   

Zoom Media Group, Inc.

  Media/Content/Info   Senior Secured   December 2014   Interest rate PRIME + 5.25% or Floor rate of 8.50%   $ 4,000        3,858        3,858   
           

 

 

   

 

 

 

Subtotal: Under 1 Year Maturity

  

    3,858        3,858   
           

 

 

   

 

 

 

1-5 Years Maturity

  

   

Zoom Media Group, Inc.

  Media/Content/Info   Senior Secured   December 2015   Interest rate PRIME + 7.25% and PIK + 3.75% or Floor rate of 10.50%   $ 4,288        4,122        4,071   
           

 

 

   

 

 

 

Subtotal: 1-5 Years Maturity

  

    4,122        4,071   
           

 

 

   

 

 

 

Subtotal: Media/Content/Info (1.22%)*

  

    7,981        7,929   
           

 

 

   

 

 

 

Medical Devices & Equipment

  

   

Under 1 Year Maturity

  

   

Oraya Therapeutics, Inc.(9)(11)

  Medical Devices & Equipment   Senior Secured   December 2014   Interest rate Fixed 7.00%   $ 500        500        500   
           

 

 

   

 

 

 

Subtotal: Under 1 Year Maturity

  

    500        500   
           

 

 

   

 

 

 

1-5 Years Maturity

  

   

Baxano Surgical, Inc.(3)

  Medical Devices & Equipment   Senior Secured   March 2017   Interest rate PRIME + 7.75% or Floor rate of 12.5%   $ 7,500        7,222        7,222   

Home Dialysis Plus, Inc.

  Medical Devices & Equipment   Senior Secured   April 2017   Interest rate PRIME + 6.35% or Floor rate of 9.60%   $ 10,000        9,732        9,732   

InspireMD, Inc.(3)(5)(10)

  Medical Devices & Equipment   Senior Secured   February 2017   Interest rate PRIME + 5.00% or Floor rate of 10.50%   $ 10,000        9,696        9,696   

Medrobotics Corporation

  Medical Devices & Equipment   Senior Secured   March 2016   Interest rate PRIME + 7.85% or Floor rate of 11.10%   $ 4,561        4,489        4,454   

 

See notes to consolidated financial statements.

 

26


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

(dollars in thousands)

 

Portfolio Company

 

Sub-Industry

  Type of
Investment(1)
 

Maturity
Date

 

Interest Rate and Floor

  Principal
Amount
    Cost(2)     Value(3)  

NetBio, Inc.

  Medical Devices & Equipment   Senior Secured   August 2017   Interest rate PRIME + 5.00% or Floor rate of 11.00%   $ 5,000      $ 4,788      $ 4,788   

NinePoint Medical, Inc.

  Medical Devices & Equipment   Senior Secured   January 2016   Interest rate PRIME + 5.85% or Floor rate of 9.10%   $ 5,946        5,911        5,794   

Oraya Therapeutics, Inc.(9)(11)

  Medical Devices & Equipment   Senior Secured   September 2015   Interest rate PRIME + 5.50% or Floor rate of 10.25%   $ 7,064        6,980        7,162   

SonaCare Medical, LLC (pka US HIFU, LLC)(11)

  Medical Devices & Equipment   Senior Secured   April 2016   Interest rate PRIME + 7.75% or Floor rate of 11.00%   $ 5,667        5,754        5,818   

United Orthopedic Group, Inc.

  Medical Devices & Equipment   Senior Secured   July 2016   Interest rate PRIME + 8.60% or Floor rate of 11.85%   $ 25,000        24,647        25,166   

ViewRay, Inc.

  Medical Devices & Equipment   Senior Secured   June 2017   Interest rate PRIME + 7.00% or Floor rate of 10.25%, PIK Interest 1.50%   $ 15,000        14,489        14,489   
           

 

 

   

 

 

 

Subtotal: 1-5 Years Maturity

  

    93,707        94,320   
           

 

 

   

 

 

 

Subtotal: Medical Devices & Equipment (14.59%)*

  

    94,206        94,819   
           

 

 

   

 

 

 

Semiconductors

  

   

1-5 Years Maturity

  

   

Achronix Semiconductor Corporation

  Semiconductors   Senior Secured   January 2015   Interest rate PRIME + 10.60% or Floor rate of 13.85%   $ 1,032        1,023        1,006   

SiTime Corporation

  Semiconductors   Senior Secured   September 2016   Interest rate PRIME + 6.50% or Floor rate of 9.75%   $ 3,500        3,473        3,473   
           

 

 

   

 

 

 

Subtotal: 1-5 Years Maturity

  

    4,495        4,479   
           

 

 

   

 

 

 

Subtotal: Semiconductors (0.69%)*

  

    4,495        4,479   
           

 

 

   

 

 

 

Software

  

   

Under 1 Year Maturity

  

   

Clickfox, Inc.

  Software   Senior Secured   September 2014   Interest rate PRIME + 6.75% or Floor rate of 10.00%   $ 2,000        1,979        1,979   

StartApp, Inc.

  Software   Senior Secured   December 2014   Interest rate PRIME + 2.75% or Floor rate of 6.00%   $ 200        191        191   

Touchcommerce, Inc.

  Software   Senior Secured   December 2014   Interest rate Prime + 2.25% or Floor rate of 6.50%   $ 3,111        3,071        2,970   
           

 

 

   

 

 

 

Subtotal: Under 1 Year Maturity

  

    5,241        5,140   
           

 

 

   

 

 

 

1-5 Years Maturity

  

   

Clickfox, Inc.

  Software   Senior Secured   November 2015   Interest rate PRIME + 8.25% or Floor rate of 11.50%   $ 5,842        5,530        5,530   

Hillcrest Laboratories, Inc.

  Software   Senior Secured   July 2015   Interest rate PRIME + 7.50% or Floor rate of 10.75%   $ 2,660        2,630        2,604   

Mobile Posse, Inc.

  Software   Senior Secured   December 2016   Interest rate PRIME + 7.50% or Floor rate of 10.75%   $ 4,000        3,876        3,879   

Neos Geosolutions, Inc.

  Software   Senior Secured   May 2016   Interest rate Prime + 5.75% or Floor rate of 10.50%   $ 3,771        3,808        3,705   

Sonian, Inc.

  Software   Senior Secured   July 2017   Interest rate PRIME + 7.00% or Floor rate of 10.25%   $ 5,500        5,332        5,332   

StartApp, Inc.

  Software   Senior Secured   March 2017   Interest rate PRIME + 7.75% or Floor rate of 11.00%   $ 2,500        2,507        2,498   

Touchcommerce, Inc.

  Software   Senior Secured   June 2017   Interest rate Prime + 6.00% or Floor rate of 10.25%   $ 5,000        4,688        4,767   
           

 

 

   

 

 

 

Subtotal: 1-5 Years Maturity

  

    28,372        28,315   
           

 

 

   

 

 

 

Subtotal: Software (5.15%)*

  

    33,613        33,455   
           

 

 

   

 

 

 

 

See notes to consolidated financial statements.

 

27


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

(dollars in thousands)

 

Portfolio Company

 

Sub-Industry

  Type of
Investment(1)
 

Maturity
Date

 

Interest Rate and Floor

  Principal
Amount
    Cost(2)     Value(3)  

Specialty Pharmaceuticals

  

   

1-5 Years Maturity

  

   

Rockwell Medical, Inc.

  Specialty Pharmaceuticals   Senior Secured  

March

2017

 

Interest rate PRIME + 9.25%

or Floor rate of 12.50%

  $ 20,000      $ 20,055      $ 20,055   
           

 

 

   

 

 

 

Subtotal: 1-5 Years Maturity

  

    20,055        20,055   
           

 

 

   

 

 

 

Subtotal: Specialty Pharmaceuticals (3.09%)*

  

    20,055        20,055   
           

 

 

   

 

 

 

Surgical Devices

  

   

1-5 Years Maturity

  

   

Transmedics, Inc.(11)

  Surgical Devices   Senior Secured   November 2015   Interest rate FIXED 12.95%   $ 7,250        7,207        7,207   
           

 

 

   

 

 

 

Subtotal: 1-5 Years Maturity

  

    7,207        7,207   
           

 

 

   

 

 

 

Subtotal: Surgical Devices (1.11%)*

  

    7,207        7,207   
           

 

 

   

 

 

 

Total Debt (126.46%)*

  

    835,882        821,988   
           

 

 

   

 

 

 

 

See notes to consolidated financial statements.

 

28


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

(dollars in thousands)

 

Portfolio Company

  Sub-Industry           Type of Investment(1)          

Series

  Shares     Cost(2)     Value(3)  

Equity

           

Biotechnology Tools

         

NuGEN Technologies, Inc.

  Biotechnology Tools   Equity   Preferred Series C     189,394      $        500      $        687   
         

 

 

   

 

 

 

Subtotal: Biotechnology Tools (0.11%)*

  

    500        687   
         

 

 

   

 

 

 

Communications & Networking

       

GlowPoint, Inc.(3)

  Communications &

Networking

  Equity   Common Stock     114,192        102        157   

Peerless Network, Inc.

  Communications &
Networking
  Equity   Preferred Series A     1,000,000        1,000        3,621   

Stoke, Inc.

  Communications &
Networking
  Equity   Preferred Series E     152,905        500        224   
         

 

 

   

 

 

 

Subtotal: Communications & Networking (0.62%)*

  

    1,602        4,002   
         

 

 

   

 

 

 

Consumer & Business Products

       

Caivis Acquisition Corporation

  Consumer &
Business Products
  Equity   Common Stock     295,861        819        598   

IPA Holdings, LLC

  Consumer &
Business Products
  Equity   LLC Interest     500,000        500        676   

Market Force Information, Inc.

  Consumer &
Business Products
  Equity   Preferred Series B     187,970        500        285   
         

 

 

   

 

 

 

Subtotal: Consumer & Business Products (0.24%)*

  

    1,819        1,559   
         

 

 

   

 

 

 

Diagnostic

       

Singulex, Inc.

  Diagnostic   Equity   Common Stock     937,998        750        750   
         

 

 

   

 

 

 

Subtotal: Diagnostic (0.12%)*

  

    750        750   
         

 

 

   

 

 

 

Drug Delivery

       

AcelRx Pharmaceuticals, Inc.(3)(10)

  Drug Delivery   Equity   Common Stock     89,243        178        1,009   

Merrion Pharmaceuticals,
Plc(3)(5)(10)

  Drug Delivery   Equity   Common Stock     20,000        9        —     

NuPathe, Inc.(3)

  Drug Delivery   Equity   Common Stock     50,000        146        164   

Transcept Pharmaceuticals, Inc.(3)

  Drug Delivery   Equity   Common Stock     41,570        500        140   
         

 

 

   

 

 

 

Subtotal: Drug Delivery (0.20%)*

  

    833        1,313   
         

 

 

   

 

 

 

Drug Discovery & Development

       

Acceleron Pharma, Inc.(3)

  Drug Discovery &
Development
  Equity   Common Stock     256,410        1,505        9,286   

Aveo Pharmaceuticals, Inc.(3)(10)

  Drug Discovery &
Development
  Equity   Common Stock     167,864        842        307   

Dicerna Pharmaceuticals, Inc.(12)

  Drug Discovery &
Development
  Equity   Preferred Series B     20,107        503        228   
  Drug Discovery &
Development
  Equity   Preferred Series C     142,858        1,000        1,055   
       

 

 

   

 

 

   

 

 

 

Total Dicerna Pharmaceuticals, Inc.

    162,965        1,503        1,283   

Inotek Pharmaceuticals
Corporation

  Drug Discovery &
Development
  Equity   Common Stock     15,334        1,500        —     

Merrimack Pharmaceuticals, Inc.(3)

  Drug Discovery &
Development
  Equity   Common Stock     546,448        2,000        2,912   

Paratek Pharmaceuticals, Inc.

  Drug Discovery &
Development
  Equity   Common Stock     85,450        5        —     
  Drug Discovery &
Development
  Equity   Preferred Series H     244,158        1,000        —     
       

 

 

   

 

 

   

 

 

 

Total Paratek Pharmaceuticals, Inc.

    329,608        1,005        —     
         

 

 

   

 

 

 

Subtotal: Drug Discovery & Development (2.12%)*

  

    8,355        13,788   
         

 

 

   

 

 

 

 

See notes to consolidated financial statements.

 

29


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

(dollars in thousands)

 

Portfolio Company

  Sub-Industry  

        Type of Investment(1)        

 

Series

  Shares     Cost(2)     Value(3)  

Information Services

           

Buzznet, Inc.

  Information Services   Equity   Preferred Series C     263,158      $      250      $      —     

Good Technologies, Inc. (pka Visto Corporation)

  Information Services   Equity   Common Stock     500,000        603        —     
         

 

 

   

 

 

 

Subtotal: Information Services (0.00%)*

  

    853        —     
         

 

 

   

 

 

 

Internet Consumer & Business Services

       

Blurb, Inc.

  Internet Consumer &
Business Services
  Equity   Preferred Series B     220,653        175        444   

Philotic, Inc.

  Internet Consumer &
Business Services
  Equity   Common Stock     8,121        92     

Progress Financial

  Internet Consumer &
Business Services
  Equity   Preferred Series G     218,351        250        280   

Trulia, Inc.(3)

  Internet Consumer &
Business Services
  Equity   Common Stock     29,340        141        1,035   
         

 

 

   

 

 

 

Subtotal: Internet Consumer & Business Services (0.27%)*

  

    658        1,759   
         

 

 

   

 

 

 

Media/Content/Info

       

Everyday Health, Inc. (pka Waterfront Media, Inc.)

  Media/Content/Info   Equity   Preferred Series D     145,590        1,000        425   
         

 

 

   

 

 

 

Subtotal: Media/Content/Info (0.07%)*

  

    1,000        425   
         

 

 

   

 

 

 

Medical Devices & Equipment

       

Gelesis, Inc.(6)

  Medical Devices &
Equipment
  Equity   LLC Interest     2,024,092        925        466   

Medrobotics Corporation

  Medical Devices &
Equipment
  Equity   Preferred Series E     136,798        250        269   

Novasys Medical, Inc.

  Medical Devices &
Equipment
  Equity   Preferred Series D-1     4,118,444        1,000        —     

Optiscan Biomedical, Corp.(6)

  Medical Devices &
Equipment
  Equity   Preferred Series B     6,185,567        3,000        411   
  Medical Devices &
Equipment
  Equity   Preferred Series C     1,927,309        655        135   
  Medical Devices &
Equipment
  Equity   Preferred Series D     41,352,489        3,945        4,006   
       

 

 

   

 

 

   

 

 

 

Total Optiscan Biomedical, Corp.

    49,465,365        7,600        4,552   
         

 

 

   

 

 

 

Subtotal: Medical Devices & Equipment (0.81%)*

  

    9,775        5,287   
         

 

 

   

 

 

 

Software

       

Atrenta, Inc.

  Software   Equity   Preferred Series C     1,196,845        986        1,607   
  Software   Equity   Preferred Series D     635,513        508        1,088   
       

 

 

   

 

 

   

 

 

 

Total Atrenta, Inc.

    1,832,358        1,494        2,695   

Box, Inc.

  Software   Equity   Preferred Series C     390,625        500        7,031   
  Software   Equity   Preferred Series D     158,133        500        2,846   
  Software   Equity   Preferred Series D-1     124,511        1,000        2,241   
  Software   Equity   Preferred Series D-2     220,751        2,001        3,974   
  Software   Equity   Preferred Series E     38,183        500        687   
       

 

 

   

 

 

   

 

 

 

Total Box, Inc.

    932,203        4,501        16,779   

CapLinked, Inc.

  Software   Equity   Preferred Series A-3     53,614        51        94   

ForeScout Technologies, Inc.

  Software   Equity   Preferred Series D     319,099        398        849   

HighRoads, Inc.

  Software   Equity   Preferred Series B     190,170        307        337   
         

 

 

   

 

 

 

Subtotal: Software (3.19%)*

  

    6,751        20,754   
         

 

 

   

 

 

 

 

See notes to consolidated financial statements.

 

30


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

(dollars in thousands)

 

Portfolio Company

  Sub-Industry  

        Type of Investment(1)        

 

Series

  Shares     Cost(2)     Value(3)  

Specialty Pharmaceuticals

       

QuatRx Pharmaceuticals Company

  Specialty
Pharmaceuticals
  Equity   Preferred Series E     241,829      $      750      $      —     
  Specialty
Pharmaceuticals
  Equity   Preferred Series E-1     26,955        —          —     
  Specialty
Pharmaceuticals
  Equity   Preferred Series G     4,667,636        —          —     
       

 

 

   

 

 

   

 

 

 

Total QuatRx Pharmaceuticals Company

    4,936,420        750        —     
         

 

 

   

 

 

 

Subtotal: Specialty Pharmaceuticals (0.00%)*

  

    750        —     
         

 

 

   

 

 

 

Surgical Devices

       

Gynesonics, Inc.

  Surgical Devices   Equity   Preferred Series B     219,298        250        73   
  Surgical Devices   Equity   Preferred Series C     656,538        282        123   
  Surgical Devices   Equity   Preferred Series D     1,621,553        580        749   
       

 

 

   

 

 

   

 

 

 

Total Gynesonics, Inc.

    2,497,389        1,112        945   

Transmedics, Inc.

  Surgical Devices   Equity   Preferred Series B     88,961        1,100        303   
  Surgical Devices   Equity   Preferred Series C     119,999        300        212   
  Surgical Devices   Equity   Preferred Series D     260,000        650        886   
       

 

 

   

 

 

   

 

 

 

Total Transmedics, Inc.

    468,960        2,050        1,401   
         

 

 

   

 

 

 

Subtotal: Surgical Devices (0.36%)*

  

    3,162        2,346   
         

 

 

   

 

 

 

Total Equity (8.10%)*

  

    36,808        52,670   
         

 

 

   

 

 

 

Warrant

           

Biotechnology Tools

           

Labcyte, Inc.

  Biotechnology Tools   Warrant   Preferred Series C     1,127,624        323        65   

NuGEN Technologies, Inc.

  Biotechnology Tools   Warrant   Preferred Series B     234,659        78        234   
         

 

 

   

 

 

 

Subtotal: Biotechnology Tools (0.05%)*

  

    401        299   
         

 

 

   

 

 

 

Energy Technology

           

Agrivida, Inc.

  Energy Technology   Warrant   Preferred Series C     77,447        120        243   

Alphabet Energy, Inc.

  Energy Technology   Warrant   Preferred Series A     86,329        82        176   

American Superconductor Corporation(3)

  Energy Technology   Warrant   Common Stock     512,820        391        175   

Brightsource Energy, Inc.

  Energy Technology   Warrant   Preferred Series 1     175,000        780        214   

Calera, Inc.

  Energy Technology   Warrant   Preferred Series C     44,529        513        —     

EcoMotors, Inc.

  Energy Technology   Warrant   Preferred Series B     437,500        308        475   

Fluidic, Inc.

  Energy Technology   Warrant   Preferred Series C     59,665        102        138   

Fulcrum Bioenergy, Inc.

  Energy Technology   Warrant   Preferred Series C-1     280,897        275        210   

Glori Energy, Inc.

  Energy Technology   Warrant   Preferred Series C     145,932        165        50   

GreatPoint Energy, Inc.

  Energy Technology   Warrant   Preferred Series D-1     393,212        548        —     

Polyera Corporation

  Energy Technology   Warrant   Preferred Series C     161,575        69        44   

Propel Fuels

  Energy Technology   Warrant   Preferred Series C     3,200,000        211        233   

SCIEnergy, Inc.

  Energy Technology   Warrant   Preferred Series D     1,061,623        360        2   

Scifiniti (pka Integrated Photovoltaics, Inc.)

  Energy Technology   Warrant   Preferred Series B     390,000        82        68   

Solexel, Inc.

  Energy Technology   Warrant   Preferred Series C     1,171,625        1,162        278   

Stion Corporation(6)

  Energy Technology   Warrant   Preferred Series Seed     2,154        1,378        1,627   

TAS Energy, Inc.

  Energy Technology   Warrant   Preferred Series F     428,571        299        756   

TPI Composites, Inc.

  Energy Technology   Warrant   Preferred Series B     120        172        376   

Trilliant, Inc.

  Energy Technology   Warrant   Preferred Series A     320,000        162        34   
         

 

 

   

 

 

 

Subtotal: Energy Technology (0.78%)*(13)

  

    7,179        5,099   
         

 

 

   

 

 

 

 

See notes to consolidated financial statements.

 

31


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

(dollars in thousands)

 

Portfolio Company

  Sub-Industry  

        Type of Investment(1)        

 

Series

  Shares     Cost(2)     Value(3)  

Communications & Networking

       

Intelepeer, Inc.

  Communications &
Networking
  Warrant   Preferred Series C     117,958      $      102      $      112   

OpenPeak, Inc.

  Communications &
Networking
  Warrant   Preferred Series 2     108,982        149        —     

PeerApp, Inc.

  Communications &
Networking
  Warrant   Preferred Series B     298,779        61        41   

Peerless Network, Inc.

  Communications &
Networking
  Warrant   Preferred Series A     135,000        95        368   

Ping Identity Corporation

  Communications &
Networking
  Warrant   Preferred Series B     1,136,277        52        98   

Spring Mobile Solutions, Inc.

  Communications &
Networking
  Warrant   Preferred Series D     2,834,375        417        661   

Stoke, Inc.

  Communications &
Networking
  Warrant   Preferred Series C     158,536        53        5   
  Communications &
Networking
  Warrant   Preferred Series D     72,727        65        2   
       

 

 

   

 

 

   

 

 

 

Total Stoke, Inc.

    231,263        118        7   
         

 

 

   

 

 

 

Subtotal: Communications & Networking (0.20%)*

  

    994        1,287   
         

 

 

   

 

 

 

Consumer & Business Products

         

Intelligent Beauty, Inc.

  Consumer &
Business Products
  Warrant   Preferred Series B     190,234        230        1,027   

IPA Holdings, LLC

  Consumer &
Business Products
  Warrant   Common Stock     650,000        275        408   

Market Force Information, Inc.

  Consumer &
Business Products
  Warrant   Preferred Series A     99,286        24        1   
         

 

 

   

 

 

 

Subtotal: Consumer & Business Products (0.22%)*

  

    529        1,436   
         

 

 

   

 

 

 

Diagnostic

           

Navidea Biopharmaceuticals, Inc. (pka Neoprode)(3)

  Diagnostic   Warrant   Common Stock     333,333        244        152   
         

 

 

   

 

 

 

Subtotal: Diagnostic (0.02%)*

  

    244        152   
         

 

 

   

 

 

 

Drug Delivery

           

AcelRx Pharmaceuticals, Inc.(3)(10)

  Drug Delivery   Warrant   Common Stock     176,730        786        961   

Alexza Pharmaceuticals, Inc.(3)

  Drug Delivery   Warrant   Common Stock     37,639        645        1   

BIND Therapeutics, Inc.(3)

  Drug Delivery   Warrant   Common Stock     71,359        367        294   

Celsion Corporation(3)

  Drug Delivery   Warrant   Common Stock     97,493        227        249   

Dance Biopharm, Inc.

  Drug Delivery   Warrant   Preferred Series A     97,701        74        154   

Intelliject, Inc.

  Drug Delivery   Warrant   Preferred Series B     82,500        594        1,115   

NuPathe, Inc.(3)

  Drug Delivery   Warrant   Common Stock     106,631        139        136   

Revance Therapeutics, Inc.(12)

  Drug Delivery   Warrant   Preferred Series E-5     802,675        557        330   

Transcept Pharmaceuticals, Inc.(3)

  Drug Delivery   Warrant   Common Stock     61,452        87        3   
         

 

 

   

 

 

 

Subtotal: Drug Delivery (0.50%)*

  

    3,476        3,243   
         

 

 

   

 

 

 

Drug Discovery & Development

         

Acceleron Pharma, Inc.(3)

  Drug Discovery &
Development
  Warrant   Common Stock     11,611        39        294   

ADMA Biologics, Inc.(3)

  Drug Discovery &
Development
  Warrant   Common Stock     31,750        129        73   

Anthera Pharmaceuticals, Inc.(3)

  Drug Discovery &
Development
  Warrant   Common Stock     40,178        984        9   

Cell Therapeutics, Inc.(3)

  Drug Discovery &
Development
  Warrant   Common Stock     679,040        405        601   

Cempra, Inc.(3)

  Drug Discovery &
Development
  Warrant   Common Stock     138,797        458        728   

 

See notes to consolidated financial statements.

 

32


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

(dollars in thousands)

 

Portfolio Company

  Sub-Industry  

        Type of Investment(1)        

 

Series

  Shares     Cost(2)     Value(3)  

Chroma Therapeutics, Ltd.(5)(10)

  Drug Discovery &
Development
  Warrant   Preferred Series D     325,261      $      490      $      500   

Cleveland BioLabs, Inc(3)

  Drug Discovery &
Development
  Warrant   Common Stock     156,250        105        66   

Concert Pharmaceuticals, Inc.(12)

  Drug Discovery &
Development
  Warrant   Preferred Series C     400,000        367        577   

Coronado Biosciences, Inc.(3)

  Drug Discovery &
Development
  Warrant   Common Stock     73,009        142        41   

Dicerna Pharmaceuticals, Inc.(12)

  Drug Discovery &
Development
  Warrant   Common Stock     200        28        —     
  Drug Discovery &
Development
  Warrant   Preferred Series A     21,000        237        38   
  Drug Discovery &
Development
  Warrant   Preferred Series B     26,400        310        48   
       

 

 

   

 

 

   

 

 

 

Total Dicerna Pharmaceuticals, Inc.

    47,600        575        86   

Horizon Pharma, Inc.(3)

  Drug Discovery &
Development
  Warrant   Common Stock     22,408        231        5   

Merrimack Pharmaceuticals, Inc.(3)

  Drug Discovery &
Development
  Warrant   Common Stock     302,143        155        488   

Neuralstem, Inc.(3)

  Drug Discovery &
Development
  Warrant   Common Stock     648,798        295        1,045   

Portola Pharmaceuticals, Inc.(3)

  Drug Discovery &
Development
  Warrant   Common Stock     68,702        153        683   

uniQure B.V.(5)(10)(12)

  Drug Discovery &
Development
  Warrant   Preferred Series A     185,873        218        313   
         

 

 

   

 

 

 

Subtotal: Drug Discovery & Development (0.85%)*

  

    4,746        5,509   
         

 

 

   

 

 

 

Electronics & Computer Hardware

         

Clustrix, Inc.

  Electronics &
Computer Hardware
  Warrant   Common Stock     50,000        12        16   

Identive Group, Inc.(3)

  Electronics &
Computer Hardware
  Warrant   Common Stock     992,084        247        136   

Plures Technologies, Inc.(3)

  Electronics &
Computer Hardware
  Warrant   Preferred Series A     552,467        124        100   
         

 

 

   

 

 

 

Subtotal: Electronics & Computer Hardware (0.04%)*

  

    383        252   
         

 

 

   

 

 

 

Healthcare Services, Other

           

MDEverywhere, Inc.

  Healthcare Services,
Other
  Warrant   Common Stock     129        94        55   
         

 

 

   

 

 

 

Subtotal: Healthcare Services, Other (0.01%)*

  

    94        55   
         

 

 

   

 

 

 

Information Services

           

Buzznet, Inc.

  Information Services   Warrant   Preferred Series B     19,962        9        —     

Cha Cha Search, Inc.

  Information Services   Warrant   Preferred Series G     48,232        57        10   

InXpo, Inc.

  Information Services   Warrant   Preferred Series C     648,400        98        45   
  Information Services   Warrant   Preferred Series C-1     582,015        49        40   
       

 

 

   

 

 

   

 

 

 

Total InXpo, Inc.

    1,230,415        147        85   

Jab Wireless, Inc.

  Information Services   Warrant   Preferred Series A     266,567        265        330   

RichRelevance, Inc.

  Information Services   Warrant   Preferred Series E     112,612        98        —     
         

 

 

   

 

 

 

Subtotal: Information Services (0.07%)*

  

    576        425   
         

 

 

   

 

 

 

Internet Consumer & Business Services

         

Blurb, Inc.

  Internet Consumer &
Business Services
  Warrant   Preferred Series B     218,684        299        169   
  Internet Consumer &
Business Services
  Warrant   Preferred Series C     234,280        636        248   
       

 

 

   

 

 

   

 

 

 

Total Blurb, Inc.

    452,964        935        417   

 

See notes to consolidated financial statements.

 

33


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

(dollars in thousands)

 

Portfolio Company

  Sub-Industry  

        Type of Investment(1)        

 

Series

  Shares     Cost(2)     Value(3)  

CashStar, Inc.

  Internet Consumer &
Business Services
  Warrant   Preferred Series C-2     454,545      $      102      $        47   

Gazelle, Inc.

  Internet Consumer &
Business Services
  Warrant   Preferred Series D     151,827        165        62   

Invoke Solutions, Inc.

  Internet Consumer &
Business Services
  Warrant   Common Stock     53,084        39        —     

Just Fabulous, Inc.

  Internet Consumer &
Business Services
  Warrant   Preferred Series B     137,456        589        1,057   

Prism Education Group, Inc.

  Internet Consumer &
Business Services
  Warrant   Preferred Series B     200,000        43     

Progress Financial

  Internet Consumer &
Business Services
  Warrant   Preferred Series G     174,562        78        76   

Reply! Inc.

  Internet Consumer &
Business Services
  Warrant   Preferred Series B     137,225        320        93   

ShareThis, Inc.

  Internet Consumer &
Business Services
  Warrant   Preferred Series C     493,502        546        241   

Tectura Corporation

  Internet Consumer &
Business Services
  Warrant   Preferred Series B-1     253,378        51        —     

WaveMarket, Inc.

  Internet Consumer &
Business Services
  Warrant   Preferred Series B-1     1,083,779        105        85   
         

 

 

   

 

 

 

Subtotal: Internet Consumer & Business Services (0.32%)*

  

    2,973        2,078   
         

 

 

   

 

 

 

Media/Content/Info

           

Everyday Health, Inc. (pka Waterfront Media, Inc.)

  Media/Content/Info   Warrant   Preferred Series C     110,018        60        50   

Glam Media, Inc.

  Media/Content/Info   Warrant   Preferred Series D     407,457        482        —     

Zoom Media Group, Inc.

  Media/Content/Info   Warrant   Preferred Series A     1,204        348        275   
         

 

 

   

 

 

 

Subtotal: Media/Content/Info (0.05%)*

  

    890        325   
         

 

 

   

 

 

 

Medical Devices & Equipment

           

Baxano Surgical, Inc.(3)

  Medical Devices

& Equipment

  Warrant   Common Stock     882,353        439        344   

Gelesis, Inc.(6)

  Medical Devices

& Equipment

  Warrant   LLC Interest     263,688        78        7   

Home Dialysis Plus, Inc.

  Medical Devices

& Equipment

  Warrant   Preferred Series A     300,000        245        297   

InspireMD, Inc.(3)(5)(10)

  Medical Devices

& Equipment

  Warrant   Common Stock     168,351        242        167   

Medrobotics Corporation

  Medical Devices

& Equipment

  Warrant   Preferred Series D     424,008        343        184   
  Medical Devices

& Equipment

  Warrant   Preferred Series E     34,199        27        23   
       

 

 

   

 

 

   

 

 

 

Total Medrobotics Corporation

    458,207        370        207   

MELA Sciences, Inc.(3)

  Medical Devices

& Equipment

  Warrant   Common Stock     693,202        401        94   

NetBio, Inc.

  Medical Devices

& Equipment

  Warrant   Common Stock     2,568        408        398   

NinePoint Medical, Inc.

  Medical Devices

& Equipment

  Warrant   Preferred Series A-1     587,840        170        288   

Novasys Medical, Inc.

  Medical Devices

& Equipment

  Warrant   Common Stock     109,449        2        —     
  Medical Devices &
Equipment
  Warrant   Preferred Series D     526,840        125        —     
  Medical Devices &
Equipment
  Warrant   Preferred Series D-1     53,607        6        —     
       

 

 

   

 

 

   

 

 

 

Total Novasys Medical, Inc.

    689,896        133        —     

 

See notes to consolidated financial statements.

 

34


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

(dollars in thousands)

 

Portfolio Company

  Sub-Industry  

        Type of Investment(1)        

 

Series

  Shares     Cost(2)     Value(3)  

Optiscan Biomedical, Corp.(6)

  Medical Devices &
Equipment
  Warrant   Preferred Series D     10,535,275      $   1,252      $      232   

Oraya Therapeutics, Inc.

  Medical Devices &
Equipment
  Warrant   Common Stock     95,498        66        23   
  Medical Devices &
Equipment
  Warrant   Preferred Series C     716,948        677        134   
       

 

 

   

 

 

   

 

 

 

Total Oraya Therapeutics, Inc.

    812,446        743        157   

SonaCare Medical, LLC (pka US HIFU, LLC)

  Medical Devices &
Equipment
  Warrant   Preferred Series A     409,704        188        201   

United Orthopedic Group, Inc.

  Medical Devices &
Equipment
  Warrant   Preferred Series A     423,076        608        785   

ViewRay, Inc.

  Medical Devices &
Equipment
  Warrant   Preferred Series C     312,500        333        331   
         

 

 

   

 

 

 

Subtotal: Medical Devices & Equipment (0.54%)*

  

    5,610        3,508   
         

 

 

   

 

 

 

Semiconductors

           

Achronix Semiconductor Corporation

  Semiconductors   Warrant   Preferred Series C     360,000        160        194   

SiTime Corporation

  Semiconductors   Warrant   Preferred Series G     195,683        24        12   
         

 

 

   

 

 

 

Subtotal: Semiconductors (0.03%)*

  

    184        206   
         

 

 

   

 

 

 

Software

           

Atrenta, Inc.

  Software   Warrant   Preferred Series D     392,670        121        330   

Box, Inc.

  Software   Warrant   Preferred Series B     271,070        72        4,701   
  Software   Warrant   Preferred Series C     199,219        117        3,331   
  Software   Warrant   Preferred Series D-1     62,255        194        625   
       

 

 

   

 

 

   

 

 

 

Total Box, Inc.

    532,544        383        8,657   

Braxton Technologies, LLC

  Software   Warrant   Preferred Series A     168,750        187        —     

Central Desktop, Inc.

  Software   Warrant   Preferred Series B     522,769        108        187   

Clickfox, Inc.

  Software   Warrant   Preferred Series B     1,038,563        330        495   
  Software   Warrant   Preferred Series C     592,019        730        363   
       

 

 

   

 

 

   

 

 

 

Total Clickfox, Inc.

    1,630,582        1,060        858   

Daegis Inc. (pka Unify Corporation)(3)

  Software   Warrant   Common Stock     718,860        1,433        83   

ForeScout Technologies, Inc.

  Software   Warrant   Preferred Series E     80,587        41        82   

Hillcrest Laboratories, Inc.

  Software   Warrant   Preferred Series E     1,865,650        55        139   

Mobile Posse, Inc.

  Software   Warrant   Preferred Series C     396,430        130        129   

Neos Geosolutions, Inc.

  Software   Warrant   Preferred Series 3     221,150        22        —     

Sonian, Inc.

  Software   Warrant   Preferred Series C     185,949        106        105   

SugarSync, Inc.

  Software   Warrant   Preferred Series CC     332,726        78        48   
  Software   Warrant   Preferred Series DD     107,526        34        16   
       

 

 

   

 

 

   

 

 

 

Total Sugarsync, Inc.

    440,252        112        64   

Touchcommerce, Inc.

  Software   Warrant   Preferred Series E     992,595        251        248   

White Sky, Inc.

  Software   Warrant   Preferred Series B-2     124,295        54        4   

WildTangent, Inc.

  Software   Warrant   Preferred Series 3     100,000        238        123   
         

 

 

   

 

 

 

Subtotal: Software (1.69%)*

  

    4,301        11,009   
         

 

 

   

 

 

 

Specialty Pharmaceuticals

           

QuatRx Pharmaceuticals Company

  Specialty

Pharmaceuticals

  Warrant   Preferred Series E     155,324        307        —     
         

 

 

   

 

 

 

Subtotal: Specialty Pharmaceuticals (0.00%)*

  

    307        —     
         

 

 

   

 

 

 

 

See notes to consolidated financial statements.

 

35


Table of Contents

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS

December 31, 2013

(dollars in thousands)

 

Portfolio Company

  Sub-Industry  

        Type of Investment(1)        

 

Series

  Shares     Cost(2)     Value(3)  

Surgical Devices

           

Gynesonics, Inc.

  Surgical Devices   Warrant   Preferred Series C     180,480      $        74      $        27   
  Surgical Devices   Warrant   Preferred Series D     1,575,965        320        383   
       

 

 

   

 

 

   

 

 

 

Total Gynesonics, Inc.

    1,756,445        394        410   

Transmedics, Inc.

  Surgical Devices   Warrant   Preferred Series B     40,436        225        9   
  Surgical Devices   Warrant   Preferred Series D     175,000        100        335   
       

 

 

   

 

 

   

 

 

 

Total Transmedics, Inc.

    215,436        325        344   
         

 

 

   

 

 

 

Subtotal: Surgical Devices (0.12%)*

  

    719        754   
         

 

 

   

 

 

 

Total Warrants (5.48%)*

  

    33,606        35,637   
         

 

 

   

 

 

 

Total Investments (140.04%)*

  

  $ 906,297      $ 910,295   
         

 

 

   

 

 

 

 

* Value as a percent of net assets
(1) Preferred and common stock, warrants, and equity interests are generally non-income producing.
(2) Gross unrealized appreciation, gross unrealized depreciation, and net depreciation for federal income tax purposes totaled $48.8 million, $44.5 million and $4.3 million respectively. The tax cost of investments is $906.2 million
(3) Except for warrants in twenty-five publicly traded companies and common stock in nine publicly traded companies, all investments are restricted at December 31, 2013 and were valued at fair value as determined in good faith by the Valuation Committee of the Board of Directors. No unrestricted securities of the same issuer are outstanding. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies.
(4) Debt investments of this portfolio company have been pledged as collateral under the Wells Facility.
(5) Non-U.S. company or the company’s principal place of business is outside the United States.
(6) Affiliate investment that is defined under the Investment Company Act of 1940 as companies in which HTGC owns at least 5% but not more than 25% of the voting securities of the company.
(7) Control investment that is defined under the Investment Company Act of 1940 as companies in which HTGC owns at least 25% of the voting securities of the company or has greater than 50% representation on its board.
(8) Debt is on non-accrual status at December 31, 2013, and is therefore considered non-income producing.
(9) Convertible Senior Debt
(10) Indicates assets that the Company deems not “qualifying assets” under section 55(a) of the Investment Company Act of 1940, as amended. Qualifying assets must represent at least 70% of the Company’s total assets at the time of acquisition of any additional non-qualifying assets.
(11) Denotes that all or a portion of the debt investment secures the notes offered in the Debt Securitization (as defined in Note 4).
(12) Subsequent to December 31, 2013, this company completed an initial public offering. Note that the December 31, 2013 fair value does not reflect any potential impact of the conversion of our preferred shares to common shares which may include reverse split associated with the offering.
(13) In our quarterly and annual reports filed with the Commission prior to the Annual Report on Form 10-K for the year ended December 31, 2013, we referred to this industry sector as “Clean Tech.”

 

See notes to consolidated financial statements.

 

36


Table of Contents

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

1. Description of Business and Basis of Presentation

Hercules Technology Growth Capital, Inc. (the “Company”) is a specialty finance company focused on providing senior secured loans to venture capital-backed companies in technology-related markets, including technology, biotechnology, life science, and energy and renewables technology industries at all stages of development. The Company sources its investments through its principal office located in Palo Alto, CA, as well as through its additional offices in Boston, MA, New York, NY and McLean, VA. The Company was incorporated under the General Corporation Law of the State of Maryland in December 2003.

The Company is an internally managed, non-diversified closed-end investment company that has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). From incorporation through December 31, 2005, the Company was taxed as a corporation under Subchapter C of the Internal Revenue Code of 1986, (the “Code”). Effective January 1, 2006, the Company has elected to be treated for tax purposes as a regulated investment company, or RIC, under the Code (see Note 5).

Hercules Technology II, L.P. (“HT II”), Hercules Technology III, L.P. (“HT III”), and Hercules Technology IV, L.P. (“HT IV”), are Delaware limited partnerships that were formed in January 2005, September 2009 and December 2010, respectively. HT II and HT III were licensed to operate as small business investment companies (“SBICs”) under the authority of the Small Business Administration (“SBA”) on September 27, 2006 and May 26, 2010, respectively. As SBICs, HT II and HT III are subject to a variety of regulations concerning, among other things, the size and nature of the companies in which they may invest and the structure of those investments. HT IV was formed in anticipation of receiving an additional SBIC license; however, the Company has not yet applied for such license, and HT IV currently has no material assets or liabilities. The Company also formed Hercules Technology SBIC Management, LLC, or (“HTM”), a limited liability company in November 2003. HTM is a wholly owned subsidiary of the Company and serves as the limited partner and general partner of HT II and HT III (see Note 4 to the Company’s consolidated financial statements.)

HT II and HT III hold approximately $143.7 million and $290.0 million in assets, respectively, and they accounted for approximately 9.5% and 19.3% of our total assets, respectively, prior to consolidation at March 31, 2014.

The Company also established wholly owned subsidiaries, all of which are structured as Delaware corporations and limited liability companies, to hold portfolio companies organized as limited liability companies, or LLCs (or other forms of pass-through entities). By investing through these wholly owned subsidiaries, the Company is able to benefit from the tax treatment of these entities and create a tax structure that is more advantageous with respect to the Company’s RIC status.

The consolidated financial statements include the accounts of the Company, its subsidiaries and its consolidated securitization VIE. All inter-company accounts and transactions have been eliminated in consolidation. In accordance with Article 6 of Regulation S-X under the Securities Act of 1933 and the Securities and Exchange Act of 1934, the Company does not consolidate portfolio company investments. The accompanying consolidated interim financial statements are presented in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information, and pursuant to the requirements for reporting on Form 10-Q and Article 10 of Regulation S-X under the Securities Act of 1933 and the Securities Exchange Act of 1934. Accordingly, certain disclosures accompanying annual consolidated financial statements prepared in accordance with U.S. GAAP are omitted. In the opinion of management, all adjustments consisting solely of normal recurring accruals considered necessary for the fair presentation of consolidated financial statements for the interim periods have been included. The current period’s results of operations are not necessarily indicative of results that ultimately may be achieved for the year. Therefore, the interim unaudited consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the period ended December 31, 2013. The year-end consolidated statement of assets and liabilities data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Financial statements prepared on a U.S. GAAP basis require management to make estimates and assumptions that affect the amounts and disclosures reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions could change in the future as more information becomes known, which could impact the amounts reported and disclosed herein.

 

37


Table of Contents

2. Summary of Significant Accounting Policies

Principles of Consolidation

The Consolidated Financial Statements include the accounts of the Company and its subsidiaries and all VIEs of which the Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation.

A VIE is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. The primary beneficiary of a VIE is the party with both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and the obligation to absorb the losses or the right to receive benefits that could potentially be significant to the VIE.

To assess whether the Company has the power to direct the activities of a VIE that most significantly impact its economic performance, the Company considers all the facts and circumstances including its role in establishing the VIE and its ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE’s economic performance and identifying which party, if any, has power over those activities. In general, the party that makes the most significant decisions affecting the VIE is determined to have the power to direct the activities of a VIE. To assess whether the Company has the obligation to absorb the losses or the right to receive benefits that could potentially be significant to the VIE, the Company considers all of its economic interests, including debt and equity interests, servicing rights and fee arrangements, and any other variable interests in the VIE. If the Company determines that it is the party with the power to make the most significant decisions affecting the VIE, and the Company has a potentially significant interest in the VIE, then it consolidates the VIE.

The Company performs ongoing reassessments, usually quarterly, of whether it is the primary beneficiary of a VIE. The reassessment process considers whether the Company has acquired or divested the power to direct the activities of the VIE through changes in governing documents or other circumstances. The Company also reconsiders whether entities previously determined not to be VIEs have become VIEs, based on certain events, and therefore are subject to the VIE consolidation framework.

As of the date of this report, the only VIE consolidated by the Company is its securitization VIE formed in conjunction with the issuance of the Asset-Backed Notes (See Note 4).

Valuation of Investments

At March 31, 2014, 76.8% of the Company’s total assets represented investments in portfolio companies that are valued at fair value by the Board of Directors. Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those securities for which a market quotation is readily available and (ii) for all other securities and assets, fair value is as determined in good faith by the Board of Directors. The Company’s investments are carried at fair value in accordance with the 1940 Act and Accounting Standards Codification topic 820 Fair Value Measurements and Disclosures (“ASC 820”). The Company’s debt securities are primarily invested in venture capital-backed companies in technology-related markets, including technology, biotechnology, life science and energy and renewables technology industries. Given the nature of lending to these types of businesses, substantially all of the Company’s investments in these portfolio companies are considered Level 3 assets under ASC 820 because there is no known or accessible market or market indexes for these investment securities to be traded or exchanged. As such, the Company values substantially all of its investments at fair value as determined in good faith pursuant to a consistent valuation policy and the Company’s Board of Directors in accordance with the provisions of ASC 820 and the 1940 Act. Due to the inherent uncertainty in determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments determined in good faith by its Board of Directors may differ significantly from the value that would have been used had a readily available market existed for such investments, and the differences could be material.

The Company may from time to time engage an independent valuation firm to provide the Company with valuation assistance with respect to certain portfolio investments on a quarterly basis. The Company intends to continue to engage an independent valuation firm to provide management with assistance regarding the Company’s determination of the fair value of selected portfolio investments each quarter unless directed by the Board of Directors to cancel such valuation services. The scope of services rendered by an independent valuation firm is at the discretion of the Board of Directors. The Company’s Board of Directors is ultimately and solely responsible for determining the fair value of the Company’s investments in good faith.

With respect to investments for which market quotations are not readily available or when such market quotations are deemed not to represent fair value, the Company’s Board of Directors has approved a multi-step valuation process each quarter, as described below:

 

38


Table of Contents

(1) the Company’s quarterly valuation process begins with each portfolio company being initially valued by the investment professionals responsible for the portfolio investment;

(2) preliminary valuation conclusions are then documented and business based assumptions are discussed with the Company’s investment committee;

(3) the Valuation Committee of the Board of Directors reviews the preliminary valuation of the investments in the portfolio as provided by the investment committee, which incorporates the results of the independent valuation firm as appropriate;

(4) the Board of Directors, upon the recommendation of the Valuation Committee, discusses valuations and determines the fair value of each investment in our portfolio in good faith based on the input of, where applicable, the respective independent valuation firm and the investment committee.

ASC 820 establishes a framework for measuring the fair value of the assets and liabilities and outlines a fair value hierarchy which prioritizes the inputs used to measure fair value and the effect of fair value measures on earnings. ASC 820 also enhances disclosure requirements for fair value measurements based on the level within the hierarchy of the information used in the valuation. ASC 820 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

The Company has categorized all investments recorded at fair value in accordance with ASC 820 based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, defined by ASC 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:

Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets at the measurement date. The types of assets carried at Level 1 fair value generally are equities listed in active markets.

Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset in connection with market data at the measurement date and for the extent of the instrument’s anticipated life. Fair valued assets that are generally included in this category are warrants held in a public company.

Level 3—Inputs reflect management’s best estimate of what market participants would use in pricing the asset at the measurement date. It includes prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. Generally, assets carried at fair value and included in this category are the debt investments and warrants and equities held in a private company.

In accordance with ASU 2011-04, the following tables provide quantitative information about the Company’s Level 3 fair value measurements of the Company’s investments as of March 31, 2014 (unaudited) and December 31, 2013. In addition to the techniques and inputs noted in the tables below, according to the Company’s valuation policy the Company may also use other valuation techniques and methodologies when determining the Company’s fair value measurements. The below table is not intended to be all-inclusive, but rather provides information on the significant Level 3 inputs as they relate to the Company’s fair value measurements.

 

Investment Type - Level Three
Debt Investments

   Fair Value at
March 31, 2014
   

Valuation Techniques/

Methodologies

  

Unobservable Input (a)

   Range    Weighted Average  (b)
     (in thousands)                     

Pharmaceuticals - Debt

     89,267      Originated Within 6 Months    Origination Yield    9.79% - 16.97%    13.28%
     168,016      Market Comparable Companies    Hypothetical Market Yield    12.70% - 16.97%    14.68%
        Premium/(Discount)    (1.00%) - 0.50%   

Medical Devices - Debt

     37,326      Originated Within 6 Months    Origination Yield    13.69% - 17.37%    15.22%
     35,362      Market Comparable Companies    Hypothetical Market Yield Premium/(Discount)    14.52% - 17.37%
(1.00%) - 0.50%
   15.01%
     4,543      Liquidation    Probability weighting of alternative outcomes    30% - 70%   

Technology - Debt

     32,946      Originated Within 6 Months    Origination Yield    3.90% - 15.95%    14.17%
     83,091      Market Comparable Companies    Hypothetical Market Yield Premium/(Discount)    12.89% - 19.70%
0.00% - 1.00%
   14.58%
     13,933      Liquidation    Probability weighting of alternative outcomes    0.00% - 100.00%   

Energy Technology - Debt

     52,314      Originated Within 6 Months    Origination Yield    10.81% - 17.29%    13.05%
     102,936      Market Comparable Companies    Hypothetical Market Yield    12.80% - 14.39%    14.83%
        Premium/(Discount)    (0.50%) - 1.00%   

Lower Middle Market - Debt

     19,383      Originated Within 6 Months    Origination Yield    11.84%    11.84%
     73,973      Market Comparable Companies    Adjusted SMi Leveraged Loan Indices    10.46% - 16.83%    14.19%
        Premium/(Discount)    0.00% - 1.00%   
     7,380      Liquidation    Probability weighting of alternative outcomes    50.00%   
          

Debt Investments Where Fair Value Approximates Cost

     54,203      Imminent Payoffs         
     23,686      Debt Investments Maturing in Less than One Year
  

 

 

            
   $ 798,359      Total Level Three Debt Investments
  

 

 

            

 

39


Table of Contents

 

(a) The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums (discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation would result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries note above as follows:

Pharmaceuticals, above, is comprised of debt investments in the Therapeutic, Specialty Pharmaceuticals, Drug Discovery and Development, Drug Delivery, and Diagnostics and Biotechnology industries in the Schedule of Investments.

Medical Devices, above, is comprised of debt investments in the Therapeutic, Surgical Devices, Medical Devices and Equipment and Biotechnology Tools industries in the Schedule of Investments.

Technology, above, is comprised of debt investments in the Software, Semiconductors, Internet Consumer and Business Services, Information Services, and Communications and Networking industries in the Schedule of Investments.

Lower Middle Market, above, is comprised of debt investments in the Communications and Networking, Electronics and Computer Hardware, Healthcare Services - Other, Information Services, Internet Consumer and Business Services, Media/Content/Info, and Specialty Pharmaceuticals industries in the Schedule of Investments.

Energy Technology, above, aligns with the Energy Technology Industry in the Schedule of Investments.

 

(b) The weighted averages are calculated based on the fair market value of each investment.

 

Investment Type - Level Three
Debt Investments

  Fair Value at
December 31, 2013
   

Valuation Techniques/

Methodologies

 

Unobservable Input (a)

 

Range

  Weighted Average  (c)
    (in thousands)                  

Pharmaceuticals - Debt

    25,811      Originated Within 6 Months   Origination Yield   12.56% - 14.53%   13.36%
    250,607      Market Comparable Companies   Hypothetical Market Yield   13.83% - 15.47%   14.13%
      Premium/(Discount)   (1.00%) - 0.00%  

Medical Devices - Debt

    46,900      Originated Within 6 Months   Origination Yield   13.54% - 17.37%   14.87%
    34,723      Market Comparable Companies   Hypothetical Market Yield   14.32% - 17.37%   15.23%
      Premium/(Discount)   (1.00%) - 1.00%  

Technology - Debt

    18,796      Originated Within 6 Months   Origination Yield   10.62% - 15.97%   14.26%
    98,290      Market Comparable Companies   Hypothetical Market Yield   14.72% - 21.08%   15.48%
      Premium/(Discount)   0.00% - 1.00%  
    1,643      Liquidation   Probability weighting of alternative outcomes   30.00% - 70.00%  

Energy Technology - Debt

    32,597      Originated Within 6 Months   Origination Yield   14.68% - 15.87%   15.17%
    108,238      Market Comparable Companies   Hypothetical Market Yield   15.37%   15.37%
      Premium/(Discount)   (0.50%) - 1.50%  

Lower Middle Market - Debt

    121,347      Market Comparable Companies   Hypothetical Market Yield   14.83% - 19.73%   16.12%
      Premium/(Discount)   0.00% - 1.00%  
    31,818      Broker Quote (b)   Price Quotes   99.50% - 100.25% of par  
      Par Value   $2.0 - $22.5 million  
    12,576      Liquidation   Probability weighting of alternative outcomes   20.00% - 80.00%  
         

Debt Investments Where Fair Value Approximates Amortized Cost

    15,906      Imminent Payoffs    
    22,236      Debt Investments Maturing in Less than One Year    
    500      Convertible Debt at Par    
 

 

 

         
  $ 821,988      Total Level Three Debt Investments    
 

 

 

         

 

40


Table of Contents

 

(a) The significant unobservable inputs used in the fair value measurement of the Company’s securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums (discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation would result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries note above as follows:

Pharmaceuticals, above, is comprised of debt investments in the Therapeutic, Specialty Pharmaceuticals, Drug Discovery and Development, Drug Delivery, and Diagnostics and Biotechnology industries in the Schedule of Investments.

Medical Devices, above, is comprised of debt investments in the Therapeutic, Surgical Devices, Medical Devices and Equipment and Biotechnology Tools industries in the Schedule of Investments.

Technology, above, is comprised of debt investments in the Software, Semiconductors, Internet Consumer and Business Services, Information Services, and Communications and Networking industries in the Schedule of Investments.

Lower Middle Market, above, is comprised of debt investments in the Communications and Networking, Electronics and Computer Hardware, Healthcare Services - Other, Information Services, Internet Consumer and Business Services, Media/Content/Info, and Specialty Pharmaceuticals industries in the Schedule of Investments.

Energy Technology, above, aligns with the Energy Technology Industry in the Schedule of Investments. In our quarterly and annual reports filed with the Commission prior to the 2013 Annual Report on Form 10-K, we referred to the Energy Technology Industry as “Clean Tech” and we referred to these investments as “Clean Tech” in the Schedule of Investments included in such reports.

 

(b) A broker quote valuation technique was used to derive the fair value of debt investments which are part of a syndicated facility.
(c) The weighted averages are calculated based on the fair market value of each investment.

 

Investment Type -

  Fair Value at
March 31, 2014
    Valuation  Techniques/
Methodologies
 

Unobservable Input (a)

  Range
    (in thousands)              

Level Three Equity Investments

  $ 9,961      Market Comparable Companies  

EBITDA Multiple (b)

Revenue Multiple (b)

Discount for Lack of Marketability (c)

Average Industry Volatility (d)

Risk-Free Interest Rate

Estimated Time to Exit (in months)

  6.9x - 14.0x

1.1x - 4.8x

11.70% - 31.90%

39.32% - 99.82%

0.16% - 0.42%

14 - 26

    9,895      Market Adjusted OPM Backsolve  

Average Industry Volatility (d)

Risk-Free Interest Rate

Estimated Time to Exit (in months)

  38.04% - 81.35%

0.21% - 0.88%

18 - 39

    28,123      Other   Last Round Price   $2.02 - $18.00

Level Three Warrant Investments

  $ 9,570      Market Comparable Companies  

EBITDA Multiple (b)

Revenue Multiple (b)

Discount for Lack of Marketability (c)

Average Industry Volatility (d)

Risk-Free Interest Rate

Estimated Time to Exit (in months)

  3.7x - 32.7x

0.6x - 11.3x

11.70% - 31.60%

28.23% - 98.69%

0.11% - 1.29%

12 - 48

    8,731      Market Adjusted OPM Backsolve  

Average Industry Volatility (d)

Risk-Free Interest Rate

Estimated Time to Exit (in months)

  29.88% - 99.56%

0.09% - 2.66%

9 - 45

 

 

 

       

Total Level Three Warrant and Equity Investments

  $ 66,280         
 

 

 

       

 

(a) The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity-related securities are revenue and/or EBITDA multiples and discounts for lack of marketability. Additional inputs used in the Black Scholes option pricing model include industry volatility, risk free interest rate and estimated time to exit. Significant increases (decreases) in the inputs in isolation would result in a significantly higher (lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date.
(b) Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments.
(c) Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments.
(d) Represents the range of industry volatility used by market participants when pricing the investment.

 

41


Table of Contents

Investment Type -

  Fair Value at
December  31, 2013
   

Valuation Techniques/

Methodologies

 

Unobservable Input (a)

  Range
    (in thousands)              

Level Three Equity Investments

  $ 10,244      Market Comparable Companies   EBITDA Multiple (b)   8.6x - 17.7x
      Revenue Multiple (b)   0.7x - 13.8x
      Discount for Lack of Marketability (c)   9.1%- 23.6%
      Average Industry Volatility (d)   43.4% - 110.7%
      Risk-Free Interest Rate   0.1% - 0.4%
      Estimated Time to Exit (in months)   6 - 30
    9,289     

Market Adjusted OPM

Backsolve

  Average Industry Volatility (d)   45.6% - 109.7%
      Risk-Free Interest Rate   0.1% - 0.9%
      Estimated Time to Exit (in months)   6 - 42
    18,127      Other   Average Industry Volatility (d)   44.0%
      Risk-Free Interest Rate   0.1%
      Estimated Time to Exit (in months)   12

Level Three Warrant Investments

  $ 10,200      Market Comparable Companies   EBITDA Multiple (b)   5.0x - 51.4x
      Revenue Multiple (b)   0.5x - 13.8x
      Discount for Lack of Marketability (c)   6.4% - 36.0%
      Average Industry Volatility (d)   21.3% - 110.7%
      Risk-Free Interest Rate   0.1% - 1.0%
      Estimated Time to Exit (in months)   6 - 48
    8,913     

Market Adjusted OPM

Backsolve

  Average Industry Volatility (d)   35.7% - 109.9%
      Risk-Free Interest Rate   0.1% - 2.7%
      Estimated Time to Exit (in months)   3 - 48
    9,595      Other   Average Industry Volatility (d)   44.0% - 56.9%
      Risk-Free Interest Rate   0.1% - 1.0%
      Estimated Time to Exit (in months)   12 - 48
 

 

 

       

Total Level Three Warrant and Equity Investments

  $ 66,368         
 

 

 

       

 

(a) The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity-related securities are revenue and/or EBITDA multiples and discounts for lack of marketability. Additional inputs used in the Black Scholes option pricing model include industry volatility, risk free interest rate and estimated time to exit. Significant increases (decreases) in the inputs in isolation would result in a significantly higher (lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date.
(b) Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments.
(c) Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments.
(d) Represents the range of average industry volatility used by market participants when pricing the investment.

Debt Investments

The Company follows the guidance set forth in ASC 820 which establishes a framework for measuring the fair value of assets and liabilities and outlines a fair value hierarchy which prioritizes the inputs used to measure fair value and the effect of fair value measures on earnings. The Company’s debt securities are primarily invested in venture capital-backed companies in technology- related markets, including technology, biotechnology, life science and energy and renewables technology industries. Given the nature of lending to these types of businesses, the Company’s investments in these portfolio companies are considered Level 3 assets under ASC 820 because there is no known or accessible market or market indexes for debt instruments for these investment securities to be traded or exchanged.

In making a good faith determination of the value of our investments, the Company generally starts with the cost basis of the investment, which includes the value attributed to the OID, if any, and PIK interest or other receivables which have been accrued to principal as earned. The Company then applies the valuation methods as set forth below.

The Company applies a procedure that assumes a sale of investment in a hypothetical market to a hypothetical market

participant where buyers and sellers are willing participants. The hypothetical market does not include scenarios where the underlying security was simply repaid or extinguished, but includes an exit concept. Under this process, the Company also evaluates the collateral for recoverability of the debt investments as well as applies all of its historical fair value analysis. The Company uses pricing on recently issued comparable debt securities to determine the baseline hypothetical market yields as of the measurement date.

 

42


Table of Contents

The Company considers each portfolio company’s credit rating, security liens and other characteristics of the investment to adjust the baseline yield to derive a hypothetical yield for each investment as of the measurement date. The anticipated future cash flows from each investment are then discounted at the hypothetical yield to estimate each investment’s fair value as of the measurement date.

The Company’s process includes, among other things, the underlying investment performance, the current portfolio company’s financial condition and market changing events that impact valuation, estimated remaining life, current market yield and interest rate spreads of similar securities as of the measurement date. The Company values its syndicated debt investments using broker quotes and bond indices amongst other factors. If there is a significant deterioration of the credit quality of a debt investment, the Company may consider other factors to estimate fair value, including the proceeds that would be received in a liquidation analysis.

The Company records unrealized depreciation on investments when it believes that an investment has decreased in value, including where collection of a debt investment is doubtful or, if under the in-exchange premise, when the value of a debt security was to be less than amortized cost of the investment. Conversely, where appropriate, the Company records unrealized appreciation if it believes that the underlying portfolio company has appreciated in value and, therefore, that its investment has also appreciated in value or, if under the in-exchange premise, the value of a debt security were to be greater than amortized cost.

When originating a debt instrument, the Company generally receives warrants or other equity-related securities from the borrower. The Company determines the cost basis of the warrants or other equity-related securities received based upon their respective fair values on the date of receipt in proportion to the total fair value of the debt investment and warrants or other equity-related securities received. Any resulting discount on the debt investment from recordation of the warrant or other equity instruments is accreted into interest income over the life of the loan.

Equity-Related Securities and Warrants

Securities that are traded in the over-the-counter markets or on a stock exchange will be valued at the prevailing bid price at period end. The Company has a limited number of equity securities in public companies. In accordance with the 1940 Act, unrestricted publicly traded securities for which market quotations are readily available are valued at the closing market quote on the measurement date.

The Company estimates the fair value of warrants using a Black Scholes pricing model. At each reporting date, privately held warrant and equity-related securities are valued based on an analysis of various factors including, but not limited to, the portfolio company’s operating performance and financial condition and general market conditions, price to enterprise value or price to equity ratios, discounted cash flow, valuation comparisons to comparable public companies or other industry benchmarks. When an external event occurs, such as a purchase transaction, public offering, or subsequent equity sale, the pricing indicated by that external event is utilized to corroborate the Company’s valuation of the warrant and equity-related securities. The Company periodically reviews the valuation of its portfolio companies that have not been involved in a qualifying external event to determine if the enterprise value of the portfolio company may have increased or decreased since the last valuation measurement date.

Investments measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations as of March 31, 2014 (unaudited) and as of December 31, 2013. The Company transfers investments in and out of Level 1, 2 and 3 securities as of the beginning balance sheet date, based on changes in the use of observable and unobservable inputs utilized to perform the valuation for the period. During the three-months ended March 31, 2014, there were no transfers between Levels 1 or 2.

 

43


Table of Contents
            Investments at Fair Value as of March 31, 2014  

(in thousands)

Description

   3/31/2014      Quoted Prices In
Active Markets For
Identical Assets

(Level 1)
     Significant
Other
Observable
Inputs
(Level 2)
     Significant
Unobservable
Inputs
(Level 3)
 

Senior secured debt

   $ 798,359       $ —         $ —         $ 798,359   

Preferred stock

     45,723         —           —           45,723   

Common stock

     22,966         20,710         —           2,256   

Warrants

     23,614         —           5,313         18,301   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 890,662       $ 20,710       $ 5,313       $ 864,639   
  

 

 

    

 

 

    

 

 

    

 

 

 
            Investments at Fair Value as of December 31, 2013  

(in thousands)

Description

   12/31/2013      Quoted Prices In
Active Markets For
Identical Assets

(Level 1)
     Significant
Other
Observable
Inputs
(Level 2)
     Significant
Unobservable
Inputs
(Level 3)
 

Senior secured debt

   $ 821,988       $ —         $ —         $ 821,988   

Preferred stock

     35,554         —           —           35,554   

Common stock

     17,116         15,009         —           2,107   

Warrants

     35,637         —           6,930         28,707   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 910,295       $ 15,009       $ 6,930       $ 888,356   
  

 

 

    

 

 

    

 

 

    

 

 

 

The table below presents reconciliation for all financial assets and liabilities measured at fair value on a recurring basis, excluding accrued interest components, using significant unobservable inputs (Level 3) for the three-months ended March 31, 2014 (unaudited) and year ended December 31, 2013.

 

(in thousands)

  Balance,
January 1, 2014
    Net Realized
Losses  (1)
    Net Change in
Unrealized
Appreciation
(Depreciation) (2)
    Purchases     Sales     Repayments     Gross
Transfers
into
Level 3 (3)
    Gross
Transfers
out of
Level 3 (3)
    Balance,
March 31, 2014
 

Senior Debt

  $ 821,988      $ —        $ (2,724   $ 114,283      $ —        $ (134,449   $ —        $ (739   $ 798,359   

Preferred Stock

    35,554        (250     8,699        2,433        (503     —          1,270        (1,480     45,723   

Common Stock

    2,107        —          149        —          —          —          —          —          2,256   

Warrants

    28,707        (125     (8,606     656        (548     —          —          (1,783     18,301   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total

  $ 888,356     $ (375   $ (2,482 )   $ 117,372      $ (1,051   $ (134,449   $ 1,270      $ (4,002 )   $ 864,639   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

(in thousands)

  Balance,
January 1, 2013
    Net Realized
Gains (Losses) (1)
    Net Change in
Unrealized
Appreciation
(Depreciation) (2)
    Purchases     Sales     Repayments     Gross
Transfers
into
Level 3 (4)
    Gross
Transfers
out of
Level 3 (4)
    Balance,
December 31, 2013
 

Senior Debt

  $ 827,540      $ (9,536   $ (8,208   $ 484,367      $ (8   $ (469,780   $ 769      $ (3,156   $ 821,988   

Preferred Stock

    33,178        7,968        7,682        6,198        (18,572     —          776        (1,676     35,554   

Common Stock

    2,367        —          (1,103     750        —          —          93        —          2,107   

Warrants

    22,140        5,257        6,173        6,524        (10,350     —          —          (1,037     28,707   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total

  $ 885,225     $ 3,689      $ 4,544     $ 497,839      $ (28,930   $ (469,780   $ 1,638      $ (5,869 )   $ 888,356   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

(1) Includes net realized gains (losses) recorded as realized gains or losses in the accompanying consolidated statements of operations.
(2) Included in change in net unrealized appreciation (depreciation) in the accompanying consolidated statements of operations.
(3) Transfers in/out of Level 3 during the three-months ended March 31, 2014 relate to the conversion of Paratek Pharmaceuticals, Inc. and SCI Energy, Inc. debt to equity, the exercise of warrants in Box, Inc. equity and the initial public offerings of Concert Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Everyday Health, Inc., Revance Therapeutics, Inc., and UniQure BV.
(4) Transfers in/out of Level 3 during the year ended December 31, 2013 relate to the conversion of Optiscan BioMedical, Inc., Gynesonics, Inc., Philotic, Inc., and Tethys BioScience, Inc. debt to equity, the conversion of OCZ Technology warrants to principal and the initial public offerings of Portola Pharmaceuticals, Inc., Acceleron Pharma, Inc., Bind, Inc., and ADMA Biologics, Inc.

 

44


Table of Contents

For the three-months ended March 31, 2014, approximately $8.2 million and $149,000 in net unrealized appreciation was recorded for preferred stock and common stock Level 3 investments, respectively, relating to assets still held at the reporting date. For the same period, approximately $814,000 and $2.7 million in net unrealized depreciation was recorded for warrant and debt Level 3 investments respectively relating to assets still held at the reporting date.

For the year ended December 31, 2013, approximately $4.4 million and $4.1 million in net unrealized appreciation was recorded for preferred stock and warrant Level 3 investments, respectively, relating to assets still held at the reporting date. For the same period, approximately $8.2 million and $1.1 million in net unrealized depreciation was recorded for debt and common stock Level 3 investments, respectively, relating to assets still held at the reporting date.

As required by the 1940 Act, the Company classifies its investments by level of control. “Control investments” are defined in the 1940 Act as investments in those companies that the Company is deemed to “control”. Generally, under the 1940 Act, the Company is deemed to “control” a company in which it has invested if it owns 25% or more of the voting securities of such company or has greater than 50% representation on its board. “Affiliate investments” are investments in those companies that are “affiliated companies” of the Company, as defined in the 1940 Act, which are not control investments. The Company is deemed to be an “affiliate” of a company in which it has invested if it owns 5% or more but less than 25% of the voting securities of such company. “Non-control/non-affiliate investments” are investments that are neither control investments nor affiliate investments.

The following table summarizes our realized and unrealized gain and loss and changes in our unrealized appreciation and depreciation on affiliate investments for the three-months ended March 31, 2014 and 2013 (unaudited). The Company did not hold any Control investments at either March 31, 2014 or 2013.

 

                                                                                                                                                                                         
(in thousands)   Three months ended March 31, 2014  
Portfolio Company   Type   Fair
Value at
March 31,
2014
    Investment
Income
    Net Change in
Unrealized
(Depreciation)/

Appreciation
    Reversal of
Unrealized
(Depreciation)/

Appreciation
    Realized
Gain/

(Loss)
 

Gelesis, Inc.

  Affiliate   $ 497      $ —        $ 24      $ —        $ —     

Optiscan BioMedical, Corp.

  Affiliate     5,032        —          247        —          —     

Stion Corporation

  Affiliate     5,664        1,475        (224     —          —     
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total

    $ 11,193      $ 1,475      $ 47      $ —        $ —     
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 
(in thousands)   Three months ended March 31, 2013  
Portfolio Company   Type   Fair
Value at
March 31,
2013
    Investment
Income
    Net Change in
Unrealized
(Depreciation)/

Appreciation
    Reversal of
Unrealized
(Depreciation)/

Appreciation
    Realized
Gain/
(Loss)
 

Gelesis, Inc.

  Affiliate   $ 1,888      $ —        $ 222      $ —        $ —     

Optiscan BioMedical, Corp.

  Affiliate     12,308        610        212        —          —     
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total

    $ 14,196      $ 610      $ 434      $ —        $ —     
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

During the year ended December 31, 2013, Stion Corporation became classified as an affiliate.

 

45


Table of Contents

A summary of the composition of the Company’s investment portfolio as of March 31, 2014 (unaudited) and December 31, 2013 at fair value is shown as follows:

 

     March 31, 2014     December 31, 2013  

(in thousands)

   Investments at Fair
Value
     Percentage of Total
Portfolio
    Investments at Fair
Value
     Percentage of Total
Portfolio
 

Senior secured debt with warrants

   $ 500,899         56.2 %   $ 634,820         69.7

Senior secured debt

     321,074         36.0 %     222,805         24.5

Preferred stock

     45,723         5.1 %     35,554         3.9

Common Stock

     22,966         2.7 %     17,116         1.9
  

 

 

    

 

 

   

 

 

    

 

 

 
   $ 890,662         100.0 %   $ 910,295         100.0
  

 

 

    

 

 

   

 

 

    

 

 

 

The decline in senior secured debt with warrants is consistent with the overall decline in the investment portfolio at March 31, 2014 from December 31, 2013 and the increase in senior secured debt is due to the addition of seven new debt investments in the three-months ended March 31, 2014 partially offset by the payoff of two existing debt investments included in the period ended December 31, 2013.

A summary of the Company’s investment portfolio, at value, by geographic location as of March 31, 2014 (unaudited) and December 31, 2013 is shown as follows:

 

     March 31, 2014     December 31, 2013  

(in thousands)

   Investments at Fair
Value
     Percentage of Total
Portfolio
    Investments at Fair
Value
     Percentage of Total
Portfolio
 

United States

   $ 843,941         94.8   $ 864,003         94.9

Canada

     26,201         2.9     25,798         2.8

Israel

     10,012         1.1     9,863         1.1

Netherlands

     10,008         1.1     10,131         1.1

England

     500         0.1     500         0.1
  

 

 

    

 

 

   

 

 

    

 

 

 
   $ 890,662         100.0   $ 910,295         100.0
  

 

 

    

 

 

   

 

 

    

 

 

 

The following table shows the fair value the Company’s portfolio by industry sector at March 31, 2014 (unaudited) and December 31, 2013:

 

     March 31, 2014     December 31, 2013  

(in thousands)

   Investments
at Fair  Value
     Percentage of
Total  Portfolio
    Investments
at Fair  Value
     Percentage of
Total  Portfolio
 

Drug Discovery & Development

   $ 206,535         23.2   $ 219,169         24.1

Energy Technology

     166,482         18.7     164,466         18.1

Internet Consumer & Business Services

     105,964         11.9     122,073         13.4

Medical Devices & Equipment

     99,061         11.1     103,614         11.4

Software

     79,077         8.9     65,218         7.2

Drug Delivery

     63,335         7.1     62,022         6.8

Specialty Pharmaceuticals

     40,217         4.5     20,055         2.2

Communications & Networking

     35,526         4.0     35,979         4.0

Media/Content/Info

     29,447         3.3     8,679         1.0

Healthcare Services, Other

     20,626         2.3     29,080         3.2

Information Services

     15,102         1.7     46,565         5.1

Surgical Devices

     10,353         1.1     10,307         1.0

Semiconductors

     9,464         1.1     4,685         0.5

Biotechnology Tools

     4,541         0.5     5,275         0.6

Consumer & Business Products

     3,282         0.4     2,995         0.3

Diagnostic

     858         0.1     902         0.1

Electronics & Computer Hardware

     792         0.1     9,211         1.0
  

 

 

    

 

 

   

 

 

    

 

 

 
   $ 890,662         100.0   $ 910,295         100.0
  

 

 

    

 

 

   

 

 

    

 

 

 

 

46


Table of Contents

During the three-months ended March 31, 2014, the Company funded investments in debt securities and equity investments totaling approximately $110.4 million and $1.5 million, respectively. The Company converted approximately $2.0 million of warrants to equity in three portfolio companies during the three-months ended March 31, 2014.

During the three-months ended March 31, 2013, the Company funded investments in debt securities and equity investments totaling approximately $136.3 million and $2.0 million, respectively. The Company converted approximately $836,000 of debt to equity in three portfolio companies during the three-months ended March 31, 2013.

No single portfolio investment represents more than 10% of the fair value of the investments as of March 31, 2014 and December 31, 2013.

During the three-month periods ended March 31, 2014, we recognized net realized gains of approximately $4.9 million. These net realized gains include gross realized gains of approximately $5.4 million primarily from the sale of investments in five portfolio companies, including Cell Therapeutics ($1.3 million), Neuralstem ($1.2 million), Portola Pharmaceuticals ($700,000), AcelRx ($485,000) and Dicerna ($200,000). These gains were partially offset by gross realized losses of approximately $500,000 from the liquidation of the Company’s investments in five portfolio companies.

During the three-month period ended March 31, 2013, the Company recognized net realized gains of approximately $2.0 million on the portfolio. During the three-month period ended March 31, 2013, the Company recorded gross realized gains of approximately $3.6 million from the sale of investments in three portfolio companies. These gains were partially offset by the liquidation of the Company’s investments in five portfolio companies of approximately $1.6 million in gross realized losses.

Loan origination and commitment fees received in full at the inception of a loan are deferred and amortized into fee income as an enhancement to the related loan’s yield over the contractual life of the loan. Loan exit fees to be paid at the termination of the loan are accreted into interest income over the contractual life of the loan. The Company had approximately $3.9 million and $4.0 million of unamortized fees at March 31, 2014 and December 31, 2013, respectively, and approximately $14.6 million and $14.4 million in exit fees receivable at March 31, 2014 and December 31, 2013, respectively.

The Company has debt investments in its portfolio that contain a payment-in-kind (“PIK”) provision. The PIK interest, computed at the contractual rate specified in each loan agreement, is added to the principal balance of the loan and recorded as interest income. To maintain the Company’s status as a RIC, this non-cash source of income must be paid out to stockholders in the form of dividends even though the Company has not yet collected the cash. Amounts necessary to pay these dividends may come from available cash or the liquidation of certain investments. The Company recorded approximately $852,000 and $779,000 in PIK income during the three-months ended March 31, 2014 and 2013, respectively.

In certain investment transactions, the Company may provide advisory services. For services that are separately identifiable and external evidence exists to substantiate fair value, income is recognized as earned, which is generally when the investment transaction closes. The Company had no income from advisory services in the three-month periods ended March 31, 2014 and 2013.

In the majority of cases, the Company collateralizes its investments by obtaining a first priority security interest in a portfolio company’s assets, which may include its intellectual property. In other cases, the Company may obtain a negative pledge covering a company’s intellectual property. At March 31, 2014, approximately 61.5% of our portfolio company debt investments were secured by a first priority security in all of the assets of the portfolio company, including their intellectual property, and 38.5% of the debt investments were to portfolio companies that were prohibited from pledging or encumbering their intellectual property. At March 31, 2014 the Company had no equipment only liens on any of our portfolio companies.

 

47


Table of Contents

3. Fair Value of Financial Instruments

Fair value estimates are made at discrete points in time based on relevant information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. The Company believes that the carrying amounts of its financial instruments, consisting of cash and cash equivalents, receivables, accounts payable and accrued liabilities, approximate the fair values of such items due to the short maturity of such instruments. The Convertible Senior Notes, 2019 Notes payable (the “April 2019 Notes” and the “September 2019 Notes”, together the “2019 Notes”), the Asset-Backed Notes and the SBA debentures as sources of liquidity remain a strategic advantage due to their flexible structure, long-term duration, and low fixed interest rates. At March 31, 2014, the April 2019 Notes were trading on the New York Stock Exchange for $1.035 per dollar at par value, and the September 2019 Notes were trading on the New York Stock Exchange for $1.030 per dollar at par value. Based on market quotations on or around March 31, 2014, the Convertible Senior Notes were trading for $1.213 per dollar at par value and the Asset-Backed Notes were trading for $1.003 per dollar at par value. Calculated based on the net present value of payments over the term of the notes using estimated market rates for similar notes and remaining terms, the fair value of the SBA debentures would be approximately $194.1 million, compared to the carrying amount of $190.2 million as of March 31, 2014.

See the accompanying Consolidated Schedule of Investments for the fair value of the Company’s investments. The methodology for the determination of the fair value of the Company’s investments is discussed in Note 2.

The liabilities of the Company below are recorded at amortized cost and not at fair value on the Consolidated Statement of Assets and Liabilities. The following table provides additional information about the level in the fair value hierarchy of the Company’s liabilities at March 31, 2014 (unaudited) and December 31, 2013:

 

(in thousands)

Description

   March 31,
2014
     Identical Assets
(Level 1)
     Observable Inputs
(Level 2)
     Unobservable
Inputs

(Level 3)
 

Convertible Senior Notes

   $ 90,938       $ —         $ 90,938       $ —     

Asset Backed Notes

   $ 63,981       $ —         $ —         $ 63,981   

April 2019 Notes

   $ 87,430       $ —         $ 87,430       $ —     

September 2019 Notes

   $ 88,451       $ —         $ 88,451       $ —     

SBA Debentures

   $ 194,128       $ —         $ —         $ 194,128   

 

(in thousands)

Description

   December  31,
2013
     Identical Assets
(Level 1)
     Observable Inputs
(Level 2)
     Unobservable
Inputs

(Level 3)
 

Convertible Senior Notes

   $ 105,206       $ —         $ 105,206       $ —     

Asset Backed Notes

   $ 89,893       $ —         $ —         $ 89,893   

April 2019 Notes

   $ 86,281       $ —         $ 86,281       $ —     

September 2019 Notes

   $ 87,248       $ —         $ 87,248       $ —     

SBA Debentures

   $ 222,742       $ —         $ —         $ 222,742   

 

48


Table of Contents

4. Borrowings Long Term

Outstanding Borrowings

At March 31, 2014 (unaudited) and December 31, 2013, the Company had the following available borrowings and outstanding borrowings:

 

     March 31, 2014      December 31, 2013  

(in thousands)

   Total
Available
     Carrying
Value (1)
     Total
Available
     Carrying
Value (1)
 

SBA Debentures (2)

   $ 190,200       $ 190,200      $ 225,000       $ 225,000   

2019 Notes

     170,364         170,364        170,364         170,364   

Asset-Backed Notes

     63,782         63,782        89,557         89,557   

Convertible Senior Notes (3)

     75,000         72,789        75,000         72,519   

Wells Facility

     75,000         —           75,000         —     

Union Bank Facility

     30,000         —           30,000         —     
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 604,346       $ 497,135      $ 664,921       $ 557,440   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

(1) Except for the Convertible Senior Notes, all carrying values are the same as the principal amount outstanding.
(2) In March 2014, the Company repaid $34.8 million of SBA debentures under HT II, priced at approximately 6.38%, including annual fees. At March 31, 2014, the total available borrowings under the SBA was $190.2 million, of which $41.2 million was available in HT II and $149.0 million was available in HT III. At December 31, 2013, the total available borrowings under the SBA was $225.0 million, of which $76.0 million was available in HT II and $149.0 million was available in HT III.
(3) Represents the aggregate principal amount outstanding of the Convertible Senior Notes less the unaccreted discount initially recorded upon issuance of the Convertible Senior Notes. The total unaccreted discount for the Convertible Senior Notes was $2.2 million at March 31, 2014 and $2.5 million at December 31, 2013.

Long-Term SBA Debentures

On September 27, 2006, HT II received a license to operate as a SBIC under the SBIC program and is able to borrow funds from the SBA against eligible investments and regulatory capital. Under the Small Business Investment Company Act and current SBA policy applicable to SBICs, a SBIC can have outstanding at any time SBA guaranteed debentures up to twice the amount of its regulatory capital. With the Company’s net investment of $38.0 million in HT II as of March 31, 2014, HT II has the capacity to issue a total of $76.0 million of SBA guaranteed debentures, subject to SBA approval, of which $41.2 million was available at March 31, 2014. As of March 31, 2014, HT II has paid the SBA commitment fees and facility fees of approximately $1.5 million and $3.6 million, respectively. As of March 31, 2014 the Company held investments in HT II in 41 companies with a fair value of approximately $98.9 million, accounting for approximately 11.1% of the Company’s total portfolio at March 31, 2014.

On May 26, 2010, HT III received a license to operate as a SBIC under the SBIC program and is able to borrow funds from the SBA against eligible investments and additional contributions to regulatory capital. With the Company’s net investment of $74.5 million in HT III as of March 31, 2014, HT III has the capacity to issue a total of $149.0 million of SBA guaranteed debentures, of which $149.0 million was outstanding as of March 31, 2014. As of March 31, 2014, HT III has paid commitment fees and facility fees of approximately $1.5 million and $3.6 million, respectively. As of March 31, 2014, the Company held investments in HT III in 31 companies with a fair value of approximately $178.5 million accounting for approximately 20.0% of the Company’s total portfolio at March 31, 2014.

SBICs are designed to stimulate the flow of private equity capital to eligible small businesses. Under present SBA regulations, eligible small businesses include businesses that have a tangible net worth not exceeding $18.0 million and have average annual fully taxed net income not exceeding $6.0 million for the two most recent fiscal years. In addition, SBICs must devote 25.0% of its investment activity to “smaller” enterprises as defined by the SBA. A smaller enterprise is one that has a tangible net worth not exceeding $6.0 million and has average annual fully taxed net income not exceeding $2.0 million for the two most recent fiscal years. SBA regulations also provide alternative size standard criteria to determine eligibility, which depend on the industry in which the business is engaged and are based on such factors as the number of employees and gross sales. According to SBA regulations, SBICs may make long-term loans to small businesses, invest in the equity securities of such businesses and provide them with consulting and advisory services. Through its wholly-owned subsidiaries HT II and HT III, the Company plans to provide long-term loans to qualifying small businesses, and in connection therewith, make equity investments.

HT II and HT III are periodically examined and audited by the SBA’s staff to determine their compliance with SBA regulations. If HT II or HT III fails to comply with applicable SBA regulations, the SBA could, depending on the severity of the violation, limit or prohibit HT II’s or HT III’s use of debentures, declare outstanding debentures immediately due and payable, and/or limit HT II or HT III from making new investments. In addition, HT II or HT III may also be limited in their ability to make distributions to the Company if they do not have sufficient capital in accordance with SBA regulations. Such actions by the SBA would, in turn, negatively affect the Company because HT II and HT III are the Company’s wholly owned subsidiaries. HT II and HT III were in compliance with the terms of the SBIC’s leverage as of March 31, 2014 as a result of having sufficient capital as defined under the SBA regulations.

 

49


Table of Contents

The rates of borrowings under various draws from the SBA beginning in March 2009 are set semiannually in March and September and range from 2.25% to 4.62%. Interest payments on SBA debentures are payable semiannually. There are no principal payments required on these issues prior to maturity and no prepayment penalties. Debentures under the SBA generally mature ten years after being borrowed. Based on the initial draw down date of March 2009, the initial maturity of SBA debentures will occur in March 2019. In addition, the SBA charges a fee that is set annually, depending on the Federal fiscal year the leverage commitment was delegated by the SBA, regardless of the date that the leverage was drawn by the SBIC. The annual fees related to HT II debentures that pooled on September 22, 2010 were 0.406% and 0.285%, depending upon the year in which the underlying commitment was closed. The annual fees on other debentures have been set at 0.906%. The annual fees related to HT III debentures that pooled on March 27, 2013 were 0.804%. The annual fees on other debentures have been set at 0.515%. The average amount of debentures outstanding for the three-months ended March 31, 2014 for HT II was approximately $63.6 million with an average interest rate of approximately 5.31%. The average amount of debentures outstanding for the three-months ended March 31, 2014 for HT III was approximately $149.0 million with an average interest rate of approximately 3.38%.

As of March 31, 2014, the maximum statutory limit on the dollar amount of combined outstanding SBA guaranteed debentures is $225.0 million, subject to periodic adjustments by the SBA. In aggregate, at March 31, 2014, with the Company’s net investment of $112.5 million, HT II and HT III have the capacity to issue a total of $225.0 million of SBA-guaranteed debentures, subject to SBA approval. In March 2014, the Company repaid $34.8 million of SBA debentures under HT II, priced at approximately 6.38%, including annual fees. At March 31, 2014, the Company has issued $190.2 million in SBA-guaranteed debentures in the Company’s SBIC subsidiaries.

The Company reported the following SBA debentures outstanding as of March 31, 2014 (unaudited) and December 31, 2013:

 

(in thousands)

Issuance/Pooling Date

   Maturity Date    Interest Rate  (1)     March 31,
2014
     December 31,
2013
 

SBA Debentures:

          

March 26, 2008

   March 1, 2018      6.38   $ —         $ 34,800   

March 25, 2009

   March 1, 2019      5.53     18,400         18,400   

September 23, 2009

   September 1, 2019      4.64     3,400         3,400   

September 22, 2010

   September 1, 2020      3.62     6,500         6,500   

September 22, 2010

   September 1, 2020      3.50     22,900         22,900   

March 29, 2011

   March 1, 2021      4.37     28,750         28,750   

September 21, 2011

   September 1, 2021      3.16     25,000         25,000   

March 21, 2012

   March 1, 2022      3.28     25,000         25,000   

March 21, 2012

   March 1, 2022      3.05     11,250         11,250   

September 19, 2012

   September 1, 2022      3.05     24,250         24,250   

March 27, 2013

   March 1, 2023      3.16     24,750         24,750   
       

 

 

    

 

 

 

Total SBA Debentures

        $ 190,200      $ 225,000   
       

 

 

    

 

 

 

 

(1) Interest rate includes annual charge

2019 Notes

On March 6, 2012, the Company and U.S. Bank National Association (the “Trustee”) entered into an indenture (the “Base Indenture”). On April 17, 2012, the Company and the Trustee entered into the First Supplemental Indenture to the Base Indenture (the “First Supplemental Indenture”), dated April 17, 2012, relating to the Company’s issuance, offer and sale of $43.0 million aggregate principal amount of 7.00% senior notes due 2019 (the “April 2019 Notes”). The sale of the April 2019 Notes generated net proceeds, before expenses, of approximately $41.7 million.

On September 24, 2012, the Company and the Trustee, entered into the Second Supplemental Indenture to the Base Indenture (the “Second Supplemental Indenture”), dated as of September 24, 2012, relating to the Company’s issuance, offer and sale of $75.0 million aggregate principal amount of 7.00% senior notes due 2019 (the “September 2019 Notes” and, together with the April 2019 Notes, the “2019 Notes”). The sale of the September 2019 Notes generated net proceeds, before expenses, of approximately $72.75 million.

 

50


Table of Contents

2019 Notes payable is compromised of:

 

     As of  
(in thousands)    March 31, 2014      December 31, 2013  

April 2019 Notes

   $ 84,490       $ 84,490   

September 2019 Notes

     85,874         85,874   
  

 

 

    

 

 

 

Carrying Value of Debt

   $ 170,364       $ 170,364   
  

 

 

    

 

 

 

April 2019 Notes

The April 2019 Notes will mature on April 30, 2019 and may be redeemed in whole or in part at the Company’s option at any time or from time to time on or after April 30, 2015, upon not less than 30 days nor more than 60 days written notice by mail prior to the date fixed for redemption thereof, at a redemption price of 100% of the outstanding principal amount thereof plus accrued and unpaid interest payments otherwise payable for the then-current quarterly interest period accrued to but not including the date fixed for redemption. The April 2019 Notes bear interest at a rate of 7.00% per year payable quarterly on January 30, April 30, July 30 and October 30 of each year, commencing on July 30, 2012, and trade on the New York Stock Exchange under the trading symbol “HTGZ.”

The April 2019 Notes are the Company’s direct unsecured obligations and rank: (i) pari passu with the Company’s other outstanding and future senior unsecured indebtedness, including without limitation, the $75.0 million in aggregate principal amount of the Convertible Senior Notes; (ii) senior to any of the Company’s future indebtedness that expressly provides it is subordinated to the April 2019 Notes; (iii) effectively subordinated to all the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grant security), to the extent of the value of the assets securing such indebtedness, including without limitation, borrowings under the Company’s Credit Facilities; (iv) structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries, including without limitation, the indebtedness of Hercules Technology II, L.P. and Hercules Technology III, L.P. and borrowings under the Company’s revolving senior secured credit facility with Wells Fargo Capital Finance, LLC.

The Base Indenture, as supplemented by the First Supplemental Indenture, contains certain covenants including covenants requiring the Company’s compliance with (regardless of whether it is subject to) the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) of the 1940 Act to comply with the restrictions on dividends, distributions and purchase of capital stock set forth in Section 18(a)(1)(B) as modified by Section 61(a)(1) of the 1940 Act and to provide financial information to the holders of the April 2019 Notes and the Trustee if the Company should no longer be subject to the reporting requirements under the Securities Exchange Act of 1934. These covenants are subject to important limitations and exceptions that are described in the Indenture, as supplemented by the First Supplemental Indenture. The Indenture provides for customary events of default and further provides that the Trustee or the holders of 25% in aggregate principal amount of the outstanding April 2019 Notes in a series may declare such April 2019 Notes immediately due and payable upon the occurrence of any event of default after expiration of any applicable grace period.

The April 2019 Notes were sold pursuant to an underwriting agreement dated April 11, 2012 among the Company and Stifel, Nicolaus & Company, Incorporated, as representative of the several underwriters named in the underwriting agreement.

In July 2012, the Company reopened the Company’s April 2019 Notes and issued an additional $41.5 million in aggregate principal amount of April 2019 Notes, which includes exercise of an over-allotment option, bringing the total amount of the April 2019 Notes issued to approximately $84.5 million in aggregate principal amount.

September 2019 Notes

The September 2019 Notes will mature on September 30, 2019 and may be redeemed in whole or in part at the Company’s option at any time or from time to time on or after September 30, 2015, upon not less than 30 days nor more than 60 days written notice by mail prior to the date fixed for redemption thereof, at a redemption price of 100% of the outstanding principal amount thereof plus accrued and unpaid interest payments otherwise payable for the then-current quarterly interest period accrued to but not including the date fixed for redemption. The September 2019 Notes bear interest at a rate of 7.00% per year payable quarterly on March 30, June 30, September 30 and December 30 of each year, commencing on December 30, 2012, and trade on the New York Stock Exchange under the trading symbol “HTGY.”

 

51


Table of Contents

The September 2019 Notes are the Company’s direct unsecured obligations and rank: (i) pari passu with the Company’s other outstanding and future senior unsecured indebtedness, including without limitation, the $75 million in aggregate principal amount of the Convertible Senior Notes; (ii) senior to any of the Company’s future indebtedness that expressly provides it is subordinated to the September 2019 Notes; (iii) effectively subordinated to all the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grants security), to the extent of the value of the assets securing such indebtedness, including without limitation, borrowings under the Company’s credit facilities; (iv) structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries, including without limitation, the indebtedness of Hercules Technology II, L.P. and Hercules Technology III, L.P. and borrowings under the Company’s revolving senior secured credit facility with Wells Fargo Capital Finance.

The Base Indenture, as supplemented by the Second Supplemental Indenture, contains certain covenants including covenants requiring the Company to comply with (regardless of whether it is subject to) the asset coverage requirements set forth in Section 18 (a)(1)(A) as modified by Section 61(a)(1) of the 1940 Act to comply with the restrictions on dividends, distributions and purchase of capital stock set forth in Section 18(a)(1)(B) as modified by Section 61(a)(1) of the 1940 Act and to provide financial information to the holders of the September 2019 Notes and the Trustee if the Company should no longer be subject to the reporting requirements under the Securities Exchange Act of 1934. These covenants are subject to important limitations and exceptions that are described in the Indenture, as supplemented by the Second Supplemental Indenture. The Indenture provides for customary events of default and further provides that the Trustee or the holders of 25% in aggregate principal amount of the outstanding September 2019 Notes in a series may declare such September 2019 Notes immediately due and payable upon the occurrence of any event of default after expiration of any applicable grace period.

The September 2019 Notes were sold pursuant to an underwriting agreement dated September 19, 2012 among the Company and Stifel, Nicolaus & Company, Incorporated, as representative of the several underwriters named in the underwriting agreement. In October 2012, the underwriters exercised their over-allotment option for an additional $10.9 million of the September 2019 Notes, bringing the total amount of the September 2019 Notes issued to approximately $85.9 million in aggregate principal amount.

For the three-months ended March 31, 2014 and 2013 (unaudited), the components of interest expense and related fees and cash paid for interest expense for the April 2019 Notes and September 2019 Notes are as follows:

 

     Three Months Ended March 31,  
(in thousands)    2014      2013  

Stated interest expense

   $ 2,981       $ 2,981   

Amortization of debt issuance cost

     240         240   
  

 

 

    

 

 

 

Total interest expense and fees

   $ 3,221      $ 3,221   
  

 

 

    

 

 

 

Cash paid for interest expense and fees

   $ 2,981       $ 2,998   

As of March 31, 2014, the Company was in compliance with the terms of the indenture, and respective supplemental indenture, governing the April 2019 Notes and September 2019 Notes.

Asset-Backed Notes

On December 19, 2012, the Company completed a $230.7 million term debt securitization in connection with which an affiliate of the Company’s made an offer of $129.3 million in aggregate principal amount of fixed-rate asset-backed notes (the “Asset-Backed Notes”), which Asset-Backed Notes were rated A2(sf) by Moody’s Investors Service, Inc. The Asset-Backed Notes were issued by Hercules Capital Funding Trust 2012-1 pursuant to a note purchase agreement, dated as of December 12, 2012, by and among the Company, Hercules Capital Funding 2012-1 LLC, as Trust Depositor (the “Trust Depositor”), Hercules Capital Funding Trust 2012-1, as Issuer (the “Issuer”), and Guggenheim Securities, LLC, as Initial Purchaser, and are backed by a pool of senior loans made to certain of the Company’s portfolio companies and secured by certain assets of those portfolio companies and are to be serviced by the Company. Interest on the Asset-Backed Notes will be paid, to the extent of funds available, at a fixed rate of 3.32% per annum. The Asset-Backed Notes have a stated maturity of December 16, 2017.

As part of this transaction, the Company entered into a sale and contribution agreement with the Trust Depositor under which the Company has agreed to sell or have contributed to the Trust Depositor certain senior loans made to certain of the Company’s portfolio companies (the “Loans”). The Company has made customary representations, warranties and covenants in the sale and contribution agreement with respect to the Loans as of the date of their transfer to the Trust Depositor.

 

52


Table of Contents

In connection with the issuance and sale of the Asset-Backed Notes, the Company has made customary representations, warranties and covenants in the note purchase agreement. The Asset-Backed Notes are secured obligations of the Issuer and are non-recourse to the Company. The Issuer also entered into an indenture governing the Asset-Backed Notes, which indenture includes customary representations, warranties and covenants. The Asset-Backed Notes were sold without being registered under the Securities Act of 1933, as amended (the “Securities Act”), to “qualified institutional buyers” in compliance with the exemption from registration provided by Rule 144A under the Securities Act and to institutional “accredited investors” (as defined in Rule 501(a)(1), (2), (3) or (7) under the Securities Act) who in each case, are “qualified purchasers” for purposes of Section 3(c)(7) under the 1940 Act. In addition, the Trust Depositor entered into an amended and restated trust agreement, which includes customary representation, warranties and covenants.

The Loans are serviced by the Company pursuant to a sale and servicing agreement, which contains customary representations, warranties and covenants. The Company performs certain servicing and administrative functions with respect to the Loans. The Company is entitled to receive a monthly fee from the Issuer for servicing the Loans. This servicing fee is equal to the product of one-twelfth (or in the case of the first payment date, a fraction equal to the number of days from and including December 5, 2012 through and including January 15, 2013 over 360) of 2.00% and the aggregate outstanding principal balance of the Loans, excluding all defaulted Loans and all purchased Loans, as of the first day of the related collection period (the period from the 5th day of the immediately preceding calendar month through the 4th day of the calendar month in which a payment date occurs, and for the first payment date, the period from and including December 5, 2012, to the close of business on January 4, 2013).

The Company also serves as administrator to the Issuer under an administration agreement, which includes customary representations, warranties and covenants.

At March 31, 2014 and December 31, 2013, the Asset Backed Notes had an outstanding principal balance of $63.8 million and $89.6 million, respectively.

Under the terms of the Asset Backed Notes, the Company is required to maintain a reserve cash balance, funded through interest and principal collections from the underlying securitized debt portfolio, which may be used to pay monthly interest and principal payments on the Asset-Backed Notes. The Company has segregated these funds and classified them as Restricted Cash. There was approximately $4.8 million and $6.3 million of Restricted Cash as of March 31, 2014 and December 31, 2013, respectively, funded through interest collections.

Convertible Senior Notes

In April 2011, the Company issued $75.0 million in aggregate principal amount of 6.00% convertible senior notes (the “Convertible Senior Notes”) due 2016. As of March 31, 2014, the carrying value of the Convertible Senior Notes, comprised of the aggregate principal amount outstanding less the unaccreted discount initially recorded upon issuance of the Convertible Senior Notes, is approximately $72.8 million.

The Convertible Senior Notes mature on April 15, 2016 (the “Maturity Date”), unless previously converted or repurchased in accordance with their terms. The Convertible Senior Notes bear interest at a rate of 6.00% per year payable semiannually in arrears on April 15 and October 15 of each year, commencing on October 15, 2011. The Convertible Senior Notes are the Company’s senior unsecured obligations and rank senior in right of payment to the Company’s existing and future indebtedness that is expressly subordinated in right of payment to the Convertible Senior Notes; equal in right of payment to the Company’s existing and future unsecured indebtedness that is not so subordinated; effectively junior in right of payment to any of the Company’s secured indebtedness (including unsecured indebtedness that the Company later secure) to the extent of the value of the assets securing such indebtedness; and structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company’s subsidiaries, financing vehicles or similar facilities.

Prior to the close of business on the business day immediately preceding October 15, 2015, holders may convert their Convertible Senior Notes only under certain circumstances set forth in the Indenture. On or after October 15, 2015 until the close of business on the scheduled trading day immediately preceding the Maturity Date, holders may convert their Convertible Senior Notes at any time. Upon conversion, the Company will pay or deliver, as the case may be, at the Company’s election, cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock. The conversion rate will initially be 84.0972 shares of common stock per $1,000 principal amount of Convertible Senior Notes (equivalent to an initial conversion price of approximately $11.89 per share of common stock). The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, if certain corporate events occur prior to the Maturity Date, the conversion rate will be increased for converting holders. As of March 31, 2014, the conversion rate was 86.5029 shares of common stock per $1,000 principal amount of Convertible Senior Notes (equivalent to an adjusted conversion price of approximately $11.56 per share of common stock).

The Company may not redeem the Convertible Senior Notes prior to maturity. No sinking fund is provided for the Convertible Senior Notes. In addition, if certain corporate events occur, holders of the Convertible Senior Notes may require the Company to repurchase for cash all or part of their Convertible Senior Notes at a repurchase price equal to 100% of the principal amount of the Convertible Senior Notes to be repurchased, plus accrued and unpaid interest through, but excluding, the required repurchase date.

 

53


Table of Contents

The Convertible Senior Notes are accounted for in accordance with ASC 470-20 (previously FASB Staff Position No. APB 14- 1, “Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement)”). In accounting for the Convertible Senior Notes, the Company estimated at the time of issuance that the values of the debt and the embedded conversion feature of the Convertible Senior Notes were approximately 92.8% and 7.2%, respectively. The original issue discount of 7.2% attributable to the conversion feature of the Convertible Senior Notes was recorded in “capital in excess of par value” in the consolidated statement of assets and liabilities. As a result, the Company recorded interest expense comprised of both stated interest expense as well as accretion of the original issue discount resulting in an estimated effective interest rate of approximately 8.1%.

As of March 31, 2014 (unaudited) and December 31, 2013, the components of the carrying value of the Convertible Senior Notes were as follows:

 

(in thousands)    As of March 31, 2014     As of December 31, 2013  

Principal amount of debt

   $ 75,000      $ 75,000   

Original issue discount, net of accretion

     (2,211     (2,481
  

 

 

   

 

 

 

Carrying value of debt

   $ 72,789      $ 72,519   
  

 

 

   

 

 

 

For the three-months ended March 31, 2014 and 2013 (unaudited), the components of interest expense, fees and cash paid for interest expense for the Convertible Senior Notes were as follows:

 

     Three Months Ended March,  
(in thousands)    2014      2013  

Stated interest expense

   $ 1,125       $ 1,125   

Accretion of original issue discount

     271         271   

Amortization of debt issuance cost

     144         144   
  

 

 

    

 

 

 

Total interest expense

   $ 1,540       $ 1,540   
  

 

 

    

 

 

 

Cash paid for interest expense

   $ —         $ —     

The estimated effective interest rate of the debt component of the Convertible Senior Notes, equal to the stated interest of 6.0% plus the accretion of the original issue discount, was approximately 8.1% for both the three-months ended March 31, 2014 and 2013. As of March 31, 2014, the Company is in compliance with the terms of the indentures governing the Convertible Senior Notes.

Wells Facility

In August 2008, the Company entered into a $50.0 million two-year revolving senior secured credit facility with Wells Fargo Capital Finance (the “Wells Facility”). On June 20, 2011, the Company renewed the Wells Facility. Under this three-year senior secured facility, Wells Fargo Capital Finance has made commitments of $75.0 million. The facility contains an accordion feature, in which the Company can increase the credit line up to an aggregate of $300.0 million, funded by additional lenders and with the agreement of Wells Fargo Capital Finance and subject to other customary conditions. The Company expects to continue discussions with various other potential lenders to join the new facility; however, there can be no assurances that additional lenders will join the Wells Facility.

On August 1, 2012, the Company entered into an amendment to the Wells Facility. The amendment reduces the interest rate floor by 75 basis points to 4.25% and extends the maturity date by one year to August 2015. Additionally, an amortization period of 12 months was added to pay down the principal balance as of the maturity date, and the unused line fee was reduced.

Borrowings under the Wells Facility will generally bear interest at a rate per annum equal to LIBOR plus 3.50%, with a floor of 4.25% and an advance rate of 50% against eligible debt investments. The Wells Facility is secured by debt investments in the borrowing base. The Wells Facility requires payment of a non-use fee on a scale of 0.0% to 0.50% of the average monthly outstanding balance. The monthly payment of a non-use fee thereafter shall depend on the average balance that was outstanding on a scale between 0.0% and 0.50%. For the three-month period ended March 31, 2014, this non-use fee was approximately $101,000. On June 20, 2011 the Company paid an additional $1.1 million in structuring fees in connection with the Wells Facility which is being amortized through the end of the term.

The Wells Facility includes various financial and operating covenants applicable to the Company and the Company’s subsidiaries, in addition to those applicable to Hercules Funding II, LLC. These covenants require the Company to maintain certain financial ratios and a minimum tangible net worth in an amount, when added to outstanding subordinated indebtedness, that is in excess of $362.0 million plus 90% of the cumulative amount of equity raised after June 30, 2012. In addition, the tangible net worth covenant will increase by 90 cents on the dollar for every dollar of equity capital that the Company subsequently raises. As of March 31, 2014, the minimum tangible net worth covenant has increased to $478.5 million as a result of the Company’s follow-on public offerings. The Wells Facility provides for customary events of default, including, but not limited to, payment defaults, breach of representations or covenants, bankruptcy events and change of control. The Company was in compliance with all covenants at March 31, 2014.

At March 31, 2014 there were no borrowings outstanding on this facility.

 

54


Table of Contents

Union Bank Facility

On February 10, 2010, the Company entered a $20.0 million one-year revolving senior secured credit facility with Union Bank (the “Union Bank Facility”). On November 2, 2011, the Company renewed and amended the Union Bank Facility and added a new lender under the Union Bank Facility. Union Bank and RBC Capital Markets (“RBC”) have made commitments of $30.0 million and $25.0 million, respectively. The Union Bank Facility contains an accordion feature, in which the Company can increase the credit line up to an aggregate of $150.0 million, funded by additional lenders and with the agreement of Union Bank and subject to other customary conditions. The Company expects to continue discussions with various other potential lenders to join the new facility; however, there can be no assurances that additional lenders will join the Union Bank Facility.

On March 30, 2012 the Company entered into an amendment to the Union Bank Facility which permitted the Company to issue additional senior notes relating to the offer and sale of the Company’s 2019 Notes. On September 17, 2012, the Company entered into an amendment to the Union Bank Facility. Pursuant to the terms of the amendment, the Company is permitted to increase the Company’s unsecured indebtedness by an aggregate original principal amount not to exceed $200.0 million incurred after March 30, 2012 in one or more issuances, provided certain conditions are satisfied for each issuance.

On December 17, 2012, the Company further amended the Union Bank Facility to remove RBC from the Union Bank Facility. Following the removal of RBC, the Union Bank Facility consists solely of Union Bank’s commitment of $30.0 million. In connection with the amendment, the maximum availability under the Union Bank Facility, subject to a borrowing base, was reduced from $55.0 million to $30.0 million. The Union Bank Facility contains an accordion feature, in which the Company could increase the credit line by up to $95.0 million in the aggregate, funded by commitments from additional lenders and with the agreement of Union Bank and subject to other customary conditions. There can be no assurances that additional lenders will join the Union Bank Facility.

Borrowings under the Union Bank Facility will generally bear interest at a rate per annum equal to LIBOR plus 2.25% with a floor of 4.0%. The Union Bank Facility requires the payment of a non-use fee of 0.50% annually. For the three-month period ended March 31, 2014, this nonuse fee was $37,500. The Union Bank Facility is collateralized by debt investments in the Company’s portfolio companies, and includes an advance rate equal to 50.0% of eligible debt investments placed in the collateral pool. The Union Bank Facility generally requires payment of interest on a monthly basis. All outstanding principal is due upon maturity.

The Union Bank Facility requires various financial and operating covenants. These covenants require the Company to maintain certain financial ratios and a minimum tangible net worth in an amount, when added to outstanding subordinated indebtedness, that is in excess of $314.0 million plus 90% of the amount of net cash proceeds received from the sale of common stock after March 31, 2011. As of March 31, 2014, the minimum tangible net worth covenant has increased to $472.8 million as a result of follow-on public offerings. Union Bank Facility also provides for customary events of default, including, but not limited to, payment defaults, breach of representations or covenants, bankruptcy events and change of control. The Company was in compliance with all covenants at March 31, 2014.

At March 31, 2014 there were no borrowings outstanding on this facility. The Company Further amended the Union Bank Facility on January 31, 2014. As amended, the Union Bank Facility will expire as of May 2, 2014. The Company continues to explore potential financing arrangements with Union Bank that may be implemented following the expiration of the Union Bank Facility.

Citibank Credit Facility

The Company, through Hercules Funding Trust I, an affiliated statutory trust, had a securitized credit facility (the “Citibank Credit Facility”) with Citigroup Global Markets Realty Corp. which expired under normal terms. During the first quarter of 2009, the Company paid off all principal and interest owed under the Citibank Credit Facility. Citigroup has an equity participation right through a warrant participation agreement on the pool of debt investments and warrants collateralized under the Citibank Credit Facility. Pursuant to the warrant participation agreement, the Company granted to Citigroup a 10% participation in all warrants held as collateral. However, no additional warrants were included in collateral subsequent to the facility amendment on May 2, 2007. As a result, Citigroup is entitled to 10% of the realized gains on the warrants until the realized gains paid to Citigroup pursuant to the agreement equal $3,750,000 (the “Maximum Participation Limit”). The obligations under the warrant participation agreement continue even after the Citibank Credit Facility is terminated until the Maximum Participation Limit has been reached.

During the three-months ended March 31, 2014, the Company reduced the Company’s realized gain by approximately $78,000 for Citigroup’s participation in the gain on sale of equity securities which were obtained from exercising a portfolio company warrant which was included in the collateral pool. The Company recorded a decrease on participation liability and an increase on unrealized appreciation by a net amount of approximately $45,000 as a result of current quarter depreciation of fair value on the pool of warrants collateralized under the warrant participation agreement. The value of their participation right on unrealized gains in the related equity investments was approximately $325,000 as of March 31, 2014 and is included in accrued liabilities. There can be no assurances that the unrealized appreciation of the warrants will not be higher or lower in future periods due to fluctuations in the value of the warrants, thereby increasing or reducing the effect on the cost of borrowing. Since inception of the agreement, the Company has paid Citigroup approximately $1.7 million under the warrant participation agreement thereby reducing the Company’s realized gains by this amount. The Company will continue to pay Citigroup under the warrant participation agreement until the Maximum Participation Limit is reached or the warrants expire. Warrants subject to the Citigroup participation agreement are set to expire between February 2016 and March 2017.

 

55


Table of Contents

5. Income taxes

The Company has elected to be taxed as a RIC under Subchapter M of the Code and intends to continue to operate so as to qualify to be taxed as a RIC under Subchapter M of the Code and, as such, will not be subject to federal income tax on the portion of taxable income and gains distributed to stockholders.

To qualify as a RIC, the Company is required to meet certain income and asset diversification tests in addition to distributing at least 90% of its investment company taxable income, as defined by the Code. The amount to be paid out as a dividend is determined by the Board of Directors each quarter and is based upon the annual earnings estimated by the management of the Company. To the extent that the Company’s earnings fall below the amount of dividends declared, however, a portion of the total amount of the Company’s dividends for the fiscal year may be deemed a return of capital for tax purposes to the Company’s stockholders.

Taxable income includes the Company’s taxable interest, dividend and fee income, as well as taxable net capital gains. Taxable income generally differs from net income for financial reporting purposes due to temporary and permanent differences in the recognition of income and expenses, and generally excludes net unrealized appreciation or depreciation, as gains or losses are not included in taxable income until they are realized.

Taxable income includes non-cash income, such as changes in accrued and reinvested interest and dividends, which includes contractual payment-in-kind interest, and the amortization of discounts and fees. Cash collections of income resulting from contractual PIK interest arrangements or the amortization of discounts and fees generally occur upon the repayment of the loans or debt securities that include such items. Non-cash taxable income is reduced by non-cash expenses, such as realized losses and depreciation and amortization expense.

During the three-months ended March 31, 2014, the Company declared a distribution of $0.31 per share. The determination of the tax attributes of the Company’s distributions is made annually as of the end of the Company’s fiscal year based upon its taxable income for the full year and distributions paid for the full year. As a result, a determination made on a quarterly basis may not be representative of the actual tax attributes of the Company’s distributions for a full year. If the Company had determined the tax attributes of our distributions year-to-date as of March 31, 2014, approximately 100% would be from ordinary income and spillover earnings from 2013. However there can be no certainty to shareholders that this determination is representative of what the tax attributes of its 2013 distributions to shareholders will actually be.

As a RIC, the Company will be subject to a 4% nondeductible federal excise tax on certain undistributed income unless the Company distributes in a timely manner an amount at least equal to the sum of (1) 98% of its ordinary income for each calendar year, (2) 98.2% of its capital gain net income for the 1-year period ending October 31 in that calendar year and (3) any income realized, but not distributed, in the preceding year (the “Excise Tax Avoidance Requirements”). The Company will not be subject to excise taxes on amounts on which the Company is required to pay corporate income tax (such as retained net capital gains). Depending on the level of taxable income earned in a tax year, the Company may choose to carry over taxable income in excess of current year distributions from such taxable income into the next tax year and pay a 4% excise tax on such income, as required. The maximum amount of excess taxable income that may be carried over for distribution in the next year under the Code is the total amount of dividends paid in the following year, subject to certain declaration and payment guidelines. To the extent the Company chooses to carry over taxable income into the next tax year, dividends declared and paid by the Company in a year may differ from taxable income for that year as such dividends may include the distribution of current year taxable income, the distribution of prior year taxable income carried over into and distributed in the current year, or returns of capital.

Taxable income for the three-month period ended March 31, 2014 was approximately $12.3 million or $0.20 per share. Taxable net realized gains for the same period were $3.5 million or approximately $0.06 per share. Taxable income for the three-month period ended March 31, 2013 was approximately $14.7 million or $0.27 per share. Taxable net realized gains for the same period were $1.1 million or approximately $0.02 per share.

The Company intends to distribute approximately $3.8 million of spillover earnings from the year ended December 31, 2013 to our shareholders in 2014.

 

56


Table of Contents

6. Shareholders’ Equity

On August 16, 2013, the Company entered into an “At-The-Market” (“ATM”) equity distribution agreement with JMP Securities LLC (“JMP”). The equity distribution agreement provides that the Company may offer and sell up to 8.0 million shares of its common stock from time to time through JMP, as its sales agent. Sales of the Company’s common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at the market,” as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made directly on the NYSE or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices. There were no sales under the ATM Program for the three-months ended March 31, 2014.

The Company has issued stock options for common stock subject to future issuance, of which 770,417 and 833,923 were outstanding at March 31, 2014 and December 31, 2013, respectively.

7. Equity Incentive Plan

The Company and its stockholders have authorized and adopted the 2004 Equity Incentive Plan (the “2004 Plan”) for purposes of attracting and retaining the services of its executive officers and key employees. Under the 2004 Plan, the Company is authorized to issue 7.0 million shares of common stock. On June 1, 2011, stockholders approved an amended and restated plan and provided an increase of 1.0 million shares, authorizing the Company to issue 8.0 million shares of common stock under the 2004 Plan.

The Company and its stockholders have authorized and adopted the 2006 Non-Employee Director Plan (the “2006 Plan” and, together with the 2004 Plan, the “Plans”) for purposes of attracting and retaining the services of its Board of Directors. Under the 2006 Plan, the Company is authorized to issue 1.0 million shares of common stock. The Company filed an exemptive relief request with the Securities and Exchange Commission (“SEC”) to allow options to be issued under the 2006 Plan which was approved on October 10, 2007.

On June 21, 2007, the stockholders approved amendments to the 2004 Plan and the 2006 Plan allowing for the grant of restricted stock. The amended Plans limit the combined maximum amount of restricted stock that may be issued under both Plans to 10% of the outstanding shares of the Company’s stock on the effective date of the Plans plus 10% of the number of shares of stock issued or delivered by the Company during the terms of the Plans. The amendments further specify that no one person shall be granted awards of restricted stock relating to more than 25% of the shares available for issuance under the 2004 Plan. Further, the amount of voting securities that would result from the exercise of all of the Company’s outstanding warrants, options and rights, together with any restricted stock issued pursuant to the Plans, at the time of issuance shall not exceed 25% of its outstanding voting securities, except that if the amount of voting securities that would result from such exercise of all of the Company’s outstanding warrants, options and rights issued to the Company’s directors, officers and employees, together with any restricted stock issued pursuant to the Plans, would exceed 15% of the Company’s outstanding voting securities, then the total amount of voting securities that would result from the exercise of all outstanding warrants, options and rights, together with any restricted stock issued pursuant to the Plans, at the time of issuance shall not exceed 20% of our outstanding voting securities.

 

57


Table of Contents

The following table summarizes the common stock options activities for the three-months ended March 31, 2014 and 2013 (unaudited):

 

     For the Three Months Ended March 31,  
     2014      2013  
     Common
Stock
Options
    Weighted
Average
Exercise
Price
     Common
Stock
Options
    Weighted
Average
Exercise
Price
 

Outstanding at December 31,

     833,923      $ 12.53         2,574,749      $ 12.00   

Granted

     —        $ —           27,000      $ 12.16   

Exercised

     (61,755   $ 11.77         (80,256   $ 11.31   

Forfeited

     (1,751   $ 11.39         (4,613   $ 9.65   

Expired

     —        $ —           —        $ —     
  

 

 

      

 

 

   

Outstanding at March 31,

     770,417      $ 12.59         2,516,880      $ 12.03   
  

 

 

      

 

 

   

Shares Expected to Vest at March 31,

     518,046      $ 12.59         408,065      $ 12.03   

The following table summarizes common stock options outstanding and exercisable at March 31, 2014 (unaudited):

 

(Dollars in thousands, except exercise price)

   Options outstanding      Options exercisable  

Range of exercise prices

   Number of
shares
     Weighted
average
remaining
contractual
life
     Aggregate
intrinsic
value
     Weighted
average
exercise
price
     Number
of shares
     Weighted
average
remaining
contractual
life
     Aggregate
intrinsic
value
     Weighted
average
exercise
price
 

$4.21 - $9.25

     50,640         2.99       $ 401,575       $ 6.14         37,469         2.39       $ 338,090       $ 5.05   

$9.90 - $14.86

     601,277         5.16         1,041,241       $ 12.56         214,902         3.14         713,075       $ 10.75   

$15.44 - $16.13

     118,500         6.60         —         $ 15.46         —           —           —         $ —     
  

 

 

       

 

 

       

 

 

       

 

 

    

$4.21 - $16.13

     770,417         5.24       $ 1,442,816       $ 12.59         252,371         3.03       $ 1,051,165       $ 9.90   
  

 

 

       

 

 

       

 

 

       

 

 

    

Options generally vest 33% one year after the date of grant and ratably over the succeeding 24 months. All options may be exercised for a period ending seven years after the date of grant. At March 31, 2014, options for approximately 252,000 shares were exercisable at a weighted average exercise price of approximately $9.90 per share with weighted average of remaining contractual term of 3.03 years.

The Company determined that the fair value of options granted under the 2006 and 2004 Plans during the three-months ended March 31, 2013 was approximately $54,000. No options were granted during the three-months ended March 31, 2014. During the three-months ended March 31, 2014 and 2013, approximately $140,000 and $95,000 of share-based cost due to stock option grants was expensed, respectively. As of March 31, 2014, there was $1.0 million of total unrecognized compensation costs related to stock options. These costs are expected to be recognized over a weighted average period of 2.30 years.

The fair value of options granted is based upon a Black Scholes option pricing model using the assumptions in the following table for the three-month period ended March 31, 2013. No options were granted during the three-months ended March 31, 2014.

 

     Three Months
Ended March 31,
     2013

Expected Volatility

   46.90%

Expected Dividends

   10%

Expected term (in years)

   4.5

Risk-free rate

   0.65% - 0.80%

During the three-months ended March 31, 2014 the Company did not grant any restricted stock pursuant to the Plans. During the three-months ended March 31, 2013, the Company granted approximately 606,001 shares of restricted stock pursuant to the Plans. See “Subsequent Events”.

The Company determined that the fair value of restricted stock granted under the 2006 and 2004 Plans during the three-month period ended March 31, 2013 was approximately $7.7 million. No shares of restricted stock were granted during the three-months ended March 31, 2014. During the three-month periods ended March 31, 2014 and 2013, the Company expensed approximately $1.4 million and $1.1 million of compensation expense related to restricted stock, respectively. As of March 31, 2014, there was approximately $8.6 million of total unrecognized compensation costs related to restricted stock. These costs are expected to be recognized over a weighted average period of 2.09 years.

 

58


Table of Contents

The following table summarizes the activities for our unvested restricted stock for the three-months ended March 31, 2014 and 2013 (unaudited):

 

     For the Three-Month Period Ended March 31,  
     2014      2013  
     Restricted
Stock Units
    Weighted
Average
Exercise
Price
     Restricted
Stock Units
    Weighted
Average
Exercise
Price
 

Unvested at December 31

     1,035,897      $ 11.94         899,789      $ 10.73   

Granted

     —        $ —           606,001      $ 12.72   

Vested

     (284,490   $ 12.21         (201,263   $ 10.39   

Forfeited

     —        $ —           (6,076   $ 10.54   

Unvested at March 31,

     751,407      $ 11.84         1,298,451      $ 11.71   

The SEC, through an exemptive order granted on June 22, 2010, approved amendments to the Plans which allow participants to elect to have the Company withhold shares of the Company’s common stock to pay for the exercise price and applicable taxes with respect to an option exercise (“net issuance exercise”). The exemptive order also permits the holders of restricted stock to elect to have the Company withhold shares of Hercules stock to pay the applicable taxes due on restricted stock at the time of vesting. Each individual can make, and does not preclude the participant from electing to make, a cash payment at the time of option exercise or to pay taxes on restricted stock.

8. Earnings Per Share

Shares used in the computation of the Company’s basic and diluted earnings per share are as follows (unaudited):

 

     Three Months Ended March 31,  

(in thousands, except per share data)

       2014             2013      

Numerator

    

Net increase in net assets resulting from operations

   $ 22,185     $ 16,689   

Less: Dividends declared-common and restricted shares

     (19,165 )     (13,382
  

 

 

   

 

 

 

Undistributed earnings

     3,020       3,307   
  

 

 

   

 

 

 

Undistributed earnings-common shares

     3,020       3,307   

Add: Dividend declared-common shares

     18,928       13,051   
  

 

 

   

 

 

 

Numerator for basic and diluted change in net assets per common share

   $ 21,948     $ 16,358   
  

 

 

   

 

 

 

Denominator

    

Basic weighted average common shares outstanding

     60,870       53,682   

Common shares issuable

     1,825       141   
  

 

 

   

 

 

 

Weighted average common shares outstanding assuming dilution

     62,695       53,823   

Change in net assets per common share

    

Basic

   $ 0.36     $ 0.30   

Diluted

   $ 0.35     $ 0.30   

 

59


Table of Contents

For the purpose of calculating diluted earnings per share for three-months ended March 31, 2014 and 2013, the dilutive effect of the Convertible Senior Notes under the treasury stock method is included in this calculation because the Company’s share price was greater than the conversion price in effect ($11.56 and $11.78, respectively) for the Convertible Senior Notes for such period.

The calculation of change in net assets resulting from operations per common share—assuming dilution, excludes all anti- dilutive shares. For the three-months ended March 31, 2014 and 2013, the number of anti-dilutive shares, as calculated based on the weighted average closing price of the Company’s common stock for the periods, was approximately 797,489 and 2,630,003 shares, respectively.

At March 31, 2014, the Company was authorized to issue 100,000,000 shares of common stock with a par value of $0.001. Each share of common stock entitles the holder to one vote.

9. Financial Highlights

Following is a schedule of financial highlights for the three-months ended March 31, 2014 and 2013:

 

     Three Months Ended
March 31,
 
     2014     2013  

Per share data:

    

Net asset value at beginning of period

   $ 10.51      $ 9.75   

Net investment income (1)

     0.30        0.28   

Net realized gain on investments

     0.08        0.03   

Net unrealized depreciation on investments

     (0.02     (0.01
  

 

 

   

 

 

 

Total from investment operations

     0.36        0.30   

Net increase/(decrease) in net assets from capital share transactions

     (0.01     0.18   

Distributions

     (0.31     (0.25

Stock-based compensation expense included in investment income (2)

     0.03        0.02   
  

 

 

   

 

 

 

Net asset value at end of period

   $ 10.58      $ 10.00   
  

 

 

   

 

 

 

Ratios and supplemental data:

    

Per share market value at end of period

   $ 14.07      $ 12.25   

Total return (3)

     (12.42 %)      14.59

Shares outstanding at end of period

     61,760        61,554   

Weighted average number of common shares outstanding

     60,870        53,682   

Net assets at end of period

   $   653,302      $   615,608   

Ratio of operating expense to average net assets

     10.74     12.23

Ratio of net investment income before provision for income tax expense and investment gains and losses to average net assets

     11.26     11.54

Average debt outstanding

   $ 536,110      $ 593,940   

Weighted average debt per common share

   $ 8.81      $ 11.06   

 

(1) Net investment income per share is calculated as net investment income divided by the weighted average shares outstanding.
(2) Stock option expense is a non-cash expense that has no effect on net asset value. Pursuant to ASC 718, net investment loss includes the expense associated with the granting of stock options which is offset by a corresponding increase in paid-in capital.
(3) The total return for the three-month periods ended March 31, 2014 and 2013 equals the change in the ending market value over the beginning of the period price per share plus dividends paid per share during the period, divided by the beginning price assuming the dividend is reinvested on the date of the distribution.

 

60


Table of Contents

10. Commitments and Contingencies

The Company’s commitments and contingencies consist primarily of unused commitments to extend credit in the form of loans to the Company’s portfolio companies. The balance of unfunded contractual commitments to extend credit at March 31, 2014 totaled approximately $189.4 million. Approximately $95.6 million of these unfunded contractual commitments as of March 31, 2014 are dependent upon the portfolio company reaching certain milestones before the debt commitment becomes available. Since a portion of these commitments may expire without being drawn, unfunded contractual commitments do not necessarily represent future cash requirements. In addition, the Company had approximately $238.0 million of non-binding term sheets outstanding at March 31, 2014. Non-binding outstanding term sheets are subject to completion of the Company’s due diligence and final approval process, as well as the negotiation of definitive documentation with the prospective portfolio companies. Not all non-binding term sheets are expected to close and do not necessarily represent the Company’s future cash requirements.

Certain premises are leased under agreements which expire at various dates through March 2020. Total rent expense amounted to approximately $388,000 and $329,000 during the three-month periods ended March 31, 2014 and 2013, respectively. Future commitments under the credit facility and operating leases were as follows at March 31, 2014:

 

     Payments due by period  
     (in thousands)  

Contractual Obligations(1)(2)

   Total      Less than
1 year
     1 - 3
years
     3 - 5
years
     After
5 years
 

Borrowings (3) (4)

   $ 497,135       $ —         $ 63,782       $ 72,789       $ 360,564   

Operating Lease Obligations (5)

     7,309         1,514         2,987         1,551         1,257   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 504,444       $ 1,514       $ 66,769       $ 74,340       $ 361,821   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

(1) Excludes commitments to extend credit to our portfolio companies.
(2) The Company also has a warrant participation agreement with Citigroup. See Note 4 to the Company’s consolidated financial statements.
(3) Includes $190.2 million in borrowings under the SBA debentures, $170.4 million of the 2019 Notes, $63.8 million in aggregate principal amount of the Asset-Backed Notes and $72.8 million of the Convertible Senior Notes.
(4) Except for the Convertible Senior Notes, all carrying values are the same as the principal amount outstanding. The aggregate principal amount outstanding of the Convertible Senior Notes is $75.0 million less the unaccreted discount initially recorded upon issuance of the Convertible Senior Notes. The total unaccreted discount for the Convertible Senior Notes was $2.2 million at March 31, 2014.
(5) Long-term facility leases.

The Company may, from time to time, be involved in litigation arising out of its operations in the normal course of business or otherwise. Furthermore, third parties may try to seek to impose liability on the Company in connection with the activities of its portfolio companies. While the outcome of any current legal proceedings cannot at this time be predicted with certainty, the Company does not expect any current matters will materially affect the Company’s financial condition or results of operations; however, there can be no assurance whether any pending legal proceedings will have a material adverse effect on the Company’s financial condition or results of operations in any future reporting period.

11. Recent Accounting Pronouncements

In June 2013, the FASB issued ASU 2013-08, “Financial Services – Investment Companies (Topic 946): Amendments to the Scope, Measurement, and Disclosure Requirements,” which amends the criteria that define an investment company and clarifies the measurement guidance and requires new disclosures for investment companies. Under ASU 2013-08, an entity already regulated under the 1940 Act is automatically an investment company under the new GAAP definition, so the Company has concluded that there is no impact from adopting this standard on the Company’s statement of assets and liabilities or results of operations. The Company has adopted this standard for its fiscal year ending December 31, 2014.

 

61


Table of Contents

12. Subsequent Events

Dividend Declaration

On April 28, 2014 the Board of Directors declared a cash dividend of $0.31 per share to be paid on May 19, 2014 to shareholders of record as of May 12, 2014. This dividend represents the Company’s thirty-fifth consecutive dividend declaration since our initial public offering, bringing the total cumulative dividend declared to date to $9.37 per share.

Restricted Stock Units Grants

In April 2014, the Company granted approximately 982,000 restricted stock units pursuant to the Plans.

Portfolio Company Developments

As of March 31, 2014, the Company held warrants or equity positions in four companies that have filed registration statements on Form S-1 with the SEC in contemplation of potential initial public offerings, including Box, Inc., Dance Biopharm, Inc. and two companies which filed confidentially under the JOBS Act. In addition, subsequent to March 31, 2014 the following portfolio company completed an initial public offering:

 

  1. In April 2014, Glori Energy, Inc. (NASDAQ: GLRI), a Hercules portfolio company, completed a $185 million reverse merger with Infinity Cross Border Acquisition Corp. (NASDAQ: INXB) and closed a share tender offer and a warrant tender offer.

 

62


Table of Contents
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

The matters discussed in this report, as well as in future oral and written statements by management of Hercules Technology Growth Capital, Inc., that are forward-looking statements are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements. Forward-looking statements relate to future events or our future financial performance. We generally identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. Important assumptions include our ability to originate new investments, achieve certain margins and levels of profitability, the availability of additional capital, and the ability to maintain certain debt to asset ratios. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this report should not be regarded as a representation by us that our plans or objectives will be achieved. The forward-looking statements contained in this report include statements as to:

 

   

our future operating results;

 

   

our business prospects and the prospects of our prospective portfolio companies;

 

   

the impact of investments that we expect to make;

 

   

our informal relationships with third parties including in the venture capital industry;

 

   

the expected market for venture capital investments and our addressable market;

 

   

the dependence of our future success on the general economy and its impact on the industries in which we invest;

 

   

our ability to access debt markets and equity markets;

 

   

the ability of our portfolio companies to achieve their objectives;

 

   

our expected financings and investments;

 

   

our regulatory structure and tax status;

 

   

our ability to operate as a BDC, a SBIC and a RIC;

 

   

the adequacy of our cash resources and working capital;

 

   

the timing of cash flows, if any, from the operations of our portfolio companies;

 

   

the timing, form and amount of any dividend distributions;

 

   

the impact of fluctuations in interest rates on our business;

 

   

the valuation of any investments in portfolio companies, particularly those having no liquid trading market; and

 

   

our ability to recover unrealized losses.

 

63


Table of Contents

The following discussion should be read in conjunction with our consolidated financial statements and related notes and other financial information appearing elsewhere in this report. In addition to historical information, the following discussion and other parts of this report contain forward-looking information that involve risks and uncertainties. Our actual results could differ materially from those anticipated by such forward-looking information due to the factors discussed under Item 1A—“Risk Factors” of Part II of this quarterly report on Form 10-Q, Item 1A—“Risk Factors” of our annual report on Form 10-K filed with the SEC on February 27, 2014 and under “Forward-Looking Statements” of this Item 2.

Overview

We are a specialty finance company focused on providing senior secured loans to venture capital-backed companies in technology-related markets, including technology, biotechnology, life science, and energy and renewables technology industries at all stages of development. We source our investments through our principal office located in Palo Alto, CA, as well as through our additional offices in Boston, MA, New York, NY and McLean, VA.

Our goal is to be the leading structured debt financing provider of choice for venture capital-backed companies in technology- related markets requiring sophisticated and customized financing solutions. Our strategy is to evaluate and invest in a broad range of technology-related markets including technology, biotechnology, life science, and energy and renewables technology industries and to offer a full suite of growth capital products. We invest primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. We invest primarily in private companies but also have investments in public companies.

We use the term “structured debt with warrants” to refer to any debt investment, such as a senior or subordinated secured loan, that is coupled with an equity component, including warrants, options or rights to purchase common or preferred stock. Our structured debt with warrants investments typically are secured by some or all of the assets of the portfolio company.

Our investment objective is to maximize our portfolio total return by generating current income from our debt investments and capital appreciation from our equity-related investments. Our primary business objectives are to increase our net income, net operating income and net asset value by investing in structured debt with warrants and equity of venture capital-backed companies in technology-related markets with attractive current yields and the potential for equity appreciation and realized gains. Our equity ownership in our portfolio companies may represent a controlling interest. In some cases, we receive the right to make additional equity investments in our portfolio companies in connection with future equity financing rounds. Capital that we provide directly to venture capital-backed companies in technology-related markets is generally used for growth and general working capital purposes as well as in select cases for acquisitions or recapitalizations.

We also make investments in qualifying small businesses through our two wholly-owned SBICs. Our SBIC subsidiaries, HT II and HT III, hold approximately $143.7 million and $290.0 million in assets, respectively, and accounted for approximately 9.5% and 19.3% of our total assets, respectively, prior to consolidation at March 31, 2014. As of March 31, 2014, the maximum statutory limit on the dollar amount of combined outstanding SBA guaranteed debentures is $225.0 million, subject to periodic adjustments by the SBA. In aggregate, at March 31, 2014, with our net investment of $112.5 million, HT II and HT III have the capacity to issue a total of $225.0 million of SBA-guaranteed debentures, subject to SBA approval. In March 2014, we repaid $34.8 million of SBA debentures under HT II, priced at approximately 6.38%, including annual fees. At March 31, 2014, we have issued $190.2 million in SBA-guaranteed debentures in our SBIC subsidiaries.

We have qualified as and have elected to be treated for tax purposes as a RIC under the Code. Pursuant to this election, we generally will not have to pay corporate-level taxes on any income that we distribute to our stockholders. However, our qualification and election to be treated as a RIC requires that we comply with provisions contained in the Code. For example, as a RIC we must receive 90% or more of our income from qualified earnings, typically referred to as “good income,” as well as satisfy asset diversification and income distribution requirements.

We are an internally managed, non-diversified, closed-end investment company that has elected to be regulated as a business development company under the 1940 Act. As a business development company, we are required to comply with certain regulatory requirements. For instance, we generally have to invest at least 70% of our total assets in “qualifying assets,” which includes securities of private U.S. companies, cash, cash equivalents and high-quality debt investments that mature in one year or less.

Our portfolio is comprised of, and we anticipate that our portfolio will continue to be comprised of, investments primarily in technology-related companies at various stages of their development. Consistent with requirements under the 1940 Act, we invest primarily in United-States based companies and to a lesser extent in foreign companies.

We regularly engage in discussions with third parties with respect to various potential transactions. We may acquire an investment or a portfolio of investments or an entire company or sell a portion of our portfolio on an opportunistic basis. We, our subsidiaries or our affiliates may also agree to manage certain other funds that invest in debt, equity or provide other financing or

 

64


Table of Contents

services to companies in a variety of industries for which we may earn management or other fees for our services. We may also invest in the equity of these funds, along with other third parties, from which we would seek to earn a return and/or future incentive allocations. Some of these transactions could be material to our business. Consummation of any such transaction will be subject to completion of due diligence, finalization of key business and financial terms (including price) and negotiation of final definitive documentation as well as a number of other factors and conditions including, without limitation, the approval of our board of directors and required regulatory or third party consents and, in certain cases, the approval of our stockholders. Accordingly, there can be no assurance that any such transaction would be consummated. Any of these transactions or funds may require significant management resources either during the transaction phase or on an ongoing basis depending on the terms of the transaction.

Portfolio and Investment Activity

The total fair value of our investment portfolio was $890.7 million at March 31, 2014, as compared to $910.3 million at December 31, 2013.

The fair value of our debt investment portfolio at March 31, 2014 was approximately $798.4 million, compared to a fair value of approximately $822.0 million at December 31, 2013. The fair value of the equity portfolio at March 31, 2014 was approximately $68.7 million, compared to a fair value of approximately $52.7 million at December 31, 2013. The fair value of the warrant portfolio at March 31, 2014 was approximately $23.6 million, compared to a fair value of approximately $35.6 million at December 31, 2013.

Portfolio Activity

Our investments in portfolio companies take a variety of forms, including unfunded contractual commitments and funded investments. From time to time, unfunded contractual commitments depend upon a portfolio company reaching certain milestones before the debt commitment is available to the portfolio company, which is expected to affect our funding levels. These commitments will be subject to the same underwriting and ongoing portfolio maintenance as the on-balance sheet financial instruments that we hold. Debt commitments generally fund over the two succeeding quarters from close. Not all debt commitments represent our future cash requirements. Similarly, unfunded contractual commitments may expire without being drawn and do not represent our future cash requirements.

Prior to entering into a contractual commitment, we generally issue a non-binding term sheet to a prospective portfolio company. Non-binding term sheets are subject to completion of our due diligence and final approval process, as well as the negotiation of definitive documentation with the prospective portfolio companies and generally convert to contractual commitments within approximately 90 days of signing. Not all non-binding term sheets are expected to close and do not necessarily represent our future cash requirements.

Our portfolio activity for the three-month period ended March 31, 2014 (unaudited) and the year ended December 31, 2013 was comprised of the following:

 

(in millions)

   March 31, 2014      December 31, 2013  

Debt Commitments (1)

     

New portfolio company

   $ 115.4       $ 535.0   

Existing portfolio company

     38.8         165.1   
  

 

 

    

 

 

 

Total

   $ 154.2       $ 700.1   

Funded Debt Investments

     

New portfolio company

   $ 92.4       $ 373.1   

Existing portfolio company

     18.0         118.0   
  

 

 

    

 

 

 

Total

   $ 110.4       $ 491.1   

Funded Equity Investments

     

New portfolio company

   $ —         $ —     

Existing portfolio company

     1.5         3.9   
  

 

 

    

 

 

 

Total

   $ 1.5       $ 3.9   

Unfunded Contractual Commitments (2)

     

Total

   $ 189.4       $ 151.0   

Non-Binding Term Sheets

     

New portfolio company

   $ 238.0       $ 28.0   

Existing portfolio company

     —           10   
  

 

 

    

 

 

 

Total

   $ 238.0       $ 38.0   

 

(1) Includes restructured loans and renewals in addition to new commitments.
(2) The amount for March 31, 2014 includes unfunded contractual commitments in 31 new and existing portfolio companies. Approximately $95.6 million of these unfunded contractual commitments as of March 31, 2014 are dependent upon the portfolio company reaching certain milestones before the debt commitment becomes available.

 

65


Table of Contents

We receive payments in our debt investment portfolio based on scheduled amortization of the outstanding balances. In addition, we receive principal repayments for some of our loans prior to their scheduled maturity date. The frequency or volume of these early principal repayments may fluctuate significantly from period to period. During the three-month period ended March 31, 2014, we received approximately $132.6 million in aggregate principal repayments. Of the approximately $132.6 million of aggregate principal repayments, approximately $82.0 million were early principal repayments related to 10 portfolio companies, approximately $6.6 million were early repayments due to current quarter M&A transactions related to two portfolio companies and approximately $44.0 million were scheduled principal payments.

Total portfolio investment activity (inclusive of unearned income) for the three-month period ended March 31, 2014 (unaudited) and for the year ended December 31, 2013 was as follows:

 

(in millions)    March 31, 2014     December 31, 2013  

Beginning Portfolio

   $ 910.3     $ 906.3   

New fundings

     105.0       473.6   

Restructure fundings

     6.9       23.6   

Warrants not related to current period fundings

     0.1       3.5   

Principal payments received on investments

     (44.0 )     (176.2

Early payoffs

     (88.6     (300.6

Restructure payoffs

     —          (9.8

Accretion of loan discounts and paid-in-kind principal

     6.7       31.9   

Acceleration of loan discounts and loan fees due to early payoff or restructure

     (1.8 )     (0.7

New loan fees

     (2.1 )     (14.3

Conversion of “Other Assets”

     —          —     

Debt converted to Equity

     —          —     

Warrants converted to Equity

     2.0       0.2   

Proceeds from sale of investments

     (2.2 )     (22.5

Net realized (loss) gain on investments

     (0.6 )     (16.7

Net change in unrealized appreciation (depreciation)

     (1.0 )     12.0   
  

 

 

   

 

 

 

Ending Portfolio

   $ 890.7     $ 910.3   
  

 

 

   

 

 

 

The following table shows the fair value of our portfolio of investments by asset class as of March 31, 2014 (unaudited) and December 31, 2013.

 

     March 31, 2014     December 31, 2013  

(in thousands)

   Investments at Fair
Value
     Percentage of Total
Portfolio
    Investments at Fair
Value
     Percentage of Total
Portfolio
 

Senior secured debt with warrants

   $ 500,899         56.2 %   $ 634,820         69.7

Senior secured debt

     321,074         36.0 %     222,805         24.5

Preferred stock

     45,723         5.1 %     35,554         3.9

Common stock

     22,966         2.7 %     17,116         1.9
  

 

 

    

 

 

   

 

 

    

 

 

 
   $ 890,662         100.0 %   $ 910,295         100.0
  

 

 

    

 

 

   

 

 

    

 

 

 

The decline in senior secured debt with warrants is consistent with the overall decline in our investment portfolio at March 31, 2014 from December 31, 2013 and the increase in senior secured debt is due to the addition of seven new debt investments in the three-months ended March 31, 2014 partially offset by the payoff of two existing debt investments included in the period ended December 31, 2013.

A summary of our investment portfolio at value by geographic location is as follows:

 

     March 31, 2014     December 31, 2013  

(in thousands)

   Investments at Fair
Value
     Percentage of Total
Portfolio
    Investments at Fair
Value
     Percentage of Total
Portfolio
 

United States

   $ 843,941         94.8 %   $ 864,003         94.9

Canada

     26,201         2.9 %     25,798         2.8

Israel

     10,012         1.1 %     9,863         1.1

Netherlands

     10,008         1.1 %     10,131         1.1

England

     500         0.1 %     500         0.1
  

 

 

    

 

 

   

 

 

    

 

 

 
   $ 890,662         100.0 %   $ 910,295         100.0
  

 

 

    

 

 

   

 

 

    

 

 

 

 

66


Table of Contents

As of March 31, 2014, we held warrants or equity positions in four companies that have filed registration statements on Form S-1 with the SEC in contemplation of potential initial public offerings, specifically, Box, Inc. (“BOX”), Dance Biopharm, Inc. and two companies that filed confidentially under the JOBS Act. There can be no assurance that these companies will complete their initial public offerings in a timely manner or at all.

Changes in Portfolio

We generate revenue in the form of interest income, primarily from our investments in debt securities, and commitment and facility fees. Fees generated in connection with our debt investments are recognized over the life of the loan or, in some cases, recognized as earned. In addition, we generate revenue in the form of capital gains, if any, on warrants or other equity-related securities that we acquire from our portfolio companies. Our investments generally range from $1.0 million to $40.0 million. As of March 31, 2014, our debt investments have a term of between two and seven years and typically bear interest at a rate ranging from the prevailing U.S. prime rate, or Prime or the London Interbank Offered Rate, or LIBOR, to approximately 15%. In addition to the cash yields received on our debt investments, in some instances, our debt investments may also include any of the following: end-of-term payments, exit fees, balloon payment fees, commitment fees, success fees, PIK provisions or prepayment fees which may be required to be included in income prior to receipt.

Loan origination and commitment fees received in full at the inception of a loan are deferred and amortized into fee income as an enhancement to the related loan’s yield over the contractual life of the loan. We recognize nonrecurring fees amortized over the remaining term of the loan commencing in the quarter relating to specific loan modifications. Loan exit fees to be paid at the termination of the loan are accreted into interest income over the contractual life of the loan. We had approximately $3.9 million and $4.0 million of unamortized fees at March 31, 2014 and December 31, 2013, respectively, and approximately $14.6 million and $14.4 million in exit fees receivable at March 31, 2014 and December 31, 2013, respectively.

We have debt investments in our portfolio that contain a PIK provision. The PIK interest, computed at the contractual rate specified in each loan agreement, is added to the principal balance of the loan and recorded as interest income. To maintain our status as a RIC, this non-cash source of income must be paid out to stockholders in the form of dividends even though we have not yet collected the cash. Amounts necessary to pay these dividends may come from available cash or the liquidation of certain investments. We recorded approximately $852,000 and $779,000 in PIK income in the three-month periods ended March 31, 2014 and 2013, respectively.

In the majority of cases, we collateralize our investments by obtaining a first priority security interest in a portfolio company’s assets, which may include its intellectual property. In other cases, we obtain a negative pledge covering a company’s intellectual property. At March 31, 2014, approximately 61.5% of our portfolio company debt investments were secured by a first priority security in all of the assets of the portfolio company, including their intellectual property, and 38.5% of the debt investments were to portfolio companies that were prohibited from pledging or encumbering their intellectual property. At March 31, 2014 we had no equipment only liens on any of our portfolio companies.

Interest on debt securities is generally payable monthly, with amortization of principal typically occurring over the term of the security. In addition, certain of our loans may include an interest-only period ranging from three to eighteen months or longer. In limited instances in which we choose to defer amortization of the loan for a period of time from the date of the initial investment, the principal amount of the debt securities and any accrued but unpaid interest become due at the maturity date.

The effective yield on our debt investments during the three-month periods ended March 31, 2014 and 2013 was 17.9% and 14.3%, respectively. This increase in effective yield between periods is primarily due to the effect of fee accelerations that occurred from increased early payoffs during the three months ended March 31, 2014 as compared to the three months ended March 31, 2013. The effective yield is derived by dividing total investment income by the weighted average earning investment portfolio assets outstanding during the quarter which exclude non-interest earning assets such as warrants and equity investments. The overall weighted average yield to maturity of our debt investments was approximately 13.3% at both March 31, 2014 and December 31, 2013. The weighted average yield to maturity is computed using the interest rates in effect at the inception of each of the loans, and includes amortization of the loan facility fees, commitment fees and market premiums or discounts over the expected life of the debt investments, weighted by their respective costs when averaged and based on the assumption that all contractual loan commitments have been fully funded and held to maturity.

Portfolio Composition

Our portfolio companies are primarily privately held companies and public companies which are active in the drug discovery and development, energy technology, internet consumer and business services, medical device

 

67


Table of Contents

and equipment, software, drug delivery, specialty pharmaceuticals, communications and networking, media/content/info, healthcare services, information services, surgical devices, semiconductors, biotechnology tools, consumer and business products, diagnostic and electronics and computer hardware industry sectors. These sectors are characterized by high margins, high growth rates, consolidation and product and market extension opportunities. Value for companies in these sectors is often vested in intangible assets and intellectual property.

As of March 31, 2014, approximately 64.9% of the fair value of our portfolio was composed of investments in four industries: 23.2% was composed of investments in the drug discovery and development industry, 18.7% was composed of investments in the energy technology industry, 11.9% was composed of investments in the internet consumer and business services industry and 11.1% was composed of investments in the medical device and equipment industry.

The following table shows the fair value of our portfolio by industry sector at March 31, 2014 (unaudited) and December 31, 2013:

 

     March 31, 2014     December 31, 2013  

(in thousands)

   Investments at
Fair Value
     Percentage of  Total
Portfolio
    Investments at
Fair Value
     Percentage of Total
Portfolio
 

Drug Discovery & Development

   $ 206,535         23.2   $ 219,169         24.1

Energy Technology

     166,482         18.7     164,466         18.1

Internet Consumer & Business Services

     105,964         11.9     122,073         13.4

Medical Devices & Equipment

     99,061         11.1     103,614         11.4

Software

     79,077         8.9     65,218         7.2

Drug Delivery

     63,335         7.1     62,022         6.8

Specialty Pharmaceuticals

     40,217         4.5     20,055         2.2

Communications & Networking

     35,526         4.0     35,979         4.0

Media/Content/Info

     29,447         3.3     8,679         1.0

Healthcare Services, Other

     20,626         2.3     29,080         3.2

Information Services

     15,102         1.7     46,565         5.1

Surgical Devices

     10,353         1.1     10,307         1.0

Semiconductors

     9,464         1.1     4,685         0.5

Biotechnology Tools

     4,541         0.5     5,275         0.6

Consumer & Business Products

     3,282         0.4     2,995         0.3

Diagnostic

     858         0.1     902         0.1

Electronics & Computer Hardware

     792         0.1     9,211         1.0
  

 

 

    

 

 

   

 

 

    

 

 

 
   $ 890,662         100.0   $ 910,295         100.0
  

 

 

    

 

 

   

 

 

    

 

 

 

Industry and sector concentrations vary as new loans are recorded and loans pay off. Loan revenue, consisting of interest, fees, and recognition of gains on equity and equity-related interests, can fluctuate materially when a loan is paid off or a related warrant or equity interest is sold. Revenue recognition in any given year can be highly concentrated among several portfolio companies.

For the three-months ended March 31, 2014 and the year ended December 31, 2013, our ten largest portfolio companies represented approximately 29.5% and 29.3% of the total fair value of our investments in portfolio companies, respectively. At both March 31, 2014 and December 31, 2013, we had one investment that represented 5% or more of our net assets. At March 31, 2014, we had five equity investments representing approximately 71.0% of the total fair value of our equity investments, and each represented 5% or more of the total fair value of our equity investments. At December 31, 2013, we had six equity investments which represented approximately 75.7% of the total fair value of our equity investments, and each represented 5% or more of the total fair value of our equity investments.

As of March 31, 2014, 100% of our debt investments were in a senior secured first lien position, and approximately 98.0% of the debt investment portfolio was priced at floating interest rates or floating interest rates with a Prime-or LIBOR-based interest rate floor. As a result, we believe we are well positioned to benefit should market interest rates increase.

Our investments in senior secured debt with warrants have equity enhancement features, typically in the form of warrants or other equity-related securities designed to provide us with an opportunity for capital appreciation. Our warrant coverage generally ranges from 3% to 20% of the principal amount invested in a portfolio company, with a strike price generally equal to the most recent equity financing round. As of March 31, 2014, we held warrants in 107 portfolio companies, with a fair value of approximately $23.6 million. The fair value of our warrant portfolio decreased by approximately 33.7%, as compared to a fair value of $35.6 million at December 31, 2013 primarily related to the reversal of unrealized appreciation related to the exercise of our warrant positions in Neuralstem, Inc. ($751,000) and Box, Inc. ($8.3 million) to preferred stock.

 

68


Table of Contents

Our existing warrant holdings currently would require us to invest approximately $68.6 million to exercise such warrants as of March 31, 2014. Warrants may appreciate or depreciate in value depending largely upon the underlying portfolio company’s performance and overall market conditions. Of the warrants which we have monetized since inception, we have realized warrant gain multiples in the range of approximately 1.01x to 14.91x based on the historical rate of return on our investments. However, our warrants may not appreciate in value and, in fact, may decline in value. Accordingly, we may not be able to realize gains from our warrant portfolio.

As required by the 1940 Act, we classify our investments by level of control. “Control investments” are defined in the 1940 Act as investments in those companies that we are deemed to “control”, which, in general, includes a company in which we own 25% or more of the voting securities of such company or have greater than 50% representation on its board. “Affiliate investments” are investments in those companies that are “affiliated companies” of ours, as defined in the 1940 Act, which are not control investments. We are deemed to be an “affiliate” of a company in which we have invested if we own 5% or more, but less than 25%, of the voting securities of such company. “Non-control/non-affiliate investments” are investments that are neither control investments nor affiliate investments.

The following table summarizes our realized and unrealized gain and loss and changes in our unrealized appreciation and depreciation on affiliate investments for the three-month periods ended March 31, 2014 and 2013 (unaudited). We did not hold any Control investments at either March 31, 2014 or 2013.

 

                                                                                                                                                                                         
(in thousands)                Three months ended March 31, 2014  
Portfolio Company    Type    Fair Value at
March 31,
2014
     Investment
Income
     Net Change in
Unrealized
(Depreciation)/

Appreciation
    Reversal of
Unrealized
(Depreciation)/

Appreciation
     Realized
Gain/
(Loss)
 

Gelesis, Inc.

   Affiliate    $ 497       $ —         $ 24      $ —         $ —     

Optiscan BioMedical, Corp.

   Affiliate      5,032         —           247        —           —     

Stion Corporation

   Affiliate      5,664         1,475         (224     —           —     
     

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Total

      $ 11,193       $ 1,475       $ 47      $ —         $ —     
     

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 
(in thousands)                Three months ended March 31, 2013  
Portfolio Company    Type    Fair Value at
March 31,
2013
     Investment
Income
     Net Change in
Unrealized
(Depreciation)/

Appreciation
    Reversal of
Unrealized
(Depreciation)/

Appreciation
     Realized
Gain/
(Loss)
 

Gelesis, Inc.

   Affiliate    $ 1,888       $ —         $ 222      $ —         $ —     

Optiscan BioMedical, Corp.

   Affiliate      12,308         610         212        —           —     
     

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Total

      $ 14,196       $ 610       $ 434      $ —         $ —     
     

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

During the year ended December 31, 2013 Stion Corporation became classified as an affiliate.

Portfolio Grading

We use an investment grading system, which grades each debt investments on a scale of 1 to 5 to characterize and monitor our expected level of risk on the debt investments in our portfolio with 1 being the highest quality. The following table shows the distribution of our outstanding debt investments on the 1 to 5 investment grading scale at fair value as of March 31, 2014 (unaudited) and December 31, 2013, respectively:

 

     March 31, 2014     December 31, 2013  

(in thousands)

   Number of
Companies
     Debt Investments at
Fair Value
     Percentage of Total
Portfolio
    Number of
Companies
     Debt Investments at
Fair Value
     Percentage of Total
Portfolio
 

Investment Grading

                

1

     20       $ 225,685         28.3     15       $ 162,586         19.8

2

     35         391,172         49.0     42         429,804         52.3

3

     18         158,956         19.9     18         184,692         22.5

4

     3         14,615         1.8     4         30,687         3.7

5

     4         7,931         1.0     5         14,219         1.7
     

 

 

    

 

 

      

 

 

    

 

 

 
      $ 798,359         100.0      $ 821,988         100.0
     

 

 

    

 

 

      

 

 

    

 

 

 

 

69


Table of Contents

As of March 31, 2014, our debt investments had a weighted average investment grading of 2.05, as compared to 2.20 at December 31, 2013. Our policy is to lower the grading on our portfolio companies as they approach the point in time when they will require additional equity capital. Additionally, we may downgrade our portfolio companies if they are not meeting our financing criteria or are underperforming relative to their respective business plans. Various companies in our portfolio will require additional funding in the near term or have not met their business plans and therefore have been downgraded until their funding is complete or their operations improve.

At March 31, 2014, we had three debt investments on non-accrual with a cumulative cost and fair value of approximately $24.0 million and $7.7 million, respectively. At December 31, 2013 we had two debt investments on non-accrual with a cumulative cost and fair value of approximately $23.3 million and $12.6 million, respectively.

Results of Operations

Comparison of the three-month periods ended March 31, 2014 and 2013

Investment Income

Total investment income for the three-month period ended March 31, 2014 was approximately $35.8 million as compared to approximately $31.0 million for the three-month period ended March 31, 2013.

Interest income for the three-month period ended March 31, 2014 totaled approximately $30.8 million as compared to approximately $28.9 million for the three-month period ended March 31, 2013. The increase in interest income is attributable to an increase in accelerations related to early payoffs and material loan modifications (cumulative increase of approximately $3.9 million) partially offset by a decline in the debt investment portfolio and a decrease in default interest income (cumulative decrease of approximately $2.0 million).

Income from commitment, facility and loan related fees for the three-month period ended March 31, 2014 totaled approximately $4.9 million as compared to approximately $2.0 million for the three-month period ended March 31, 2013. The increase in fee income is primarily attributable to an increase in accelerations related to early payoffs and material loan modifications (cumulative increase of approximately $1.1 million) as well as an increase in prepayment penalties collected on early payoffs (an increase of approximately $1.7 million).

The following table shows the PIK-related activity for the three-months ended March 31, 2014 and 2013, at cost (unaudited):

 

     Three Months Ended March 31,  

(in thousands)

   2014     2013  

Beginning PIK loan balance

   $ 4,982      $ 3,309   

PIK interest capitalized during the period

     659        697   

Payments received from PIK loans

     (1,205     (142
  

 

 

   

 

 

 

Ending PIK loan balance

   $ 4,436      $ 3,864   
  

 

 

   

 

 

 

The increase in payments received from PIK loans during the three-months ended March 31, 2014 is due to the addition of nine PIK loans which have incurred PIK capitalizations during the period and the payoff of two PIK loans during the three-month period ended March 31, 2014.

In certain investment transactions, we may earn income from advisory services; however, we had no income from advisory services in the three-month periods ended March 31, 2014 and 2013, respectively.

Operating Expenses

Our operating expenses are comprised of interest and fees on our borrowings, general and administrative expenses and employee compensation and benefits. Our operating expenses totaled approximately $17.5 million and $15.9 million during the three month periods ended March 31, 2014 and 2013, respectively.

Interest and Fees on our Borrowings

Interest and fees on our borrowings totaled approximately $9.2 million for the three-month period ended March 31, 2014 as compared to approximately $8.7 million for the three-month period ended March 31, 2013. This increase was primarily attributable to an acceleration of amortization related to the partial early payoffs of SBA obligations and our Asset-Backed Notes (cumulative acceleration of approximately $937,000) partially offset by a decrease in interest expense related to the same events of approximately $483,000.

 

70


Table of Contents

We had a weighted average cost of debt, comprised of interest and fees, of approximately 6.9% for the three-months ended March 31, 2014, as compared to 5.9% for the three-months ended March 31, 2013. The increase was primarily driven by the acceleration of interest and fees related to the partial early payoffs of SBA obligations and our Asset-Backed Notes as described above.

General and Administrative Expenses

General and administrative expenses include legal fees, consulting fees, accounting fees, printer fees, insurance premiums, rent, expenses associated with the workout of underperforming investments and various other expenses. Our general and administrative expenses increased to $2.5 million from $2.2 million for the three-month periods ended March 31, 2014 and 2013, respectively. These increases were primarily due to increased marketing expense related to enhancement of our website, investor relations and legal expenses.

Employee Compensation

Employee compensation and benefits totaled approximately $4.2 million for the three-month period ended March 31, 2014 as compared to approximately $3.8 million for the three-month period ended March 31, 2013. This increase was primarily due to increasing our staff by six active employees at March 31, 2014 from March 31, 2013.

Stock-based compensation totaled approximately $1.6 million for the three-month period ended March 31, 2014 as compared to approximately $1.2 million for the three-month period ended March 31, 2013. This increase was primarily due to the restricted stock units granted March 6, 2013. Compensation expense related to this grant amortized during the entire three-month period ended March 31, 2014 compared to a partial period ended March 31, 2013.

Net Investment Realized Gains and Losses and Net Unrealized Appreciation and Depreciation

Realized gains or losses are measured by the difference between the net proceeds from the repayment or sale and the cost basis of an investment without regard to unrealized appreciation or depreciation previously recognized, and includes investments written off during the period, net of recoveries. Net change in unrealized appreciation or depreciation primarily reflects the change in portfolio investment values during the reporting period, including the reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.

A summary of realized gains and losses for the three-month periods ended March 31, 2014 and 2013 is as follows:

 

     Three Months Ended
March 31,
 
(in thousands)    2014     2013  

Realized gains

   $ 5,382      $ 3,613   

Realized losses

     (510     (1,622
  

 

 

   

 

 

 

Net realized gains

   $ 4,872      $ 1,991   
  

 

 

   

 

 

 

During the three-month period ended March 31, 2014, we recognized net realized gains of approximately $4.9 million. These net realized gains include gross realized gains of approximately $5.4 million primarily from the sale of investments in five portfolio companies, including Cell Therapeutics ($1.3 million), Neuralstem ($1.2 million), Portola Pharmaceuticals ($700,000), AcelRx ($485,000) and Dicerna ($200,000). These gains were partially offset by gross realized losses of approximately $500,000 from the liquidation of our investments in five portfolio companies.

During the three-month period ended March 31, 2013, we recognized net realized gains of approximately $2.0 million. These net realized gains include gross realized gains of approximately $3.6 million primarily from the sale of investments in three portfolio companies. These gains were partially offset by gross realized losses of approximately $1.6 million from the liquidation of our investments in five portfolio companies.

 

71


Table of Contents

The net unrealized appreciation and depreciation of our investments is based on fair value of each investment determined in good faith by our Board of Directors. The following table itemizes the change in net unrealized appreciation/depreciation of investments for the three-month periods ended March 31, 2014 and 2013:

 

     Three Months Ended
March 31,
 
     2014     2013  

(in thousands)

   Amount     Amount  

Gross unrealized appreciation on portfolio investments

   $ 25,249      $ 13,224   

Gross unrealized depreciation on portfolio investments

     (25,296     (14,059

Reversal of prior period net unrealized appreciation upon a realization event

     (1,656     (2,461

Reversal of prior period net unrealized depreciation upon a realization event

     739        1,613   

Net unrealized appreciation (depreciation) on taxes payable

     (72     —     

Citigroup Warrant Participation

     45        181   
  

 

 

   

 

 

 

Net unrealized appreciation (depreciation) on portfolio investments

   $ (991   $ (1,502
  

 

 

   

 

 

 

During the three-months ended March 31, 2014, we recorded approximately $1.0 million of net unrealized depreciation from our debt, equity and warrant investments. Approximately $12.0 million is attributed to net unrealized appreciation on equity.

This unrealized appreciation was offset by approximately $10.3 million attributed to net unrealized depreciation on our warrant investments, including approximately $1.5 million of net unrealized depreciation due to the reversal of prior period net unrealized appreciation upon being realized as a gain. Additionally, this unrealized appreciation was offset by approximately $2.7 million of net unrealized depreciation on our debt investments, which primarily related to $7.2 million of unrealized depreciation for collateral based impairments and the reversal of approximately $300,000 of prior period net unrealized appreciation upon being realized as a loss due to the write-off or early payoff of debt investments.

Net unrealized appreciation decreased by approximately $72,000 as a result of estimated taxes payable for the three-months ended March 31, 2014.

During the three-months ended March 31, 2014, net unrealized appreciation increased by approximately $45,000 as a result of net depreciation of fair value on the pool of warrants collateralized under the warrant participation agreement.

During the three-months ended March 31, 2013, we recorded approximately $1.5 million of net unrealized depreciation from our debt, equity and warrant investments. Approximately $1.9 million is attributed to net unrealized appreciation on equity, of which approximately $93,000 is due to the reversal of prior period net unrealized appreciation upon being realized as a gain and approximately $268,000 is due to the reversal of prior period net unrealized depreciation upon being realized as a loss. Approximately $3.8 million is attributed to net unrealized appreciation on our warrant investments, of which approximately $1.9 million is due to the reversal of prior period net unrealized appreciation upon being realized as a gain and approximately $1.3 million is due to the reversal of prior period net unrealized depreciation upon being realized as a loss.

During the three-months ended March 31, 2013, net unrealized appreciation increased by approximately $181,000 as a result of current quarter net depreciation of fair value on the pool of warrants collateralized under the warrant participation agreement.

 

72


Table of Contents

The following table itemizes the change in net unrealized appreciation/(depreciation) in the investment portfolio by category for the three-month periods ended March 31, 2014 and 2013 (unaudited).

 

     Three Months Ended March 31, 2014  

(in millions)

   Debt     Equity      Warrants     Total  

Collateral based impairments

   $ (7.2   $ —         $ (0.2 )   $ (7.4

Reversals due to Debt Payoffs & Warrant/Equity sales

     (0.3     0.2         (9.6     (9.7

Fair Value Market/Yield Adjustments*

         

Level 1 & 2 Assets

     —          3.5         0.1        3.6   

Level 3 Assets

     4.8        8.3         (0.6     12.5   
  

 

 

   

 

 

    

 

 

   

 

 

 

Total Fair Value Market/Yield Adjustments

     4.8        11.8         (0.5     16.1   
  

 

 

   

 

 

    

 

 

   

 

 

 

Total Net Change in Unrealized Appreciation/(Depreciation)

   $ (2.7   $ 12.0       $ (10.3   $ (1.0
  

 

 

   

 

 

    

 

 

   

 

 

 
     Three Months Ended March 31, 2013  

(in millions)

   Debt     Equity      Warrants     Total  

Collateral based impairments

   $ (5.7   $ —         $ —          (5.7

Reversals due to Debt Payoffs & Warrant/Equity sales

     —          0.2         (1.0     (0.8

Fair Value Market/Yield Adjustments*

         

Level 1 & 2 Assets

     —          0.1         0.2        0.3   

Level 3 Assets

     (1.5     1.6         4.4        4.5   
  

 

 

   

 

 

    

 

 

   

 

 

 

Total Fair Value Market/Yield Adjustments

     (1.5     1.7         4.6        4.8   
  

 

 

   

 

 

    

 

 

   

 

 

 

Total Net Change in Unrealized Appreciation/(Depreciation)

   $ (7.2   $ 1.9       $ 3.6      $ (1.7
  

 

 

   

 

 

    

 

 

   

 

 

 

 

* Level 1 assets are generally equities listed in active markets and level 2 assets are generally warrants held in a public company. Observable market prices are typically the primary input in valuing level 1 and 2 assets. Level 3 asset valuations require inputs that are both significant and unobservable. Generally, level 3 assets are debt investments and warrants and equities held in a private company. See Note 2 to the financial statements discussing ASC 820.

Income and Excise Taxes

We account for income taxes in accordance with the provisions of ASC 740, Income Taxes, which requires that deferred income taxes be determined based upon the estimated future tax effects of differences between the financial statement and tax basis of assets and liabilities given the provisions of the enacted tax law. Valuation allowances are used to reduce deferred tax assets to the amount likely to be realized. We intend to distribute approximately $3.8 million of spillover earnings from the year ended December 31, 2013 to our shareholders in 2014.

Net Increase in Net Assets Resulting from Operations and Earnings Per Share

For the three-month periods ended March 31, 2014 and 2013, the net increase in net assets resulting from operations totaled approximately $22.2 million and approximately $16.7 million, respectively. These changes are made up of the items previously described.

The basic and fully diluted net change in net assets per common share was $0.36 and $0.35 for the three-month period ended March 31, 2014, whereas both the basic and fully diluted net change in net assets per common share for the three-month period ended March 31, 2013 was $0.30.

For the purpose of calculating diluted earnings per share for three-months ended March 31, 2014 and 2013, the dilutive effect of the Convertible Senior Notes under the treasury stock method is included in this calculation because our share price was greater than the conversion price in effect ($11.56 and $11.78, respectively) for the Convertible Senior Notes for such period.

 

73


Table of Contents

Financial Condition, Liquidity, and Capital Resources

Our liquidity and capital resources are derived from our Wells Facility, Union Bank Facility (together the “Credit Facilities”), SBA debentures, Convertible Senior Notes, 2019 Notes, Asset-Backed Notes and cash flows from operations, including investment sales and repayments, and income earned. Our primary use of funds from operations includes investments in portfolio companies and payments of fees and other operating expenses we incur. We have used, and expect to continue to use, our borrowings and the proceeds from the rotation of our portfolio and from public and private offerings of securities to finance our investment objectives. We may raise additional equity or debt capital through both registered offerings off a shelf registration, “At-The-Market”, or ATM, and private offerings of securities, by securitizing a portion of our investments or borrowing, including from the SBA through our SBIC subsidiaries.

On August 16, 2013, we entered into an ATM equity distribution agreement with JMP Securities LLC, or JMP. The equity distribution agreement provides that we may offer and sell up to 8.0 million shares of our common stock from time to time through JMP, as our sales agent. Sales of our common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at the market,” as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made directly on the NYSE or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices. There were no sales under the ATM Program for the three-month period ended March 31, 2014.

At March 31, 2014, we had $75.0 million of Convertible Senior Notes payable, $170.4 million of 2019 Notes, $63.8 million of Asset-Backed Notes and $190.2 million of SBA debentures payable. We had no borrowings outstanding under either the Wells Facility or the Union Bank Facility.

At March 31, 2014, we had $329.5 million in available liquidity, including $224.5 million in cash and cash equivalents. We had available borrowing capacity of approximately $75.0 million under the Wells Facility and $30.0 million under the Union Bank Facility, subject to existing terms and advance rates and regulatory requirements. We primarily invest cash on hand in interest bearing deposit accounts.

At March 31, 2014, we had $112.5 million of cash in restricted accounts related to our SBIC that we may use to fund new investments in the SBIC. With our net investments of $38.0 million and $74.5 million in HT II and HT III, respectively, we have the combined capacity to issue a total of $225.0 million of SBA guaranteed debentures, subject to SBA approval. At March 31, 2014, we have issued $190.2 million in SBA-guaranteed debentures in our SBIC subsidiaries.

At March 31, 2014, we had approximately $4.8 million of restricted cash. Our restricted cash consists of collections of interest and principal payments on assets that are securitized. In accordance with the terms of the related securitized Asset-Backed Notes, based on current characteristics of the securitized debt investment portfolios, the restricted funds may be used to pay monthly interest and principal on the securitized debt and are not distributed to us or available for our general operations. During the three-months ended March 31, 2014, we principally funded our operations from (i) cash receipts from interest, dividend and fee income from our investment portfolio and (ii) cash proceeds from the realization of portfolio investments through the repayments of debt investments and the sale of debt and equity investments.

During the three-months ended March 31, 2014, our operating activities provided $35.8 million of cash and cash equivalents, compared to $47.7 million used during the three-months ended March 31, 2013. This $83.5 million increase in cash provided by operating activities resulted primarily from an increase in principal payments received on investments of approximately $56.7 million, and a decrease in purchases of investments of approximately $25.2 million. During the three-months ended March 31, 2014, our investing activities provided $1.5 million of cash, compared to approximately $900,000 used during three-months ended March 31, 2013. This $2.4 million increase in cash provided by investing activities was primarily due to a reduction of approximately $2.3 million in cash, classified as restricted cash, on assets that are securitized.

During the three-months ended March 31, 2014, our financing activities used $81.2 million of cash, compared to $72.5 million provided during the three-months ended March 31, 2013. This $153.7 million decrease in cash provided by financing activities was primarily due to a decrease in proceeds from issuance of common stock of $96.5 million and an increase in repayments of Asset-Backed Notes and credit facilities of $25.8 million and $25.5 million, respectively.

As of March 31, 2014, net assets totaled $653.3 million, with a net asset value per share of $10.58. We intend to generate additional cash primarily from cash flows from operations, including income earned from investments in our portfolio companies and, to a lesser extent, from the temporary investment of cash in other high-quality debt investments that mature in one year or less as well as from future borrowings as required to meet our lending activities. Our primary use of funds will be investments in portfolio companies and cash distributions to holders of our common stock.

As required by the 1940 Act, our asset coverage must be at least 200% after each issuance of senior securities. As of March 31, 2014 our asset coverage ratio under our regulatory requirements as a business development company was 312.8%, excluding our SBA debentures as a result of our exemptive order from the SEC which allows us to exclude all SBA leverage from our asset coverage ratio. As a result of the SEC exemptive order, our ratio of total assets on a consolidated basis to outstanding indebtedness may be less than 200%, which while providing increased investment flexibility, also may increase our exposure to risks associated with leverage. Total leverage when including our SBA debentures was 231.4% at March 31, 2014.

 

74


Table of Contents

Outstanding Borrowings

At March 31, 2014 (unaudited) and December 31, 2013, we had the following available borrowings and outstanding amounts:

 

     March 31, 2014      December 31, 2013  

(in thousands)

   Total
Available
     Carrying
Value (1)
     Total
Available
     Carrying
Value (1)
 

SBA Debentures (2)

   $ 190,200       $ 190,200      $ 225,000       $ 225,000   

2019 Notes

     170,364         170,364        170,364         170,364   

Asset-Backed Notes

     63,782         63,782        89,557         89,557   

Convertible Senior Notes (3)

     75,000         72,789        75,000         72,519   

Wells Facility

     75,000         —           75,000         —     

Union Bank Facility

     30,000         —           30,000         —     
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 604,346       $ 497,135      $ 664,921       $ 557,440   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

(1) Except for the Convertible Senior Notes, all carrying values are the same as the principal amount outstanding.
(2) In March 2014, we repaid $34.8 million of SBA debentures under HT II, priced at approximately 6.38%, including annual fees. At March 31, 2014, the total available borrowings under the SBA was $190.2 million, of which $41.2 million was available in HT II and $149.0 million was available in HT III. At December 31, 2013, the total available borrowings under the SBA was $225.0 million, of which $76.0 million was available in HT II and $149.0 million was available in HT III.
(3) Represents the aggregate principal amount outstanding of the Convertible Senior Notes less the unaccreted discount initially recorded upon issuance of the Convertible Senior Notes. The total unaccreted discount for the Convertible Senior Notes was $2.2 million at March 31, 2014 and $2.5 million at December 31, 2013.

Our net asset value may decline as a result of economic conditions in the United States. Our continued compliance with the

covenants under our Credit Facilities, Convertible Senior Notes, 2019 Notes Payable, Asset-Backed Notes and SBA debentures

depend on many factors, some of which are beyond our control. Material net asset devaluation could have a material adverse effect on our operations and could require us to reduce our borrowings in order to comply with certain covenants, including the ratio of total assets to total indebtedness. We believe that our current cash and cash equivalents, cash generated from operations, and funds available from our Credit Facilities will be sufficient to meet our working capital and capital expenditure commitments for at least the next 12 months.

Debt financing costs are fees and other direct incremental costs we incur in obtaining debt financing and are recognized as prepaid expenses and amortized into the consolidated statement of operations as loan fees over the term of the related debt instrument. Prepaid financing costs, net of accumulated amortization, as of March 31, 2014 (unaudited) and December 31, 2013 were as follows:

 

(in thousands)

   March 31, 2014      December 31, 2013  

Wells Facility

   $ 281       $ 398   

SBA Debenture

     4,528         5,074   

Convertible Debt

     1,179         1,323   

Asset Backed Notes

     1,820         2,686   

2019 Notes

     5,079         5,319   
  

 

 

    

 

 

 
   $ 12,887       $ 14,800   
  

 

 

    

 

 

 

Commitments

In the normal course of business, we are party to financial instruments with off-balance sheet risk. These consist primarily of unfunded contractual commitments to extend credit, in the form of loans, to our portfolio companies. Unfunded contractual commitments to provide funds to portfolio companies are not reflected on our balance sheet. Our unfunded contractual commitments may be significant from time to time. As of March 31, 2014, we had unfunded contractual commitments of approximately $189.4 million. Approximately $95.6 million of these unfunded contractual commitments are dependent upon the portfolio company reaching certain milestones before the contractual commitment becomes available. These commitments will be subject to the same underwriting and ongoing portfolio maintenance as are the on-balance sheet financial instruments that we hold. Since these commitments may expire without being drawn upon, the total commitment amount does not necessarily represent our future cash requirements. We intend to use cash flow from normal and early principal repayments, and proceeds from borrowings and notes to fund these commitments. However, there can be no assurance that we will have sufficient capital available to fund these commitments as they come due.

 

75


Table of Contents

In addition, we had approximately $238.0 million of non-binding term sheets outstanding to 14 new companies, which generally convert to contractual commitments within approximately 90 days of signing. Non-binding outstanding term sheets are subject to completion of our due diligence and final approval process, as well as the negotiation of definitive documentation with the prospective portfolio companies. Not all non-binding term sheets are expected to close and do not necessarily represent future cash requirements.

Contractual Obligations

The following table shows our contractual obligations as of March 31, 2014 (unaudited):

 

     Payments due by period
(in thousands)
 

Contractual Obligations(1)(2)

   Total      Less than
1 year
     1 - 3 years      3 -  5
years
     After 5
years
 

Borrowings (3) (4)

   $ 497,135       $ —         $ 63,782       $ 72,789       $ 360,564   

Operating Lease Obligations (5)

     7,309         1,514         2,987         1,551         1,257   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 504,444       $ 1,514       $ 66,769       $ 74,340       $ 361,821   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

(1) Excludes commitments to extend credit to our portfolio companies.
(2) We also have a warrant participation agreement with Citigroup. See Note 4 to our consolidated financial statements.
(3) Includes $190.2 million in borrowings under the SBA debentures, $170.4 million of the 2019 Notes, $63.8 million in aggregate principal amount of the Asset-Backed Notes and $72.8 million of the Convertible Senior Notes.
(4) Except for the Convertible Senior Notes, all carrying values are the same as the principal amount outstanding. The aggregate principal amount outstanding of the Convertible Senior Notes is $75.0 million less the unaccreted discount initially recorded upon issuance of the Convertible Senior Notes. The total unaccreted discount for the Convertible Senior Notes was $2.2 million at March 31, 2014.
(5) Long-term facility leases.

Certain premises are leased under agreements which expire at various dates through March 2020. Total rent expense amounted to approximately $388,000 and $329,000 during the three-month periods ended March 31, 2014 and 2013, respectively.

We and our executives and directors are covered by Directors and Officers Insurance, with the directors and officers being indemnified by us to the maximum extent permitted by Maryland law subject to the restrictions in the 1940 Act.

 

76


Table of Contents

Borrowings

Long-term SBA Debentures

On September 27, 2006, HT II received a license to operate as a SBIC under the SBIC program and is able to borrow funds from the SBA against eligible investments and regulatory capital. Under the Small Business Investment Company Act and current SBA policy applicable to SBICs, a SBIC can have outstanding at any time SBA guaranteed debentures up to twice the amount of its regulatory capital. With our net investment of $38.0 million in HT II as of March 31, 2014, HT II has the capacity to issue a total of $76.0 million of SBA guaranteed debentures, subject to SBA approval, of which $41.2 million was available at March 31, 2014. As of March 31, 2014, HT II has paid the SBA commitment fees and facility fees of approximately $1.5 million and $3.6 million, respectively. As of March 31, 2014 we held investments in HT II in 41 companies with a fair value of approximately $98.9 million, accounting for approximately 11.1% of our total portfolio at March 31, 2014.

On May 26, 2010, HT III received a license to operate as a SBIC under the SBIC program and is able to borrow funds from the SBA against eligible investments and additional contributions to regulatory capital. With our net investment of $74.5 million in HT III as of March 31, 2014, HT III has the capacity to issue a total of $149.0 million of SBA guaranteed debentures, of which $149.0 million was outstanding as of March 31, 2014. As of March 31, 2014, HT III has paid commitment fees and facility fees of approximately $1.5 million and $3.6 million, respectively. As of March 31, 2014, we held investments in HT III in 31 companies with a fair value of approximately $178.5 million accounting for approximately 20.0% of our total portfolio at March 31, 2014.

SBICs are designed to stimulate the flow of private equity capital to eligible small businesses. Under present SBA regulations, eligible small businesses include businesses that have a tangible net worth not exceeding $18.0 million and have average annual fully taxed net income not exceeding $6.0 million for the two most recent fiscal years. In addition, SBICs must devote 25.0% of its investment activity to “smaller” enterprises as defined by the SBA. A smaller enterprise is one that has a tangible net worth not exceeding $6.0 million and has average annual fully taxed net income not exceeding $2.0 million for the two most recent fiscal years. SBA regulations also provide alternative size standard criteria to determine eligibility, which depend on the industry in which the business is engaged and are based on such factors as the number of employees and gross sales. According to SBA regulations, SBICs may make long-term loans to small businesses, invest in the equity securities of such businesses and provide them with consulting and advisory services. Through its wholly-owned subsidiaries HT II and HT III, we plan to provide long-term loans to qualifying small businesses, and in connection therewith, make equity investments.

HT II and HT III are periodically examined and audited by the SBA’s staff to determine their compliance with SBA regulations. If HT II or HT III fails to comply with applicable SBA regulations, the SBA could, depending on the severity of the violation, limit or prohibit HT II’s or HT III’s use of debentures, declare outstanding debentures immediately due and payable, and/or limit HT II or HT III from making new investments. In addition, HT II or HT III may also be limited in their ability to make distributions to us if they do not have sufficient capital in accordance with SBA regulations. Such actions by the SBA would, in turn, negatively affect us because HT II and HT III are our wholly owned subsidiaries. HT II and HT III were in compliance with the terms of the SBIC’s leverage as of March 31, 2014 as a result of having sufficient capital as defined under the SBA regulations.

The rates of borrowings under various draws from the SBA beginning in March 2009 are set semiannually in March and September and range from 2.25% to 4.62%. Interest payments on SBA debentures are payable semiannually. There are no principal payments required on these issues prior to maturity and no prepayment penalties. Debentures under the SBA generally mature ten years after being borrowed. Based on the initial draw down date of March 2009, the initial maturity of SBA debentures will occur in March 2019. In addition, the SBA charges a fee that is set annually, depending on the Federal fiscal year the leverage commitment was delegated by the SBA, regardless of the date that the leverage was drawn by the SBIC. The annual fees related to HT II debentures that pooled on September 22, 2010 were 0.406% and 0.285%, depending upon the year in which the underlying commitment was closed. The annual fees on other debentures have been set at 0.906%. The annual fees related to HT III debentures that pooled on March 27, 2013 were 0.804%. The annual fees on other debentures have been set at 0.515%. The average amount of debentures outstanding for the three-months ended March 31, 2014 for HT II was approximately $63.6 million with an average interest rate of approximately 5.31%. The average amount of debentures outstanding for the three-months ended March 31, 2014 for HT III was approximately $149.0 million with an average interest rate of approximately 3.38%.

As of March 31, 2014, the maximum statutory limit on the dollar amount of combined outstanding SBA guaranteed debentures is $225.0 million, subject to periodic adjustments by the SBA. In aggregate, at March 31, 2014, with our net investment of $112.5 million, HT II and HT III have the capacity to issue a total of $225.0 million of SBA-guaranteed debentures, subject to SBA approval. In March 2014, we repaid $34.8 million of SBA debentures under HT II, priced at approximately 6.38%, including annual fees. At March 31, 2014, we have issued $190.2 million in SBA-guaranteed debentures in our SBIC subsidiaries.

 

77


Table of Contents

We reported the following SBA debentures outstanding as of March 31, 2014 (unaudited) and December 31, 2013:

 

(in thousands)

Issuance/Pooling Date

   Maturity Date    Interest Rate  (1)     March 31,
2014
     December 31,
2013
 

SBA Debentures:

          

March 26, 2008

   March 1, 2018      6.38   $ —         $ 34,800   

March 25, 2009

   March 1, 2019      5.53     18,400         18,400   

September 23, 2009

   September 1, 2019      4.64     3,400         3,400   

September 22, 2010

   September 1, 2020      3.62     6,500         6,500   

September 22, 2010

   September 1, 2020      3.50     22,900         22,900   

March 29, 2011

   March 1, 2021      4.37     28,750         28,750   

September 21, 2011

   September 1, 2021      3.16     25,000         25,000   

March 21, 2012

   March 1, 2022      3.28     25,000         25,000   

March 21, 2012

   March 1, 2022      3.05     11,250         11,250   

September 19, 2012

   September 1, 2022      3.05     24,250         24,250   

March 27, 2013

   March 1, 2023      3.16     24,750         24,750   
       

 

 

    

 

 

 

Total SBA Debentures

        $ 190,200       $ 225,000   
       

 

 

    

 

 

 

 

(1) Interest rate includes annual charge

2019 Notes

On March 6, 2012, we and U.S. Bank National Association (the “Trustee”) entered into an indenture (the “Base Indenture”). On April 17, 2012, we and the Trustee entered into the First Supplemental Indenture to the Base Indenture (the “First Supplemental Indenture”), dated April 17, 2012, relating to our issuance, offer and sale of $43.0 million aggregate principal amount of 7.00% senior notes due 2019 (the “April 2019 Notes”). The sale of the April 2019 Notes generated net proceeds, before expenses, of approximately $41.7 million.

On September 24, 2012, we and the Trustee, entered into the Second Supplemental Indenture to the Base Indenture (the “Second Supplemental Indenture”), dated as of September 24, 2012, relating to our issuance, offer and sale of $75.0 million aggregate principal amount of 7.00% senior notes due 2019 (the “September 2019 Notes” and, together with the April 2019 Notes, the “2019 Notes”). The sale of the September 2019 Notes generated net proceeds, before expenses, of approximately $72.75 million.

2019 Notes payable is compromised of:

 

     As of  
(in thousands)    March 31, 2014      December 31, 2013  

April 2019 Notes

   $ 84,490       $ 84,490   

September 2019 Notes

     85,874         85,874   
  

 

 

    

 

 

 

Carrying Value of Debt

   $ 170,364       $ 170,364   
  

 

 

    

 

 

 

April 2019 Notes

The April 2019 Notes will mature on April 30, 2019 and may be redeemed in whole or in part at our option at any time or from time to time on or after April 30, 2015, upon not less than 30 days nor more than 60 days written notice by mail prior to the date fixed for redemption thereof, at a redemption price of 100% of the outstanding principal amount thereof plus accrued and unpaid interest payments otherwise payable for the then-current quarterly interest period accrued to but not including the date fixed for redemption. The April 2019 Notes bear interest at a rate of 7.00% per year payable quarterly on January 30, April 30, July 30 and October 30 of each year, commencing on July 30, 2012, and trade on the New York Stock Exchange under the trading symbol “HTGZ.”

The April 2019 Notes are our direct unsecured obligations and rank: (i) pari passu with our other outstanding and future senior unsecured indebtedness, including without limitation, the $75.0 million in aggregate principal amount of the Convertible Senior Notes; (ii) senior to any of our future indebtedness that expressly provides it is subordinated to the April 2019 Notes; (iii) effectively subordinated to all our existing and future secured indebtedness (including indebtedness that is initially unsecured to which we subsequently grant security), to the extent of the value of the assets securing such indebtedness, including without limitation, borrowings under our Credit Facilities; (iv) structurally subordinated to all existing and future indebtedness and other obligations of any of our subsidiaries, including without limitation, the indebtedness of Hercules Technology II, L.P. and Hercules Technology III, L.P. and borrowings under our revolving senior secured credit facility with Wells Fargo Capital Finance, LLC.

 

78


Table of Contents

The Base Indenture, as supplemented by the First Supplemental Indenture, contains certain covenants including covenants requiring our compliance with (regardless of whether it is subject to) the asset coverage requirements set forth in Section 18(a)(1)(A) as modified by Section 61(a)(1) of the 1940 Act to comply with the restrictions on dividends, distributions and purchase of capital stock set forth in Section 18(a)(1)(B) as modified by Section 61(a)(1) of the 1940 Act and to provide financial information to the holders of the April 2019 Notes and the Trustee if we should no longer be subject to the reporting requirements under the Securities Exchange Act of 1934. These covenants are subject to important limitations and exceptions that are described in the Indenture, as supplemented by the First Supplemental Indenture. The Indenture provides for customary events of default and further provides that the Trustee or the holders of 25% in aggregate principal amount of the outstanding April 2019 Notes in a series may declare such April 2019 Notes immediately due and payable upon the occurrence of any event of default after expiration of any applicable grace period.

The April 2019 Notes were sold pursuant to an underwriting agreement dated April 11, 2012 among the Company and Stifel, Nicolaus & Company, Incorporated, as representative of the several underwriters named in the underwriting agreement.

In July 2012, we reopened our April 2019 Notes and issued an additional $41.5 million in aggregate principal amount of April 2019 Notes, which includes exercise of an over-allotment option, bringing the total amount of the April 2019 Notes issued to approximately $84.5 million in aggregate principal amount.

September 2019 Notes

The September 2019 Notes will mature on September 30, 2019 and may be redeemed in whole or in part at our option at any time or from time to time on or after September 30, 2015, upon not less than 30 days nor more than 60 days written notice by mail prior to the date fixed for redemption thereof, at a redemption price of 100% of the outstanding principal amount thereof plus accrued and unpaid interest payments otherwise payable for the then-current quarterly interest period accrued to but not including the date fixed for redemption. The September 2019 Notes bear interest at a rate of 7.00% per year payable quarterly on March 30, June 30, September 30 and December 30 of each year, commencing on December 30, 2012, and trade on the New York Stock Exchange under the trading symbol “HTGY.”

The September 2019 Notes are our direct unsecured obligations and rank: (i) pari passu with our other outstanding and future senior unsecured indebtedness, including without limitation, the $75 million in aggregate principal amount of the Convertible Senior Notes; (ii) senior to any of our future indebtedness that expressly provides it is subordinated to the September 2019 Notes; (iii) effectively subordinated to all our existing and future secured indebtedness (including indebtedness that is initially unsecured to which we subsequently grant security), to the extent of the value of the assets securing such indebtedness, including without limitation, borrowings under our credit facilities; (iv) structurally subordinated to all existing and future indebtedness and other obligations of any of our subsidiaries, including without limitation, the indebtedness of Hercules Technology II, L.P. and Hercules Technology III, L.P. and borrowings under our revolving senior secured credit facility with Wells Fargo Capital Finance.

The Base Indenture, as supplemented by the Second Supplemental Indenture, contains certain covenants including covenants requiring us to comply with (regardless of whether it is subject to) the asset coverage requirements set forth in Section 18 (a)(1)(A) as modified by Section 61(a)(1) of the 1940 Act to comply with the restrictions on dividends, distributions and purchase of capital stock set forth in Section 18(a)(1)(B) as modified by Section 61(a)(1) of the 1940 Act and to provide financial information to the holders of the September 2019 Notes and the Trustee if we should no longer be subject to the reporting requirements under the Securities Exchange Act of 1934. These covenants are subject to important limitations and exceptions that are described in the Indenture, as supplemented by the Second Supplemental Indenture. The Indenture provides for customary events of default and further provides that the Trustee or the holders of 25% in aggregate principal amount of the outstanding September 2019 Notes in a series may declare such September 2019 Notes immediately due and payable upon the occurrence of any event of default after expiration of any applicable grace period.

The September 2019 Notes were sold pursuant to an underwriting agreement dated September 19, 2012 among the Company and Stifel, Nicolaus & Company, Incorporated, as representative of the several underwriters named in the underwriting agreement. In October 2012, the underwriters exercised their over-allotment option for an additional $10.9 million of the September 2019 Notes, bringing the total amount of the September 2019 Notes issued to approximately $85.9 million in aggregate principal amount.

 

79


Table of Contents

For the three-months ended March 31, 2014 and 2013 (unaudited), the components of interest expense and related fees and cash paid for interest expense for the April 2019 Notes and September 2019 Notes are as follows:

 

     Three Months Ended March 31,  
(in thousands)    2014      2013  

Stated interest expense

   $ 2,981       $ 2,981   

Amortization of debt issuance cost

     240         240   
  

 

 

    

 

 

 

Total interest expense and fees

   $ 3,221       $ 3,221   
  

 

 

    

 

 

 

Cash paid for interest expense and fees

   $ 2,981       $ 2,998   

As of March 31, 2014, we are in compliance with the terms of the indenture, and respective supplemental indenture, governing the April 2019 Notes and September 2019 Notes. See Note 4 to our consolidated financial statements for more detail on the 2019 Notes.

Asset-Backed Notes

On December 19, 2012, we completed a $230.7 million term debt securitization in connection with which an affiliate of ours made an offer of $129.3 million in aggregate principal amount of fixed-rate asset-backed notes (the “Asset-Backed Notes”), which Asset-Backed Notes were rated A2(sf) by Moody’s Investors Service, Inc. The Asset-Backed Notes were issued by Hercules Capital Funding Trust 2012-1 pursuant to a note purchase agreement, dated as of December 12, 2012, by and among us, Hercules Capital Funding 2012- 1 LLC, as Trust Depositor (the “Trust Depositor”), Hercules Capital Funding Trust 2012-1, as Issuer (the “Issuer”), and Guggenheim Securities, LLC, as Initial Purchaser, and are backed by a pool of senior loans made to certain of our portfolio companies and secured by certain assets of those portfolio companies and are to be serviced by us. Interest on the Asset-Backed Notes will be paid, to the extent of funds available, at a fixed rate of 3.32% per annum. The Asset-Backed Notes have a stated maturity of December 16, 2017.

As part of this transaction, we entered into a sale and contribution agreement with the Trust Depositor under which we have agreed to sell or have contributed to the Trust Depositor certain senior loans made to certain of our portfolio companies (the “Loans”). We have made customary representations, warranties and covenants in the sale and contribution agreement with respect to the Loans as of the date of their transfer to the Trust Depositor.

In connection with the issuance and sale of the Asset-Backed Notes, we have made customary representations, warranties and covenants in the note purchase agreement. The Asset-Backed Notes are secured obligations of the Issuer and are non-recourse to us. The Issuer also entered into an indenture governing the Asset-Backed Notes, which indenture includes customary representations, warranties and covenants. The Asset-Backed Notes were sold without being registered under the Securities Act of 1933, as amended (the “Securities Act”), to “qualified institutional buyers” in compliance with the exemption from registration provided by Rule 144A under the Securities Act and to institutional “accredited investors” (as defined in Rule 501(a)(1), (2), (3) or (7) under the Securities Act) who in each case, are “qualified purchasers” for purposes of Section 3(c)(7) under the 1940 Act. In addition, the Trust Depositor entered into an amended and restated trust agreement, which includes customary representation, warranties and covenants.

The Loans are serviced by us pursuant to a sale and servicing agreement, which contains customary representations, warranties and covenants. We perform certain servicing and administrative functions with respect to the Loans. We are entitled to receive a monthly fee from the Issuer for servicing the Loans. This servicing fee is equal to the product of one-twelfth (or in the case of the first payment date, a fraction equal to the number of days from and including December 5, 2012 through and including January 15, 2013 over 360) of 2.00% and the aggregate outstanding principal balance of the Loans, excluding all defaulted Loans and all purchased Loans, as of the first day of the related collection period (the period from the 5th day of the immediately preceding calendar month through the 4th day of the calendar month in which a payment date occurs, and for the first payment date, the period from and including December 5, 2012, to the close of business on January 4, 2013).

We also serve as administrator to the Issuer under an administration agreement, which includes customary representations, warranties and covenants.

At March 31, 2014 and December 31, 2013, the Asset Backed Notes had an outstanding principal balance of $63.8 million and $89.6 million, respectively.

 

80


Table of Contents

Under the terms of the Asset Backed Notes, we are required to maintain a reserve cash balance, funded through interest and principal collections from the underlying securitized debt portfolio, which may be used to pay monthly interest and principal payments on the Asset-Backed Notes. We have segregated these funds and classified them as Restricted Cash. There was approximately $4.8 million and $6.3 million of Restricted Cash as of March 31, 2014 and December 31, 2013, respectively, funded through interest collections.

Convertible Senior Notes

In April 2011, we issued $75.0 million in aggregate principal amount of 6.00% convertible senior notes (the “Convertible Senior Notes”) due 2016. As of March 31, 2014, the carrying value of the Convertible Senior Notes, comprised of the aggregate principal amount outstanding less the unaccreted discount initially recorded upon issuance of the Convertible Senior Notes, is approximately $72.8 million.

The Convertible Senior Notes mature on April 15, 2016 (the “Maturity Date”), unless previously converted or repurchased in accordance with their terms. The Convertible Senior Notes bear interest at a rate of 6.00% per year payable semiannually in arrears on April 15 and October 15 of each year, commencing on October 15, 2011. The Convertible Senior Notes are our senior unsecured obligations and rank senior in right of payment to our existing and future indebtedness that is expressly subordinated in right of payment to the Convertible Senior Notes; equal in right of payment to our existing and future unsecured indebtedness that is not so subordinated; effectively junior in right of payment to any of our secured indebtedness (including unsecured indebtedness that we later secure) to the extent of the value of the assets securing such indebtedness; and structurally junior to all existing and future indebtedness (including trade payables) incurred by our subsidiaries, financing vehicles or similar facilities.

Prior to the close of business on the business day immediately preceding October 15, 2015, holders may convert their Convertible Senior Notes only under certain circumstances set forth in the Indenture. On or after October 15, 2015 until the close of business on the scheduled trading day immediately preceding the Maturity Date, holders may convert their Convertible Senior Notes at any time. Upon conversion, we will pay or deliver, as the case may be, at our election, cash, shares of our common stock or a combination of cash and shares of our common stock. The conversion rate will initially be 84.0972 shares of common stock per $1,000 principal amount of Convertible Senior Notes (equivalent to an initial conversion price of approximately $11.89 per share of common stock). The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, if certain corporate events occur prior to the Maturity Date, the conversion rate will be increased for converting holders. As of March 31, 2014, the conversion rate was 86.5029 shares of common stock per $1,000 principal amount of Convertible Senior Notes (equivalent to an adjusted conversion price of approximately $11.56 per share of common stock).

We may not redeem the Convertible Senior Notes prior to maturity. No sinking fund is provided for the Convertible Senior Notes. In addition, if certain corporate events occur, holders of the Convertible Senior Notes may require us to repurchase for cash all or part of their Convertible Senior Notes at a repurchase price equal to 100% of the principal amount of the Convertible Senior Notes to be repurchased, plus accrued and unpaid interest through, but excluding, the required repurchase date.

The Convertible Senior Notes are accounted for in accordance with ASC 470-20 (previously FASB Staff Position No. APB 14-1, “Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement)”). In accounting for the Convertible Senior Notes, we estimated at the time of issuance that the values of the debt and the embedded conversion feature of the Convertible Senior Notes were approximately 92.8% and 7.2%, respectively. The original issue discount of 7.2% attributable to the conversion feature of the Convertible Senior Notes was recorded in “capital in excess of par value” in the consolidated statement of assets and liabilities. As a result, we record interest expense comprised of both stated interest expense as well as accretion of the original issue discount resulting in an estimated effective interest rate of approximately 8.1%.

As of March 31, 2014 (unaudited) and December 31, 2013, the components of the carrying value of the Convertible Senior Notes were as follows:

 

(in thousands)    As of March 31, 2014     As of December 31, 2013  

Principal amount of debt

   $ 75,000      $ 75,000   

Original issue discount, net of accretion

     (2,211     (2,481
  

 

 

   

 

 

 

Carrying value of debt

   $ 72,789      $ 72,519   
  

 

 

   

 

 

 

 

81


Table of Contents

For the three-months ended March 31, 2014 and 2013 (unaudited), the components of interest expense, fees and cash paid for interest expense for the Convertible Senior Notes were as follows:

 

     Three Months Ended March,  
(in thousands)    2014      2013  

Stated interest expense

   $ 1,125       $ 1,125   

Accretion of original issue discount

     271         271   

Amortization of debt issuance cost

     144         144   
  

 

 

    

 

 

 

Total interest expense

   $ 1,540       $ 1,540   
  

 

 

    

 

 

 

Cash paid for interest expense

   $ —         $ —     

The estimated effective interest rate of the debt component of the Convertible Senior Notes, equal to the stated interest of 6.0% plus the accretion of the original issue discount, was approximately 8.1% for both the three-months ended March 31, 2014 and 2013. As of March 31, 2014, we are in compliance with the terms of the indentures governing the Convertible Senior Notes.

Wells Facility

In August 2008, we entered into a $50.0 million two-year revolving senior secured credit facility with Wells Fargo Capital Finance (the “Wells Facility”). On June 20, 2011, we renewed the Wells Facility. Under this three-year senior secured facility, Wells Fargo Capital Finance has made commitments of $75.0 million. The facility contains an accordion feature, in which we can increase the credit line up to an aggregate of $300.0 million, funded by additional lenders and with the agreement of Wells Fargo Capital Finance and subject to other customary conditions. We expect to continue discussions with various other potential lenders to join the new facility; however, there can be no assurances that additional lenders will join the Wells Facility.

On August 1, 2012, we entered into an amendment to the Wells Facility. The amendment reduces the interest rate floor by 75 basis points to 4.25% and extends the maturity date by one year to August 2015. Additionally, an amortization period of 12 months was added to pay down the principal balance as of the maturity date, and the unused line fee was reduced.

Borrowings under the Wells Facility will generally bear interest at a rate per annum equal to LIBOR plus 3.50%, with a floor of 4.25% and an advance rate of 50% against eligible debt investments. The Wells Facility is secured by debt investments in the borrowing base. The Wells Facility requires payment of a non-use fee on a scale of 0.0% to 0.50% of the average monthly outstanding balance. The monthly payment of a non-use fee thereafter shall depend on the average balance that was outstanding on a scale between 0.0% and 0.50%. For the three-month period ended March 31, 2014, this non-use fee was approximately $101,000. On June 20, 2011 we paid an additional $1.1 million in structuring fees in connection with the Wells Facility which is being amortized through the end of the term.

The Wells Facility includes various financial and operating covenants applicable to us and our subsidiaries, in addition to those applicable to Hercules Funding II, LLC. These covenants require us to maintain certain financial ratios and a minimum tangible net worth in an amount, when added to outstanding subordinated indebtedness, that is in excess of $362.0 million plus 90% of the cumulative amount of equity raised after June 30, 2012. In addition, the tangible net worth covenant will increase by 90 cents on the dollar for every dollar of equity capital that we subsequently raise. As of March 31, 2014, the minimum tangible net worth covenant has increased to $478.5 million as a result of our follow-on public offerings. The Wells Facility provides for customary events of default, including, but not limited to, payment defaults, breach of representations or covenants, bankruptcy events and change of control. We were in compliance with all covenants at March 31, 2014. See Note 4 to our consolidated financial statements for more detail on the Wells Facility.

 

82


Table of Contents

Union Bank Facility

On February 10, 2010, we entered a $20.0 million one-year revolving senior secured credit facility with Union Bank (the “Union Bank Facility”). On November 2, 2011, we renewed and amended the Union Bank Facility and added a new lender under the Union Bank Facility. Union Bank and RBC Capital Markets (“RBC”) have made commitments of $30.0 million and $25.0 million, respectively. The Union Bank Facility contains an accordion feature, in which we can increase the credit line up to an aggregate of $150.0 million, funded by additional lenders and with the agreement of Union Bank and subject to other customary conditions. We expect to continue discussions with various other potential lenders to join the new facility; however, there can be no assurances that additional lenders will join the Union Bank Facility.

On March 30, 2012 we entered into an amendment to the Union Bank Facility which permitted us to issue additional senior notes relating to the offer and sale of our 2019 Notes. On September 17, 2012, we entered into an amendment to the Union Bank Facility. Pursuant to the terms of the amendment, we are permitted to increase our unsecured indebtedness by an aggregate original principal amount not to exceed $200.0 million incurred after March 30, 2012 in one or more issuances, provided certain conditions are satisfied for each issuance.

On December 17, 2012, we further amended the Union Bank Facility to remove RBC from the Union Bank Facility. Following the removal of RBC, the Union Bank Facility consists solely of Union Bank’s commitment of $30.0 million. In connection with the amendment, the maximum availability under the Union Bank Facility, subject to a borrowing base, was reduced from $55.0 million to $30.0 million. The Union Bank Facility contains an accordion feature, in which we could increase the credit line by up to $95.0 million in the aggregate, funded by commitments from additional lenders and with the agreement of Union Bank and subject to other customary conditions. There can be no assurances that additional lenders will join the Union Bank Facility.

Borrowings under the Union Bank Facility will generally bear interest at a rate per annum equal to LIBOR plus 2.25% with a floor of 4.0%. The Union Bank Facility requires the payment of a non-use fee of 0.50% annually. For the three-month period ended March 31, 2014, this nonuse fee was $37,500. The Union Bank Facility is collateralized by debt investments in our portfolio companies, and includes an advance rate equal to 50.0% of eligible debt investments placed in the collateral pool. The Union Bank Facility generally requires payment of interest on a monthly basis. All outstanding principal is due upon maturity.

The Union Bank Facility requires various financial and operating covenants. These covenants require us to maintain certain financial ratios and a minimum tangible net worth in an amount, when added to outstanding subordinated indebtedness, that is in excess of $314.0 million plus 90% of the amount of net cash proceeds received from the sale of common stock after March 31, 2011. As of March 31, 2014, the minimum tangible net worth covenant has increased to $472.8 million as a result of follow-on public offerings. Union Bank Facility also provides for customary events of default, including, but not limited to, payment defaults, breach of representations or covenants, bankruptcy events and change of control. We were in compliance with all covenants at March 31, 2014. We further amended the Union Bank Facility on January 31, 2014. As amended, the Union Bank Facility will expire as of May 2, 2014. See Note 4 to our consolidated financial statements for more detail on the Union Bank Facility. We continue to explore potential financing arrangements with Union Bank that may be implemented following the expiration of the Union Bank Facility.

Citibank Credit Facility

We, through Hercules Funding Trust I, an affiliated statutory trust, had a securitized credit facility (the “Citibank Credit Facility”) with Citigroup Global Markets Realty Corp. which expired under normal terms. During the first quarter of 2009, we paid off all principal and interest owed under the Citibank Credit Facility. Citigroup has an equity participation right through a warrant participation agreement on the pool of debt investments and warrants collateralized under the Citibank Credit Facility. Pursuant to the warrant participation agreement, we granted to Citigroup a 10% participation in all warrants held as collateral. However, no additional warrants were included in collateral subsequent to the facility amendment on May 2, 2007. As a result, Citigroup is entitled to 10% of the realized gains on the warrants until the realized gains paid to Citigroup pursuant to the agreement equal $3,750,000 (the “Maximum Participation Limit”). The obligations under the warrant participation agreement continue even after the Citibank Credit Facility is terminated until the Maximum Participation Limit has been reached.

During the three-months ended March 31, 2014, we reduced our realized gain by approximately $78,000 for Citigroup’s participation in the gain on sale of equity securities which were obtained from exercising a portfolio company warrant which was included in the collateral pool. We recorded a decrease on participation liability and an increase on unrealized appreciation by a net amount of approximately $45,000 as a result of current quarter depreciation of fair value on the pool of warrants collateralized under the warrant participation agreement. The value of their participation right on unrealized gains in the related equity investments was approximately $325,000 as of March 31, 2014 and is included in accrued liabilities. There can be no assurances that the unrealized appreciation of the warrants will not be higher or lower in future periods due to fluctuations in the value of the warrants, thereby increasing or reducing the effect on the cost of borrowing. Since inception of the agreement, we have paid

 

83


Table of Contents

Citigroup approximately $1.7 million under the warrant participation agreement thereby reducing our realized gains by this amount. We will continue to pay Citigroup under the warrant participation agreement until the Maximum Participation Limit is reached or the warrants expire. Warrants subject to the Citigroup participation agreement are set to expire between February 2016 and March 2017.

Dividends

The following table summarizes our dividends declared and paid, to be paid, or reinvested on all shares, including restricted stock, to date:

 

Date Declared

  

Record Date

  

Payment Date

   Amount Per Share  

October 27, 2005

   November 1, 2005    November 17, 2005    $ 0.03   

December 9, 2005

   January 6, 2006    January 27, 2006      0.30   

April 3, 2006

   April 10, 2006    May 5, 2006      0.30   

July 19, 2006

   July 31, 2006    August 28, 2006      0.30   

October 16, 2006

   November 6, 2006    December 1, 2006      0.30   

February 7, 2007

   February 19, 2007    March 19, 2007      0.30   

May 3, 2007

   May 16, 2007    June 18, 2007      0.30   

August 2, 2007

   August 16, 2007    September 17, 2007      0.30   

November 1, 2007

   November 16, 2007    December 17, 2007      0.30   

February 7, 2008

   February 15, 2008    March 17, 2008      0.30   

May 8, 2008

   May 16, 2008    June 16, 2008      0.34   

August 7, 2008

   August 15, 2008    September 19, 2008      0.34   

November 6, 2008

   November 14, 2008    December 15, 2008      0.34   

February 12, 2009

   February 23, 2009    March 30, 2009      0.32

May 7, 2009

   May 15, 2009    June 15, 2009      0.30   

August 6, 2009

   August 14, 2009    September 14, 2009      0.30   

October 15, 2009

   October 20, 2009    November 23, 2009      0.30   

December 16, 2009

   December 24, 2009    December 30, 2009      0.04   

February 11, 2010

   February 19, 2010    March 19, 2010      0.20   

May 3, 2010

   May 12, 2010    June 18, 2010      0.20   

August 2, 2010

   August 12, 2010    September 17,2010      0.20   

November 4, 2010

   November 10, 2010    December 17, 2010      0.20   

March 1, 2011

   March 10, 2011    March 24, 2011      0.22   

May 5, 2011

   May 11, 2011    June 23, 2011      0.22   

August 4, 2011

   August 15, 2011    September 15, 2011      0.22   

November 3, 2011

   November 14, 2011    November 29, 2011      0.22   

February 27, 2012

   March 12, 2012    March 15, 2012      0.23   

April 30, 2012

   May 18, 2012    May 25, 2012      0.24   

July 30, 2012

   August 17, 2012    August 24, 2012      0.24   

October 26, 2012

   November 14, 2012    November 21, 2012      0.24   

February 26, 2013

   March 11, 2013    March 19, 2013      0.25   

April 29, 2013

   May 14, 2013    May 21, 2013      0.27   

July 29, 2013

   August 13, 2013    August 20, 2013      0.28   

November 4, 2013

   November 18, 2013    November 25, 2013      0.31   

February 24, 2014

   March 10, 2014    March 17, 2014      0.31   

April 28, 2014

   May 12, 2014    May 19, 2014      0.31   
        

 

 

 
         $ 9.37   
        

 

 

 

 

* Dividend paid in cash and stock.

On April 28, 2014 the Board of Directors declared a cash dividend of $0.31 per share to be paid on May 19, 2014 to shareholders of record as of May 12, 2014. This dividend will represent our thirty-fifth consecutive dividend declaration since our initial public offering, bringing the total cumulative dividend declared to date to $9.37 per share.

Our Board of Directors maintains a variable dividend policy with the objective of distributing four quarterly distributions in an amount that approximates 90 - 100% of our taxable quarterly income or potential annual income for a particular year. In addition, at the end of the year, we may also pay an additional special dividend or fifth dividend, such that we may distribute approximately all of our annual taxable income in the year it was earned, while maintaining the option to spill over our excess taxable income.

 

84


Table of Contents

Distributions in excess of our current and accumulated earnings and profits would generally be treated first as a return of capital to the extent of the stockholder’s tax basis, and any remaining distributions would be treated as a capital gain. The determination of the tax attributes of our distributions is made annually as of the end of our fiscal year based upon our taxable income for the full year and distributions paid for the full year. Of the dividends declared during the years ended December 31, 2013 and 2012, 100% were distributions of ordinary income. There can be no certainty to stockholders that this determination is representative of what the tax attributes of our 2014 distributions to stockholders will actually be.

Each year a statement on Form 1099-DIV identifying the source of the distribution (i.e., paid from ordinary income, paid from net capital gains on the sale of securities, and/or a return of paid-in-capital surplus which is a nontaxable distribution) is mailed to our stockholders. To the extent our taxable earnings fall below the total amount of our distributions for that fiscal year, a portion of those distributions may be deemed a tax return of capital to our stockholders.

We operate to qualify to be taxed as a RIC under the Code. Generally, a RIC is entitled to deduct dividends it pays to its shareholders from its income to determine “taxable income.” Taxable income includes our taxable interest, dividend and fee income, as well as taxable net capital gains. Taxable income generally differs from net income for financial reporting purposes due to temporary and permanent differences in the recognition of income and expenses, and generally excludes net unrealized appreciation or depreciation, as gains or losses are not included in taxable income until they are realized. In addition, gains realized for financial reporting purposes may differ from gains included in taxable income as a result of our election to recognize gains using installment sale treatment, which generally results in the deferment of gains for tax purposes until notes or other amounts, including amounts held in escrow, received as consideration from the sale of investments are collected in cash. Taxable income includes non-cash income, such as changes in accrued and reinvested interest and dividends, which includes contractual payment-in-kind interest, and the amortization of discounts and fees. Cash collections of income resulting from contractual PIK interest arrangements or the amortization of discounts and fees generally occur upon the repayment of the loans or debt securities that include such items. Non-cash taxable income is reduced by non-cash expenses, such as realized losses and depreciation and amortization expense.

As a RIC, we will be subject to a 4% nondeductible federal excise tax on certain undistributed income unless the we distribute in a timely manner an amount at least equal to the sum of (1) 98% of our ordinary income for each calendar year, (2) 98.2% of our capital gain net income for the 1-year period ending October 31 in that calendar year and (3) any income realized, but not distributed, in the preceding year (the “Excise Tax Avoidance Requirements”). We will not be subject to excise taxes on amounts on which we are required to pay corporate income tax (such as retained net capital gains). Depending on the level of taxable income earned in a tax year, we may choose to carry over taxable income in excess of current year distributions from such taxable income into the next tax year and pay a 4% excise tax on such income, as required. The maximum amount of excess taxable income that may be carried over for distribution in the next year under the Code is the total amount of dividends paid in the following year, subject to certain declaration and payment guidelines. To the extent we choose to carry over taxable income into the next tax year, dividends declared and paid by us in a year may differ from taxable income for that year as such dividends may include the distribution of current year taxable income, the distribution of prior year taxable income carried over into and distributed in the current year, or returns of capital.

We can offer no assurance that we will achieve results that will permit the payment of any cash distributions and, if we issue senior securities, we will be prohibited from making distributions if doing so causes us to fail to maintain the asset coverage ratios stipulated by the 1940 Act or if distributions are limited by the terms of any of our borrowings. Our ability to make distributions will be limited by the asset coverage requirements under the 1940 Act.

We intend to distribute approximately $3.8 million of spillover earnings from the year ended December 31, 2013 to our shareholders in 2014.

We maintain an “opt-out” dividend reinvestment plan for our common stockholders. As a result, if we declare a dividend, cash dividends will be automatically reinvested in additional shares of our common stock unless the stockholder specifically “opts out” of the dividend reinvestment plan and chooses to receive cash dividends.

 

85


Table of Contents

Critical Accounting Policies

The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and revenues and expenses during the period reported. On an ongoing basis, our management evaluates its estimates and assumptions, which are based on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in our estimates and assumptions could materially impact our results of operations and financial condition.

Valuation of Portfolio Investments

The most significant estimate inherent in the preparation of our consolidated financial statements is the valuation of investments and the related amounts of unrealized appreciation and depreciation of investments recorded.

At March 31, 2014, approximately 76.8% of our total assets represented investments in portfolio companies that are valued at fair value by the Board of Directors. Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those securities for which a market quotation is readily available and (ii) for all other securities and assets, fair value is as determined in good faith by the Board of Directors. Our investments are carried at fair value in accordance with the 1940 Act and Accounting Standards Codification topic 820 Fair Value Measurements and Disclosures (“ASC 820”). Our debt securities are primarily invested in venture capital-backed companies in technology-related markets, including technology, biotechnology, life science and energy and renewables technology industries. Given the nature of lending to these types of businesses, our investments in these portfolio companies are generally considered Level 3 assets under ASC 820 because there is no known or accessible market or market indexes for these investment securities to be traded or exchanged. As such, we value substantially all of our investments at fair value as determined in good faith pursuant to a consistent valuation policy and our Board of Directors in accordance with the provisions of ASC 820 and the 1940 Act. Due to the inherent uncertainty in determining the fair value of investments that do not have a readily available market value, the fair value of our investments determined in good faith by our Board of Directors may differ significantly from the value that would have been used had a readily available market existed for such investments, and the differences could be material.

We may from time to time engage an independent valuation firm to provide us with valuation assistance with respect to certain of our portfolio investments on a quarterly basis. We intend to continue to engage an independent valuation firm to provide us with assistance regarding our determination of the fair value of selected portfolio investments each quarter unless directed by the Board of Directors to cancel such valuation services. The scope of the services rendered by an independent valuation firm is at the discretion of the Board of Directors. Our Board of Directors is ultimately and solely responsible for determining the fair value of our investments in good faith.

With respect to investments for which market quotations are not readily available or when such market quotations are deemed not to represent fair value, our Board of Directors has approved a multi-step valuation process each quarter, as described below:

(1) our quarterly valuation process begins with each portfolio company being initially valued by the investment professionals responsible for the portfolio investment;

(2) preliminary valuation conclusions are then documented and business based assumptions are discussed with our investment committee;

(3) the Valuation Committee of the Board of Directors reviews the preliminary valuation of the investments in the portfolio company as provided by the investment committee, which incorporates the results of the independent valuation firm as appropriate.

(4) the Board of Directors, upon the recommendation of the Valuation Committee, discusses valuations and determines the fair value of each investment in our portfolio in good faith based on the input of, where applicable, the respective independent valuation firm and the investment committee.

ASC 820 establishes a framework for measuring the fair value of the assets and liabilities and outlines a fair value hierarchy which prioritizes the inputs used to measure fair value and the effect of fair value measures on earnings. ASC 820 also enhances disclosure requirements for fair value measurements based on the level within the hierarchy of the information used in the valuation. ASC 820 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

 

86


Table of Contents

We have categorized all investments recorded at fair value in accordance with ASC 820 based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, defined by ASC 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:

Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets at the measurement date. The types of assets carried at Level 1 fair value generally are equities listed in active markets.

Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset in connection with market data at the measurement date and for the extent of the instrument’s anticipated life. Fair valued assets that are generally included in this category are warrants held in a public company.

Level 3—Inputs reflect management’s best estimate of what market participants would use in pricing the asset at the measurement date. It includes prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. Generally, assets carried at fair value and included in this category are the debt investments and warrants and equities held in a private company.

In accordance with ASU 2011-04, the following table provides quantitative information about our Level 3 fair value measurements of our investments as of March 31, 2014. In addition to the techniques and inputs noted in the table below, according to our valuation policy we may also use other valuation techniques and methodologies when determining our fair value measurements. The below table is not intended to be all-inclusive, but rather provides information on the significant Level 3 inputs as they relate to our fair value measurements.

 

Investment Type - Level Three
Debt Investments

  Fair Value at
March  31, 2014
   

Valuation Techniques/
Methodologies

 

Unobservable Input (a)

 

Range

  Weighted
Average  (b)
    (in thousands)                  

Pharmaceuticals - Debt

    89,267      Originated Within 6 Months   Origination Yield   9.79% - 16.97%   13.28%
    168,016      Market Comparable Companies   Hypothetical Market Yield   12.70% - 16.97%   14.68%
      Premium/(Discount)   (1.00%) - 0.50%  

Medical Devices - Debt

    37,326      Originated Within 6 Months   Origination Yield   13.69% - 17.37%   15.22%
    35,362      Market Comparable Companies   Hypothetical Market Yield   14.52% - 17.37%   15.01%
      Premium/(Discount)   (1.00%) -  0.50%  
    4,543      Liquidation   Probability weighting of alternative outcomes   30% - 70%  

Technology - Debt

    32,946      Originated Within 6 Months   Origination Yield   3.90% - 15.95%   14.17%
    83,091      Market Comparable Companies   Hypothetical Market Yield   12.89% - 19.70%   14.58%
      Premium/(Discount)   0.00% - 1.00%  
    13,933      Liquidation   Probability weighting of alternative outcomes   0.00% - 100.00%  

Energy Technology - Debt

    52,314      Originated Within 6 Months   Origination Yield   10.81% - 17.29%   13.05%
    102,936      Market Comparable Companies   Hypothetical Market Yield   12.80% -14.39%   14.83%
      Premium/(Discount)   (0.50%) - 1.00%  

Lower Middle Market - Debt

    19,383      Originated Within 6 Months   Origination Yield   11.84%   11.84%
    73,973      Market Comparable Companies   Adjusted SMi Leveraged Loan Indices   10.46% -16.83%   14.19%
      Premium/(Discount)   0.00% - 1.00%  
    7,380      Liquidation   Probability weighting of alternative outcomes   50.00%  
           Debt Investments Where Fair Value Approximates Cost
    54,203      Imminent Payoffs
    23,686      Debt Investments Maturing in Less than One Year
 

 

 

         
  $ 798,359      Total Level Three Debt Investments
 

 

 

         

 

(a) The significant unobservable inputs used in the fair value measurement of our debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums (discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation would result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in our Schedule of Investments are included in the industries note above as follows:

Pharmaceuticals, above, is comprised of debt investments in the Specialty Pharmaceuticals, Drug Discovery and Development, Drug Delivery, and Diagnostics and Biotechnology industries in the Schedule of Investments.

Medical Devices, above, is comprised of debt investments in the Therapeutic, Surgical Devices, Medical Devices and Equipment and Biotechnology Tools industries in the Schedule of Investments.

Technology, above, is comprised of debt investments in the Software, Semiconductors, Electronics and Computer Hardware, Internet Consumer and Business Services, Information Services, Media/Content/Info and Communications and Networking industries in the Schedule of Investments.

Lower Middle Market, above, is comprised of debt investments in the Communications and Networking, Software, Electronics and Computer Hardware, Information Services, Internet Consumer and Business Services, Media/Content/Info, and Specialty Pharmaceuticals industries in the Schedule of Investments. Energy Technology, above, aligns with the Energy Technology industry in the Schedule of Investments.

 

(b) The weighted averages are calculated based on the fair market value of each investment.

 

87


Table of Contents

Investment Type - Level Three
Debt Investments

  Fair Value at
December 31, 2013
   

Valuation Techniques/
Methodologies

 

Unobservable Input (a)

 

Range

  Weighted
Average  (c)
    (in thousands)                  

Pharmaceuticals - Debt

    25,811      Originated Within 6 Months   Origination Yield   12.56% - 4.53%   13.36%
    250,607      Market Comparable Companies   Hypothetical Market Yield   13.83% - 15.47%   14.13%
      Premium/(Discount)   (1.00%) - 0.00%  

Medical Devices - Debt

    46,900      Originated Within 6 Months   Origination Yield   13.54% - 17.37%   14.87%
    34,723      Market Comparable Companies   Hypothetical Market Yield   14.32% - 17.37%   15.23%
      Premium/(Discount)   (1.00%) - 1.00%  

Technology - Debt

    18,796      Originated Within 6 Months   Origination Yield   10.62% - 15.97%   14.26%
    98,290      Market Comparable Companies   Hypothetical Market Yield   14.72% - 21.08%   15.48%
      Premium/(Discount)   0.00% - 1.00%  
    1,643      Liquidation   Probability weighting of alternative outcomes   30.00% - 70.00%  

Energy Technology - Debt

    32,597      Originated Within 6 Months   Origination Yield   14.68% - 15.87%   15.17%
    108,238      Market Comparable Companies   Hypothetical Market Yield   15.37%   15.37%
      Premium/(Discount)   (0.50%) - 1.50%  

Lower Middle Market - Debt

    121,347      Market Comparable Companies   Hypothetical Market Yield   14.83% - 19.73%   16.12%
      Premium/(Discount)   0.00% - 1.00%  
    31,818      Broker Quote (b)   Price Quotes   99.50% - 100.25% of par  
      Par Value   $2.0 - $22.5 million  
    12,576      Liquidation   Probability weighting of alternative outcomes   20.00% - 80.00%  
    Debt Investments Where Fair Value Approximates Amortized Cost    
    15,906      Imminent Payoffs    
    22,236      Debt Investments Maturing in Less than One Year    
    500      Convertible Debt at Par    
 

 

 

         
  $ 821,988      Total Level Three Debt Investments    
 

 

 

         

 

(a) The significant unobservable inputs used in the fair value measurement of our debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums (discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation would result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in our Schedule of Investments are included in the industries note above as follows:

Pharmaceuticals, above, is comprised of debt investments in the Specialty Pharmaceuticals, Drug Discovery and Development, Drug Delivery, and Diagnostics and Biotechnology industries in the Schedule of Investments.

Medical Devices, above, is comprised of debt investments in the Therapeutic, Surgical Devices, Medical Devices and Equipment and Biotechnology Tools industries in the Schedule of Investments.

Technology, above, is comprised of debt investments in the Software, Semiconductors, Electronics and Computer Hardware, Internet Consumer and Business Services, Information Services, Media/Content/Info and Communications and Networking industries in the Schedule of Investments.

Lower Middle Market, above, is comprised of debt investments in the Communications and Networking, Software, Electronics and Computer Hardware,

Information Services, Internet Consumer and Business Services, Media/Content/Info, and Specialty Pharmaceuticals industries in the Schedule of Investments.

Energy Technology, above, aligns with the Energy Technology industry in the Schedule of Investments. In our quarterly and annual reports filed with the Commission prior to the 2013 Annual Report on Form 10-K, we referred to the Energy Technology industry as “Clean Tech” and we referred to these investments as “Clean Tech” in the Schedule of Investments included in such reports.

 

(b) A broker quote valuation technique was used to derive the fair value of debt investments which are part of a syndicated facility.
(c) The weighted averages are calculated based on the fair market value of each investment.

 

Investment Type -

   Fair Value at
March 31, 2014
   

Valuation Techniques/
Methodologies

 

Unobservable Input (a)

  Range
     (in thousands)              

Level Three Equity Investments

   $ 9,961      Market Comparable Companies   EBITDA Multiple (b)   6.9x - 14.0x
       Revenue Multiple (b)   1.1x - 4.8x
       Discount for Lack of Marketability (c)   11.70% - 31.90%
       Average Industry Volatility (d)   39.32% - 99.82%
       Risk-Free Interest Rate   0.16% - 0.42%
       Estimated Time to Exit (in months)   14 - 26
     9,895      Market Adjusted OPM Backsolve   Average Industry Volatility (d)   38.04% - 81.35%
       Risk-Free Interest Rate   0.21% - 0.88%
       Estimated Time to Exit (in months)   18 - 39
     28,123      Other   Last Round Price   $2.02 - $18.00

Level Three Warrant Investments

   $ 9,570      Market Comparable Companies   EBITDA Multiple (b)   3.7x - 32.7x
       Revenue Multiple (b)   0.6x - 11.3x
       Discount for Lack of Marketability (c)   11.70% - 31.60%
       Average Industry Volatility (d)   28.23% - 98.69%
       Risk-Free Interest Rate   0.11% - 1.29%
       Estimated Time to Exit (in months)   12 - 48
     8,731      Market Adjusted OPM Backsolve   Average Industry Volatility (d)   29.88% - 99.56%
       Risk-Free Interest Rate   0.09% - 2.66%
       Estimated Time to Exit (in months)   9 - 45
  

 

 

       

Total Level Three Warrant and Equity Investments

   $ 66,280         
  

 

 

       

 

88


Table of Contents

 

(a) The significant unobservable inputs used in the fair value measurement of our warrant and equity-related securities are revenue and/or EBITDA multiples and discounts for lack of marketability. Additional inputs used in the Black Scholes option pricing model include industry volatility, risk free interest rate and estimated time to exit. Significant increases (decreases) in the inputs in isolation would result in a significantly higher (lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date.
(b) Represents amounts used when we have determined that market participants would use such multiples when pricing the investments.
(c) Represents amounts used when we have determined market participants would take into account these discounts when pricing the investments.
(d) Represents the range of industry volatility used by market participants when pricing the investment.

 

Investment Type -

   Fair Value at
December 31, 2013
   

Valuation Techniques/
Methodologies

 

Unobservable Input (a)

  Range
     (in thousands)              

Level Three Equity Investments

   $ 10,244      Market Comparable Companies   EBITDA Multiple (b)   8.6x - 17.7x
       Revenue Multiple (b)   0.7x - 13.8x
       Discount for Lack of Marketability (c)   9.1% - 23.6%
       Average Industry Volatility (d)   43.4% - 110.7%
       Risk-Free Interest Rate   0.1% - 0.4%
       Estimated Time to Exit (in months)   6 - 30
     9,289      Market Adjusted OPM Backsolve   Average Industry Volatility (d)   45.6% - 109.7%
       Risk-Free Interest Rate   0.1% - 0.9%
       Estimated Time to Exit (in months)   6 - 42
     18,127      Other   Average Industry Volatility (d)   44.0%
       Risk-Free Interest Rate   0.1%
       Estimated Time to Exit (in months)   12

Level Three Warrant Investments

   $ 10,200      Market Comparable Companies   EBITDA Multiple (b)   5.0x - 51.4x
       Revenue Multiple (b)   0.5x - 13.8x
       Discount for Lack of Marketability (c)   6.4% - 36.0%
       Average Industry Volatility (d)   21.3% - 110.7%
       Risk-Free Interest Rate   0.1% - 1.0%
       Estimated Time to Exit (in months)   6 - 48
     8,913      Market Adjusted OPM Backsolve   Average Industry Volatility (d)   35.7% - 109.9%
       Risk-Free Interest Rate   0.1% - 2.7%
       Estimated Time to Exit (in months)   3 - 48
     9,595      Other   Average Industry Volatility (d)   44.0% - 56.9%
       Risk-Free Interest Rate   0.1% - 1.0%
       Estimated Time to Exit (in months)   12 - 48
  

 

 

       

Total Level Three Warrant and Equity Investments

   $ 66,368         
  

 

 

       

 

(a) The significant unobservable inputs used in the fair value measurement of our warrant and equity-related securities are revenue and/or EBITDA multiples and discounts for lack of marketability. Additional inputs used in the Black Scholes option pricing model include industry volatility, risk free interest rate and estimated time to exit. Significant increases (decreases) in the inputs in isolation would result in a significantly higher (lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date.
(b) Represents amounts used when we have determined that market participants would use such multiples when pricing the investments.
(c) Represents amounts used when we have determined market participants would take into account these discounts when pricing the investments.
(d) Represents the range of industry volatility used by market participants when pricing the investment.

Debt Investments

We follow the guidance set forth in ASC 820 which establishes a framework for measuring the fair value of assets and liabilities and outlines a fair value hierarchy which prioritizes the inputs used to measure fair value and the effect of fair value measures on earnings. Our debt securities are primarily invested in venture capital-backed companies in technology-related markets, including technology, biotechnology, life science and energy and renewables technology industries at all stages of development. Given the nature of lending to these types of businesses, our investments in these portfolio companies are considered Level 3 assets under ASC 820 because there is no known or accessible market or market indexes for debt instruments for these investment securities to be traded or exchanged.

In making a good faith determination of the value of our investments, we generally start with the cost basis of the investment, which includes the value attributed to the OID, if any, and PIK interest or other receivables which have been accrued to principal as earned. We then apply the valuation methods as set forth below.

We apply a procedure for debt investments that assumes a sale of investment in a hypothetical market to a hypothetical market participant where buyers and sellers are willing participants. The hypothetical market does not include scenarios where the underlying security was simply repaid or extinguished, but includes an exit concept. Under this process, we also evaluate the collateral for

 

89


Table of Contents

recoverability of the debt investments as well as apply all of its historical fair value analysis. We use pricing on recently issued comparable debt securities to determine the baseline hypothetical market yields as of the measurement date. We consider each portfolio company’s credit rating, security liens and other characteristics of the investment to adjust the baseline yield to derive a hypothetical yield for each investment as of the measurement date. The anticipated future cash flows from each investment are then discounted at the hypothetical yield to estimate each investment’s fair value as of the measurement date.

Our process includes, among other things, the underlying investment performance, the current portfolio company’s financial condition and market changing events that impact valuation, estimated remaining life, current market yield and interest rate spreads of similar securities as of the measurement date. We value our syndicated debt investments using broker quotes and bond indices amongst other factors. If there is a significant deterioration of the credit quality of a debt investment, we may consider other factors than those a hypothetical market participant would use to estimate fair value, including the proceeds that would be received in a liquidation analysis.

We record unrealized depreciation on investments when we believe that an investment has decreased in value, including where collection of a debt investment is doubtful or, if under the in-exchange premise, when the value of a debt security were to be less than amortized cost of the investment. Conversely, where appropriate, we record unrealized appreciation if we believe that the underlying portfolio company has appreciated in value and, therefore, that our investment has also appreciated in value or, if under the in-exchange premise, the value of a debt security were to be greater than amortized cost.

When originating a debt instrument, we generally receive warrants or other equity-related securities from the borrower. We determine the cost basis of the warrants or other equity-related securities received based upon their respective fair values on the date of receipt in proportion to the total fair value of the debt and warrants or other equity-related securities received. Any resulting discount on the debt investment from recordation of the warrant or other equity instruments is accreted into interest income over the life of the loan.

Equity-Related Securities and Warrants

Securities that are traded in the over-the-counter markets or on a stock exchange will be valued at the prevailing bid price at period end. We have a limited number of equity securities in public companies. In accordance with the 1940 Act, unrestricted publicly traded securities for which market quotations are readily available are valued at the closing market quote on the measurement date.

We estimate the fair value of warrants using a Black Scholes pricing model. At each reporting date, privately held warrant and equity related securities are valued based on an analysis of various factors including, but not limited to, the portfolio company’s operating performance and financial condition and general market conditions, price to enterprise value or price to equity ratios, discounted cash flow, valuation comparisons to comparable public companies or other industry benchmarks. When an external event occurs, such as a purchase transaction, public offering, or subsequent equity sale, the pricing indicated by that external event is utilized to corroborate our valuation of the warrant and equity related securities. We periodically review the valuation of our portfolio companies that have not been involved in a qualifying external event to determine if the enterprise value of the portfolio company may have increased or decreased since the last valuation measurement date.

Income Recognition

We record interest income on the accrual basis and we recognize it as earned in accordance with the contractual terms of the loan agreement to the extent that such amounts are expected to be collected. Original Issue Discount (“OID”) initially represents the value of detachable equity warrants obtained in conjunction with the acquisition of debt securities and is accreted into interest income over the term of the loan as a yield enhancement. When a loan becomes 90 days or more past due, or if management otherwise does not expect the portfolio company to be able to service its debt and other obligations, we will generally place the loan on non-accrual status and cease recognizing interest income on that loan until all principal has been paid. Any uncollected interest related to prior periods is reversed from income in the period that collection of the interest receivable is determined to be doubtful. However, we may make exceptions to this policy if the investment has sufficient collateral value and is in the process of collection. At March 31, 2014, we had three debt investments on non-accrual with a cumulative cost and approximate fair value of $24.0 million and $7.7 million, respectively, compared to two debt investments on non-accrual at December 31, 2013 a cumulative cost and approximate fair market value of $23.3 million and $12.6 million, respectively.

Paid-In-Kind and End of Term Income

Contractual paid-in-kind (“PIK”) interest, which represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on the accrual basis to the extent such amounts are expected to be collected. We will generally cease accruing PIK interest if there is insufficient value to support the accrual or we do not expect the portfolio company to be able to pay all principal and interest due. In addition, we may also be entitled to an end-of-term payment that we amortize into income over the life of the loan. To maintain our status as a RIC, PIK and end-of-term income must be paid out to

 

90


Table of Contents

stockholders in the form of dividends even though we have not yet collected the cash. Amounts necessary to pay these dividends may come from available cash or the liquidation of certain investments. We recorded approximately $852,000 and $779,000 in PIK income in the three-month periods ended March 31, 2014 and 2013, respectively.

Fee Income

Fee income, generally collected in advance, includes loan commitment and facility fees for due diligence and structuring, as well as fees for transaction services and management services rendered by us to portfolio companies and other third parties. Loan and commitment fees are amortized into income over the contractual life of the loan. Management fees are generally recognized as income when the services are rendered. Loan origination fees are capitalized and then amortized into interest income using the effective interest rate method. In certain loan arrangements, warrants or other equity interests are received from the borrower as additional origination fees.

We recognize nonrecurring fees amortized over the remaining term of the loan commencing in the quarter relating to specific loan modifications. Certain fees may still be recognized as one-time fees, including prepayment penalties, fees related to select covenant default waiver fees and acceleration of previously deferred loan fees and original issue discount (OID) related to early loan pay-off or material modification of the specific debt outstanding.

Equity Offering Expenses

Our offering costs are charged against the proceeds from equity offerings when received.

Debt Issuance Costs

Debt issuance costs are fees and other direct incremental costs incurred by us in obtaining debt financing. Debt issuance costs are recognized as prepaid expenses and amortized over the life of the related debt instrument using the straight line method, which closely approximates the effective yield method.

Stock-Based Compensation

We have issued and may, from time to time, issue additional stock options and restricted stock to employees under our 2004 Equity Incentive Plan and Board members under our 2006 Equity Incentive Plan. We follow ASC 718, formally known as FAS 123R “Share-Based Payments” to account for stock options granted. Under ASC 718, compensation expense associated with stock-based compensation is measured at the grant date based on the fair value of the award and is recognized over the vesting period. Determining the appropriate fair value model and calculating the fair value of stock-based awards at the grant date requires judgment, including estimating stock price volatility, forfeiture rate and expected option life.

Income Taxes

We operate to qualify to be taxed as a RIC under the Code. Generally, a RIC is entitled to deduct dividends it pays to its shareholders from its income to determine “taxable income.” Taxable income includes our taxable interest, dividend and fee income, as well as taxable net capital gains. Taxable income generally differs from net income for financial reporting purposes due to temporary and permanent differences in the recognition of income and expenses, and generally excludes net unrealized appreciation or depreciation, as gains or losses are not included in taxable income until they are realized. In addition, gains realized for financial reporting purposes may differ from gains included in taxable income as a result of our election to recognize gains using installment sale treatment, which generally results in the deferment of gains for tax purposes until notes or other amounts, including amounts held in escrow, received as consideration from the sale of investments are collected in cash.

Taxable income includes non-cash income, such as changes in accrued and reinvested interest and dividends, which includes contractual PIK interest arrangements, and the amortization of discounts and fees. Cash collections of income resulting from contractual PIK interest arrangements or the amortization of discounts and fees generally occur upon the repayment of the loans or debt securities that include such items. Non-cash taxable income is reduced by non-cash expenses, such as realized losses and depreciation and amortization expense.

As a RIC, we will be subject to a 4% nondeductible federal excise tax on certain undistributed income unless the we distribute in a timely manner an amount at least equal to the sum of (1) 98% of our ordinary income for each calendar year, (2) 98.2% of our capital gain net income for the 1-year period ending October 31 in that calendar year and (3) any income realized, but not distributed, in the preceding year (the “Excise Tax Avoidance Requirements”). We will not be subject to excise taxes on amounts on which we are required to pay corporate income tax (such as retained net capital gains).

 

91


Table of Contents

Depending on the level of taxable income earned in a tax year, we may choose to carry over taxable income in excess of current year distributions from such taxable income into the next tax year and pay a 4% excise tax on such income, as required. The maximum amount of excess taxable income that may be carried over for distribution in the next year under the Code is the total amount of dividends paid in the following year, subject to certain declaration and payment guidelines. To the extent we choose to carry over taxable income into the next tax year, dividends declared and paid by us in a year may differ from taxable income for that year as such dividends may include the distribution of current year taxable income, the distribution of prior year taxable income carried over into and distributed in the current year, or returns of capital.

At December 31, 2013 no excise tax was recorded. We intend to distribute approximately $3.8 million of spillover earnings from the year ended December 31, 2013 to our shareholders in 2014.

Because federal income tax regulations differ from accounting principles generally accepted in the United States, distributions in accordance with tax regulations may differ from net investment income and realized gains recognized for financial reporting purposes. Differences may be permanent or temporary. Permanent differences are reclassified among capital accounts in the financial statement to reflect their tax character. Temporary differences arise when certain items of income, expense, gain or loss are recognized at some time in the future. Differences in classification may also result from the treatment of short-term gains as ordinary income for tax purposes.

Recent Accounting Pronouncements

In June 2013, the FASB issued ASU 2013-08, “Financial Services – Investment Companies (Topic 946): Amendments to the Scope, Measurement, and Disclosure Requirements,” which amends the criteria that define an investment company and clarifies the measurement guidance and requires new disclosures for investment companies. Under ASU 2013-08, an entity already regulated under the 1940 Act is automatically an investment company under the new GAAP definition, so we have concluded that there is no impact from adopting this standard on our statement of assets and liabilities or results of operations. We have adopted this standard for our fiscal year ending December 31, 2014.

Subsequent Events

Dividend Declaration

On April 28, 2014 the Board of Directors declared a cash dividend of $0.31 per share to be paid on May 19, 2014 to shareholders of record as of May 12, 2014. This dividend represents our thirty-fifth consecutive dividend declaration since our initial public offering, bringing the total cumulative dividend declared to date to $9.37 per share.

Restricted Stock Units Grants

In April 2014, we granted approximately 982,000 restricted stock units pursuant to the Plans.

Closed and Pending Commitments

As of April 28, Hercules has:

 

  a. Closed commitments of approximately $60.0 million to new and existing portfolio companies, and funded approximately $27.1 million since the close of the first quarter of 2014.

 

  b. Pending commitments (signed non-binding term sheets) of approximately $171.0 million. The table below summarizes our year-to-date closed and pending commitments as follows:

 

Closed Commitments and Pending Commitments (in millions)

 

January 1 – March 31, 2014 Closed Commitments

   $ 155.7   

Q2-14 Closed Commitments (as of April 28, 2014)

     60.0   
  

 

 

 

Total Year-to-date 2014 Closed Commitments(a)

     215.7   

Pending Commitments (as of April 28, 2014)(b)

     171.0   
  

 

 

 

Year to date 2014 Closed and Pending Commitments

     386.7   
  

 

 

 

Notes:

 

  a. Closed Commitments may include renewals of existing credit facilities. Not all Closed Commitments result in future cash requirements. Commitments generally fund over the two succeeding quarters from close.

 

  b. Not all pending commitments (signed non-binding term sheets) are expected to close and do not necessarily represent any future cash requirements.

 

92


Table of Contents

Portfolio Company Developments

As of March 31, 2014, we held warrants or equity positions in four companies that have filed registration statements on Form S-1 with the SEC in contemplation of potential initial public offerings, including Box, Inc., Dance Biopharm, Inc. and two companies which filed confidentially under the JOBS Act. In addition, subsequent to March 31, 2014 the following portfolio company completed an initial public offering:

 

  1. In April 2014, Glori Energy, Inc. (NASDAQ: GLRI), a Hercules portfolio company, completed a $185 million reverse merger with Infinity Cross Border Acquisition Corp. (NASDAQ: INXB) and closed a share tender offer and a warrant tender offer.

 

93


Table of Contents
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are subject to financial market risks, including changes in interest rates. Interest rate risk is defined as the sensitivity of our current and future earnings to interest rate volatility, variability of spread relationships, the difference in re-pricing intervals between our assets and liabilities and the effect that interest rates may have on our cash flows. Changes in interest rates may affect both our cost of funding and our interest income from portfolio investments, cash and cash equivalents and idle funds investments. Our investment income will be affected by changes in various interest rates, including LIBOR and Prime rates, to the extent our debt investments include variable interest rates. As of March 31, 2014, approximately 98.0% of the loans in our portfolio had variable rates based on floating Prime or LIBOR rates, or variable rates with a floor. Changes in interest rates can also affect, among other things, our ability to acquire and originate loans and securities and the value of our investment portfolio.

Based on our Consolidated Statement of Assets and Liabilities as of March 31, 2014, the following table shows the approximate annualized increase (decrease) in components of net assets resulting from operations of hypothetical base rate changes in interest rates, assuming no changes in our investments and borrowings.

 

(in thousands)

Basis Point Change(1)

   Interest
Income
     Interest
Expense
     Net
Income
 

100

   $ 6,615       $ —         $ 6,615   

200

   $ 13,727       $ —         $ 13,727   

300

   $ 23,765       $ —         $ 23,765   

400

   $ 33,668       $ —         $ 33,668   

500

   $ 43,542       $ —         $ 43,542   

 

(1) A decline in interest rates would not have a material impact on our Consolidated Financial Statements.

We do not currently engage in any hedging activities. However, we may, in the future, hedge against interest rate fluctuations by using standard hedging instruments such as futures, options, and forward contracts. While hedging activities may insulate us against changes in interest rates, they may also limit our ability to participate in the benefits of lower interest rates with respect to our borrowed funds and higher interest rates with respect to our portfolio of investments. During the three-month period ended March 31, 2014, we did not engage in interest rate hedging activities.

Although we believe that the foregoing analysis is indicative of our sensitivity to interest rate changes, it does not adjust for potential changes in the credit market, credit quality, size and composition of the assets in our portfolio. It also does not adjust for other business developments, including borrowings under our Credit Facilities, SBA debentures, Convertible Senior Notes, 2019 Notes and Asset-Backed Notes, that could affect the net increase in net assets resulting from operations, or net income. Accordingly, no assurances can be given that actual results would not differ materially from the statement above.

Because we currently borrow, and plan to borrow in the future, money to make investments, our net investment income is dependent upon the difference between the rate at which we borrow funds and the rate at which we invest the funds borrowed. Accordingly, there can be no assurance that a significant change in market interest rates will not have a material adverse effect on our net investment income. In periods of rising interest rates, our cost of funds would increase, which could reduce our net investment income if there is not a corresponding increase in interest income generated by variable rate assets in our investment portfolio.

For additional information regarding the interest rate associated with each of our Credit Facilities, SBA debentures, Convertible Senior Notes, 2019 Notes and Asset-Backed Notes, please refer to “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations – Financial Condition, Liquidity and Capital Resources – Outstanding Borrowings” in this quarterly report on Form 10-Q.

 

94


Table of Contents
ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Our chief executive and chief financial officers, under the supervision and with the participation of our management, conducted an evaluation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934. As of the end of the period covered by this quarterly report on Form 10-Q, our chief executive and chief financial officers have concluded that our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and communicated to our management, including our chief executive and chief financial officers, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There have been no other changes in our internal control over financing reporting, as defined in Rules 13a-15(f) and 15d-15(f) of the Securities Exchange Act of 1934, as amended, that occurred during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

95


Table of Contents

PART II: OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

We may, from time to time, be involved in litigation arising out of our operations in the normal course of business or otherwise. Furthermore, third parties may try to seek to impose liability on us in connection with the activities of our portfolio companies. While the outcome of any current legal proceedings cannot at this time be predicted with certainty, we do not expect any current matters will materially affect our financial condition or results of operations; however, there can be no assurance whether any pending legal proceedings will have a material adverse effect on our financial condition or results of operations in any future reporting period.

 

ITEM 1A. RISK FACTORS

In addition to the risks discussed below, important risk factors that could cause results or events to differ from current expectations are described in Part I, Item 1A “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 filed with the Securities and Exchange Commission on February 27, 2014.

Our financial results could be negatively affected if a significant portfolio investment fails to perform as expected.

Our total investment in companies may be significant individually or in the aggregate. As a result, if a significant investment in one or more companies fails to perform as expected, our financial results could be more negatively affected and the magnitude of the loss could be more significant than if we had made smaller investments in more companies. The following table shows the fair value of the totals of investments held in portfolio companies at March 31, 2014 that represent greater than 5% of our net assets:

 

     March 31, 2014  
(in thousands)    Fair
Value
     Percentage of
Net Assets
 

Merrimack Pharmaceuticals, Inc.

   $ 44,324         6.8

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer.

Our financial results could be materially adversely affected if these portfolio companies or any of our other significant portfolio companies encounter financial difficulty and fail to repay their obligations or to perform as expected.

 

96


Table of Contents
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the three month period ended March 31, 2014, we issued approximately 29,000 shares of common stock to shareholders in connection with the dividend reinvestment plan. These issuances were not subject to the registration requirements of the Securities Act of 1933, as amended. The aggregate value of the shares of our common stock issued under our dividend reinvestment plan was approximately $440,000.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not Applicable

 

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable

 

ITEM 5. OTHER INFORMATION

Not Applicable

 

ITEM 6. EXHIBITS

 

Exhibit
Number

  

Description

31.1    Chief Executive Officer Certification Pursuant to Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
31.2    Chief Financial Officer Certification Pursuant to Exchange Act Rule 13a-14 (a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
32.1    Chief Executive Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
32.2    Chief Financial Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*

 

* Filed herewith.

 

97


Table of Contents

SIGNATURES

Pursuant to the requirements of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

      HERCULES TECHNOLOGY GROWTH CAPITAL, INC. (Registrant)
Dated: May 1, 2014      

/S/    MANUEL A. HENRIQUEZ

      Manuel A. Henriquez
      Chairman, President, and Chief Executive Officer
Dated: May 1, 2014      

/S/    JESSICA BARON

      Jessica Baron
      Vice President, Finance and Chief Financial Officer

 

98


Table of Contents

EXHIBIT INDEX

 

Exhibit
Number

  

Description

31.1    Chief Executive Officer Certification Pursuant to Exchange Act Rule 13a-14 (a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
31.2    Chief Financial Officer Certification Pursuant to Exchange Act Rule 13a-14 (a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
32.1    Chief Executive Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
32.2    Chief Financial Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*

 

* Filed herewith.

 

99